Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B by Reijnders, J.G.P. (Jurriën)
Optimizing Treatment Strategies Using 
Nucleos(t)ide Analogues for Patients with 
Chronic Hepatitis B
Jurriën Reijnders
Jurrien BW.indd   1 19-Oct-10   11:34:21 AM
Colofon
ISBN: 978-90-8559-095-8
© J.G.P. Reijnders, the Netherlands, 2010.
All rights reserved. No part of this thesis may be reproduced or transmitted in any for 
or by any means, without prior written submission of the author.
Layout and printing: Optima Grafi sche Communicatie, Rotterdam, The Netherlands
Illustrated by: Ed Sammelius
The work presented in this thesis was conducted at the Department of Gastroenterol-
ogy and Hepatology, Erasmus MC, University Medical Center Rotterdam, the Nether-
lands.
Financial support for printing this thesis was kindly given by the Department of Gas-
troenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, de 
Nederlandse Vereniging voor Gastroenterologie, Novartis, Gilead Sciences, Bristol-
Myers Squibb and the J.E. Jurriaanse Stichting.
Jurrien BW.indd   2 19-Oct-10   11:34:21 AM
Optimizing Treatment Strategies Using 
Nucleos(t)ide Analogues for Patients with Chronic 
Hepatitis B
Antivirale behandeling van chronische hepatitis B: het 
optimaliseren van behandelstrategieën met nucleos(t)ideanalogen
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnifi cus
Prof.dr. H.G. Schmidt
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 24 november 2010 om 15.30 uur
door
Jurriën Gerben Peter Reijnders
geboren te Klundert
Jurrien BW.indd   3 19-Oct-10   11:34:21 AM
PROMOTIECOMMISSIE
Promotor: Prof.dr. H.L.A. Janssen
Overige leden: Prof.dr. C.A.B. Boucher
 Prof.dr. J.P. Drenth
 Dr. R.A. de Man
Jurrien BW.indd   4 19-Oct-10   11:34:23 AM
TABLE OF CONTENTS
General Introduction 7
Chapter 1  Nucleos(t)ide analogues only induce temporary hepatitis B e antigen 
seroconversion in most patients with chronic hepatitis B
13
Chapter 2  Kinetics of hepatitis B surface antigen differ between treatment with 
peginterferon and entecavir
29
Chapter 3  Frequency and clinical outcomes of fl ares related to nucleos(t)ide 
analogue therapy in patients with chronic hepatitis B
43
Chapter 4  Long-term therapy with tenofovir is effective for patients co-infected 
with HIV and HBV
55
Chapter 5  Antiviral effect of entecavir in chronic hepatitis B: Infl uence of prior 
exposure to nucleos(t)ide analogues
71
Chapter 6  Entecavir shows limited effi cacy in HBeAg-positive hepatitis B 
patients with a partial virologic response to adefovir therapy
87
Chapter 7  On-treatment monitoring of adefovir therapy in chronic hepatitis B: 
Virologic response can be assessed at 24 weeks
105
Summary and discussion 121
Samenvatting en bespreking 133
Dankwoord 145
Bibliografi e 149
Curriculum vitae 151
PhD Portfolio 153
Jurrien BW.indd   5 19-Oct-10   11:34:23 AM
Jurrien BW.indd   6 19-Oct-10   11:34:23 AM
G
 en
er
al
 in
tr
od
uc
tio
n
D
er
iv
ed
 f
ro
m
:
Ja
ns
se
n 
H
LA
, R
ei
jn
d
er
s 
JG
P
 T
re
at
m
en
t 
w
ith
 n
uc
le
os
(t
)id
e 
an
al
og
ue
s 
in
 c
hr
on
ic
 h
ep
at
iti
s 
B
: W
he
re
 d
oe
s 
th
e 
ro
ad
 m
ap
 le
ad
 u
s?
 
J 
H
ep
at
o
l. 
20
09
 J
ul
;5
1(
1)
:1
-3
R
ei
jn
d
er
s 
JG
P,
 J
an
ss
en
 H
LA
. N
ew
 a
p
p
ro
ac
he
s 
in
 t
he
 m
an
ag
em
en
t 
of
 c
hr
on
ic
 h
ep
at
iti
s 
B
: r
ol
e 
of
 t
en
of
ov
ir.
 In
fe
ct
io
n 
an
d
 D
ru
g 
R
es
is
ta
nc
e 
20
09
; 2
: 1
3-
26
R
ei
jn
d
er
s 
JG
P,
 J
an
ss
en
 H
LA
. H
ow
 e
ff
ec
tiv
e 
is
 t
re
at
m
en
t 
w
ith
 a
d
ef
ov
ir 
p
lu
s 
la
m
iv
ud
in
e 
fo
r 
p
at
ie
nt
s 
w
ith
 la
m
iv
ud
in
e-
re
si
st
an
t 
ch
ro
ni
c 
he
p
at
iti
s 
B
 in
fe
ct
io
n?
 N
at
ur
e 
C
lin
ic
al
 P
ra
ct
ic
e 
G
as
tr
o
en
te
ro
lo
g
y 
&
 H
ep
at
o
lo
g
y 
20
08
;5
(1
2)
:6
68
-9
R
ei
jn
d
er
s 
JG
P,
 J
an
ss
en
 H
LA
. P
ot
en
cy
 o
f 
te
no
fo
vi
r 
in
 c
hr
on
ic
 h
ep
at
iti
s 
B
: m
on
o-
 o
r 
co
m
b
in
at
io
n 
th
er
ap
y?
 J
 H
ep
at
ol
 2
00
8;
48
(3
):3
83
-6
.
Jurrien BW.indd   7 19-Oct-10   11:34:23 AM
Jurrien BW.indd   8 19-Oct-10   11:34:28 AM
General introduction 9
Hepatitis B infection has a complex natural history and causes a wide spectrum of 
disease.(1) Although effective vaccines are available, universal vaccination has yet not 
been reached. Currently, an estimated 350 million people are chronically infected, and 
0.5-1.2 million subjects die every year due to long-term sequalae of hepatitis B related 
chronic liver disease, such as liver cirrhosis and hepatocellular carcinoma.(2) Despite 
evidence-based treatment guidelines areas of disagreement on the management of 
chronic hepatitis B virus (HBV) infection still exist.
With the currently approved treatment options the ultimate goal is to prevent the 
development of long-term sequelae of chronic liver disease. Current treatment strat-
egies consist of either therapies with fi nite duration that aims to achieve sustained 
off-treatment remission (interferon-based therapy), or long-term therapy that aims to 
maintain on-treatment response (nucleos(t)ide analogues).(3-4)
Interferon therapy
Interferon (IFN) alfa has been used since the early 1990s for the treatment of chronic 
HBV infection. It largely acts through enhancement of the immunological response of 
the host against the virus, although there is also limited direct antiviral effect on HBV 
replication.(5) This immunomodulatory mode of action is refl ected in higher rates of 
HBeAg- and HBsAg seroconversion, and a more durable response once treatment 
is discontinued (sustained response) compared to treatment with nucleos(t)ide ana-
logues.(6-10) Among HBeAg-positive patients, subjects with HBV genotype A tend 
to respond much better than subjects with genotype non-A.(11) Follow-up studies 
demonstrated that IFN had long-term benefi ts in that it promotes cumulative HBeAg- 
and HBsAg seroconversion, prevention of cirrhosis and hepatocellular carcinoma, 
and prolonged survival.(6, 9) However, IFN-based therapy is associated with a wide 
spectrum of adverse events, including fl u-like symptoms, emotional lability, and bone 
marrow depression. Still, only few patients require dose modifi cation or discontinuation 
of treatment, and symptomatic therapy fulfi ls in most instances.(12) IFN is contraindi-
cated in patients with decompensated liver cirrhosis, but has proven to be safe and 
effective in patients with advanced fi brosis and compensated liver cirrhosis.(13)
Nucleos(t)ide analogue therapy
The introduction of nucleos(t)ide analogues heralded a new era in the treatment of 
chronic hepatitis B, and provided a safe, effective, and well-tolerated alternative for 
IFN. Nucleos(t)ide analogues target the reverse transcriptase of hepatitis B virus and 
are potent inhibitors of viral replication. Current guidelines recommend that, in HBeAg-
positive patients, treatment may be stopped after HBeAg seroconversion and at least 
six months of consolidation therapy. In HBeAg-negative patients, discontinuation is 
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only possible after HBsAg loss.(3-4) Therefore, in most patients treated with nucleos(t)
ide analogues only a maintained remission seems possible, and nucleos(t)ide analogue 
therapy has to be administered for extremely long periods of time, if not indefi nitely.
Development of antiviral resistance is a major limitation to long-term effi cacy of 
nucleos(t)ide analogue therapy. It leads to reversion of virologic and histological 
improvement, and enhances the rate of disease progression.(14) One of the fi rst mani-
festations of antiviral resistance is a virologic breakthrough which is defi ned as a > 1 
log10 increase in serum HBV DNA from nadir during treatment in a patient who had an 
initial virologic response. It is usually also followed by a biochemical breakthrough.
It is currently recommended to start with monotherapy and to use an add-on strategy 
in case of development of resistant HBV mutants.(3-4, 15) However, in the last few 
years management of resistance has evolved, and treatment strategies and clinical 
guidelines have been developed, which are focused at prevention of antiviral drug 
resistance.(3, 16) First, only potent nucleos(t)ide analogues with a high genetic barrier, 
meaning drugs requiring multiple resistance mutations, should be used as monother-
apy. Second, treatment should be adapted at an early stage in case of incomplete viral 
suppression, as several studies have already shown that an initial virologic response 
is associated with lower rates of antiviral drug resistance in HBV patients in the long 
term. A third option would be to offer de novo combination of nucleos(t)ide analogue 
therapy, although the clinical benefi t in HBV-monoinfected patients will be diffi cult to 
demonstrate in the light of antiviral drugs with excellent resistance profi les.
The general aims of this thesis are (1) to explore the durability of nucleos(t)ide analogue-
induced HBeAg seroconversion, (2) to investigate the effi cacy of oral antivirals in the 
treatment-naïve chronic HBV population, and (3) to optimize treatment strategies using 
nucleos(t)ide analogues to combat antiviral drug resistance.
Jurrien BW.indd   10 19-Oct-10   11:34:28 AM
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ABSTRACT
Background
Inconsistencies in results and guideline recommendations regarding the durability of 
nucleos(t)ide analogue-induced hepatitis B e antigen (HBeAg) seroconversion require 
clarifi cation. We studied the long-term durability of nucleos(t)ide analogue-induced 
HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection.
Methods
We performed a single-center cohort study of 132 HBeAg-positive patients that had 
received nucleos(t)ide analogue therapy.
Results
During a median treatment duration of 26 months (16–43 months), HBeAg seroconver-
sion occurred in 46 of 132 subjects (35%). Forty-two subjects (91%) had follow-up 
after HBeAg seroconversion. During a median follow-up of 59 months (28–103 months) 
after HBeAg seroconversion, 13 of 42 patients (31%) demonstrated a durable remis-
sion (defi ned as HBeAg negative and HBV DNA < 10,000 copies/mL). Overall, 33 of 
42 subjects (79%) continued therapy after HBeAg seroconversion; of these, 22 (67%) 
demonstrated serological and/ or virological recurrence. Nine of 42 subjects (21%) dis-
continued therapy after HBeAg seroconversion and at least 6 months of consolidation 
therapy. Only 2 patients demonstrated a durable response in the absence of therapy. 
Disease recurrence in patients that continued therapy after HBeAg seroconversion was 
preceded by the development of resistance (80% of these patients); resistance only 
occurred in subjects given lamivudine monotherapy. In contrast, recurrence after treat-
ment discontinuation or non-compliance was observed in all patients given nucleos(t)
ide analogues.
Conclusions
Induction of HBeAg seroconversion by nucleos(t)ide analogues is temporary in most 
patients with chronic HBV infection. Long-term continuation of nucleos(t)ide analogue 
treatment, irrespective of the occurrence of HBeAg seroconversion, appears to be 
necessary.
Jurrien BW.indd   14 19-Oct-10   11:34:31 AM
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INTRODUCTION
With approximately 400 million persons infected worldwide, chronic hepatitis B virus 
(HBV) infection is a major challenge in medical health care. The current treatment 
aims to prevent development of liver cirrhosis and hepatocellular carcinoma.(1) As 
these endpoints can only be assessed after decades of infection, short-term surrogate 
outcomes are used to assess the effect of therapeutic regimens. In HBeAg-positive 
patients, an important endpoint is HBeAg loss or seroconversion, as it is usually asso-
ciated with sustained remission and a low risk for the development of cirrhosis and 
hepatocellular carcinoma.(2-7)
Nucleos(t)ide analogues interfere with the elongation of viral DNA chains through com-
petitive inhibition with the viral polymerase, and are potent inhibitors of viral replication.
(8) In general, HBeAg seroconversion rates are approximately 20% after one year of 
nucleos(t)ide analogue treatment, and these rates increase with prolonged therapy. 
International guidelines on the therapy of hepatitis B suggest that fi nite duration of 
treatment with nucleos(t)ide analogues is a reasonable option, and recommend that 
treatment may be stopped after HBeAg seroconversion and an additional 6 to 12 
months of consolidation therapy.(9-10)
However, the long-term durability of HBeAg seroconversion induced by nucleos(t)
ide analogues is controversial, as several studies have reported contradictory results. 
Whereas some authors reported nucleos(t)ide analogue-induced HBeAg seroconver-
sion to be durable in up to 90%, others reported relapse rates as high as 70%.(11-13) 
Studies investigating durable response to newer agents as entecavir (ETV) and tenofovir 
(TDF) are still scarce. Furthermore, off-treatment response data for nucleos(t)ide ana-
logues are available for relatively short periods only, whereas interferon (IFN)-induced 
response has been documented to be durable for years with increasing numbers of 
HBsAg seroconversion. (14-16)
Clearly, inconsistencies in results and guideline recommendations regarding the 
durability of nucleos(t)ide analogue-induced HBeAg seroconversion require clarifi ca-
tion. We therefore studied the long-term durability of nucleos(t)ide analogue-induced 
HBeAg seroconversion.
METHODS AND MATERIALS
Study population
All adult patients with chronic HBV infection (HBsAg-positivity for at least 6 months), 
referred to the Erasmus Medical Center between 1996 and 2009, who were treated with 
nucleos(t)ide analogue therapy for at least 6 months, and were tested HBeAg positive, 
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anti-HBe negative at the start of treatment, were eligible. Major exclusion criteria were: 
co-infection with hepatitis C virus, hepatitis D virus or human immunodefi ciency virus 
and treatment with (pegylated) interferon less than 6 months prior to start of nucleos(t)
ide analogue treatment.
Follow-up
All subjects were monitored at least every 3-6 months. Biochemical (serum alanine 
aminotransferase) and virological parameters (quantitative HBV DNA, HBeAg, and 
anti-HBe) were assessed at every visit. HBV genotype was determined in available 
serum samples. HBsAg and anti-HBs values were determined in all patients who were 
HBeAg-negative with HBV DNA levels < 1,000 copies/mL at last follow-up. A genotypic 
analysis was performed in case of virological breakthrough, defi ned as an increase in 
serum HBV DNA level > 1 log10 (10-fold) above nadir after initial virological response. 
Patients were asked to confi rm their adherence to their treatment regimen at all outpa-
tient clinic visits. Patients were defi ned as non-compliant if (1) unexpected virological 
rebounds were observed, and (2) the treating physician clearly judged the patient to 
be non-adherent.
Endpoints
HBeAg seroconversion was defi ned as loss of HBeAg with concurrent appearance of 
anti-HBe. Serological recurrence was defi ned as reappearance of HBeAg confi rmed by 
HBeAg positivity in a consecutive sample. As a viral load of more than 10,000 copies/
mL is associated with progression of liver disease(17-18), virological recurrence was 
defi ned as a rise of HBV DNA to above 10,000 copies/mL after HBeAg seroconversion 
having previously been below 10,000 copies/mL, confi rmed in a consecutive sample.
Laboratory tests
Serum alanine aminotransferase (ALT) was measured using automated techniques. 
The upper limit of normal (ULN) was 40 IU/L for male and 30 IU/L for female subjects. 
Hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and anti-body 
against HBeAg (anti-HBe) were determined using commercially available enzyme 
immunoassays. Serum HBV DNA levels were measured using a previously described 
in house developed quantitative real-time polymerase chain reaction (PCR).(19-20) 
Currently, this assay is multiplexed without compromising the lower limit of detection 
(373 copies/mL) with an internal control (pHHV) in order to control the process from 
DNA isolation through PCR.(21) HBV DNA was extracted from serum samples using 
the MagnaPureLC (Roche Applied Science, Almere, The Netherlands) as described 
before.(19) HBV genotypes were assessed by sequence alignment of the overlapping 
hepatitis B surface antigen with HBV sequences derived from GenBank. Presence of 
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HBV polymerase gene mutations was determined using InnoLiPA DR2 and DR3 line 
probe assay (Innogenetics, Gent, Belgium).
Statistical analysis
Continuous variables are expressed as means (± SD) or median (interquartile range) 
where appropriate. Follow-up times were calculated from the date of nucleos(t)ide 
analogue treatment initiation or HBeAg seroconversion to the date of event or censor-
ship. Cumulative probabilities of different endpoints were estimated by Kaplan-Meier 
analysis. Survival analysis with Cox regression model was used to analyze which of the 
following baseline factors were associated with HBeAg seroconversion and with sero-
logical and/or virological recurrence after development of HBeAg seroconversion: Age, 
gender, race, body mass index (BMI), HBV genotype, time to HBeAg seroconversion, 
viral load at initiation of nucleos(t)ide analogue therapy and at HBeAg seroconversion, 
ALT level at initiation of nucleos(t)ide analogue therapy and at HBeAg seroconversion, 
presence of cirrhosis, and treatment regimen (lamivudine (LAM) monotherapy vs. other 
treatment regimens).
RESULTS
Baseline characteristics of all patients are shown in table 1. A total of 132 patients 
with chronic HBV infection treated with nucleos(t)ide analogues in our hospital were 
included for analysis. Overall, 67 patients were treated with LAM monotherapy, 33 
with adefovir (ADV), 22 with ETV, 6 with TDF, 2 with ADV-LAM combination therapy 
and 2 with TDF-LAM. One hundred seventeen (89%) patients were nucleos(t)ide ana-
logue treatment-naïve, whereas 15 (11%) subjects had previously been treated with 
nucleos(t)ide analogues. Median duration of therapy was 26 (16-43) months. Of all 
patients, 100 (76%) subjects were men and the mean age was 38±15 years. Most 
common HBV genotypes were genotype A (35%) and D (26%).
HBeAg seroconversion
HBeAg loss occurred in 55 of 132 (42%) subjects, of whom 46 (84%) patients serocon-
verted to anti-HBe during the study period. The cumulative probabilities of achieving 
HBeAg seroconversion after 1, 2 and 4 years of treatment were 25%, 32% and 44%, 
respectively (Fig. 1). Median duration of therapy until HBeAg seroconversion was 7 
(3-14) months. In multivariate analysis, independent predictors of HBeAg seroconver-
sion were high serum ALT values (HR 1.11 per 1×ULN increase, 95%CI 1.07-1.14, 
P<0.001), and low HBV DNA levels (HR 0.81 per 1 log10 increase, 95%CI 0.68-0.96, 
P=0.02) at baseline.
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Table 1 Baseline characteristics (N=132)
Age (years) 38 ± 15
Gender (male %) 100 (76%)
Race
 Caucasian 77 (58%)
 Asian 41 (31%)
 Other 14 (11%)
BMI 24 ± 4.1
ALT (xULN)* 2.3 (1.4-4.8)
HBV DNA (log10 copies/ml) 8.2 ± 1.6
Genotype (N=127)#
 A 45 (35%)
 B 25 (20%)
 C 19 (15%)
 D 33 (26%)
 Other 5 (4%)
Cirrhosis 23 (17%)
Treatment course
 Lamivudine 67 (51%)
 Adefovir 33 (25%)
 Entecavir 22 (17%)
 Other 10 (7%)
Nucleos(t)ide analogue treatment naïve 117 (89%)
* Median and interquartile range; # In fi ve patients no serum samples with detectable HBV DNA 
were available any more.
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Figure 1 Kaplan-Meier curve for the cumulative probabilities of achieving HBeAg seroconversion 
during nucleos(t)ide analogue therapy. (a) Number of patients who have not achieved HBeAg 
seroconversion and are still in follow-up. (b) Number of patients who are still in follow-up, whether 
or not they have achieved HBeAg seroconversion.
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Serological recurrence after HBeAg seroconversion
Follow-up after HBeAg seroconversion was available in 42 of the 46 (91%) subjects, 
and analysis of recurrence was limited to these 42 patients. Median follow-up time 
after HBeAg seroconversion for these 42 subjects was 59 (28-103) months. Serologi-
cal recurrence occurred in 17 of 42 (41%) patients. Cumulative serological recurrence 
rates at 1, 2 and 4 years after nucleos(t)ide analogue induced HBeAg seroconversion 
were 17%, 31%, and 44% respectively (Fig. 2). Median duration between HBeAg 
seroconversion and recurrence was 13 (6-25) months. In 13 (76%) cases serological 
recurrence occurred more than 6 months after HBeAg seroconversion, in 10 (59%) 
more than 1 year after HBeAg seroconversion.
Number of patients 
without recurrencea
Total number of patientsb
in follow-up
42 31 24 17 17
42 38 34 30 28
44%
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Figure 2 Kaplan-Meier curve for the cumulative probabilities of developing serological recurrence, 
defi ned as reappearance of HBeAg confi rmed by HBeAg positivity in a consecutive sample, after 
HBeAg seroconversion. (a) Number of patients who have not developed serological recurrence 
and are still in follow-up. (b) Number of patients who are still in follow-up, whether or not they have 
developed serological recurrence.
Virological recurrence after HBeAg seroconversion
Eight of 42 (19%) patients had ongoing viral replication with HBV DNA levels > 10,000 
copies/mL despite the achievement of HBeAg seroconversion, and directly progressed 
to chronic HBeAg-negative HBV infection. In 6 of 8 patients resistance to LAM was 
detected shortly before the development of HBeAg seroconversion. Two patients 
(LAM and ADV monotherapy) demonstrated a partial virological response and never 
achieved HBV DNA levels less than 10,000 copies/mL throughout follow-up. In addi-
tion, virological recurrence occurred in 19 of 34 (56%) remaining subjects after the 
development of HBeAg seroconversion. Cumulated virological recurrence rates at 
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1, 2 and 4 years after nucleos(t)ide analogue induced HBeAg seroconversion were 
12%, 42% and 50%, respectively (Fig. 3). Of these 19 patients, 15 reverted to chronic 
HBeAg-positive HBV infection (12 on-treatment; 3 off-treatment), and 4 progressed to 
chronic HBeAg-negative HBV infection (all off-treatment). Median duration between 
HBeAg seroconversion and virological recurrence was 16 (12-26) months. Seventeen 
(89%) cases of virological recurrence occurred more than 6 months after HBeAg sero-
conversion, 15 (79%) cases occurred more than 1 year after HBeAg seroconversion.
Durable response
Among the 42 patients who had HBeAg seroconversion during nucleos(t)ide analogue 
therapy, only 13 (31%) had a durable response, as defi ned by continued absence of 
HBeAg and HBV DNA levels below 10,000 copies/mL, during a median follow up of 59 
months (28-103 months) after HBeAg seroconversion. Serological or virological recur-
rence was signifi cantly more frequent among LAM-treated subjects compared to all 
others (HR 3.54, 92% CI 1.33-9.42, P = 0.005). No other factors were associated with 
recurrence. Overall, 33 of 42 subjects (79%) continued nucleos(t)ide analogue therapy 
after HBeAg seroconversion; of these, 22 (67%) demonstrated serological and/or 
virological recurrence during follow-up. Disease recurrence in patients that continued 
Number of patients 
without recurrencea
Total number of patientsb
in follow-up
34 27 16 11 11
34 31 28 24 24
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0 12 24 36 48
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Figure 3 Kaplan-Meier curve for the cumulative probabilities of developing virological recurrence, 
defi ned as a rise of HBV DNA to above 10,000 copies/mL after HBeAg seroconversion having 
previously been below 10,000 copies/mL, confi rmed in a consecutive sample. (a) Number of 
patients who have not developed virological recurrence and are still in follow-up. (b) Number of 
patients who are still in follow-up, whether or not they have developed virological recurrence. 
Eight patients had ongoing viral replication with HBV DNA levels > 10,000 copies/mL despite the 
achievement of HBeAg seroconversion, and were excluded from this analysis.
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antiviral therapy after HBeAg seroconversion, was preceded by the development of 
antiviral drug resistance in 80% of these patients; resistance only occurred in subjects 
given LAM monotherapy. Nine of 42 subjects (21%) discontinued nucleos(t)ide analogue 
therapy after HBeAg seroconversion and at least six months of consolidation therapy. 
Only two patients demonstrated a durable response in the absence of therapy. The 
clinical features of the nine patients who stopped therapy after HBeAg seroconversion 
are summarized in Table 2. Among the seven with recurrence after HBeAg seroconver-
sion, fi ve had received LAM, one had received ETV and one ADV. The causes of the 
recurrence are shown by treatment regimen in Figure 4. Most recurrences in patients 
treated with LAM were attributable to antiviral resistance, whereas recurrences after 
HBeAg seroconversion on ADV or other agents were due to discontinuation of treat-
ment or unknown.
HBsAg loss
Four of the 132 treated patients became HBsAg negative during or after treatment. 
Interestingly, three of these patients had demonstrated recurrence after seroconver-
sion but then were retreated and again had an HBeAg seroconversion followed by loss 
of HBsAg. All four patients remained HBsAg-negative (and without detectable serum 
HBV DNA) even after treatment discontinuation (for 3 to 45 months).
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Figure 4 Proportion of patients who developed serological/ and or virological recurrence after 
nucleos(t)ide analogue induced HBeAg seroconversion, and causes of serological and/ or viro-
logical recurrence, specifi ed per treatment regimen.
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DISCUSSION
Our study explores the long-term durability of nucleos(t)ide analogue-induced HBeAg 
seroconversion. During a median follow-up of fi ve years after the development of 
nucleos(t)ide analogue induced HBeAg seroconversion, only 31% of patients dem-
onstrated a durable remission, defi ned as HBeAg negativity and HBV DNA levels less 
than 10,000 copies/mL. Moreover, sustained response was demonstrated in just two 
of nine patients who discontinued therapy after a consolidation therapy of at least 6 
months. On-treatment recurrence was preceded by the development of antiviral drug 
resistance in 80% of patients, which only occurred in subjects treated with LAM mono-
therapy. In contrast, recurrence after treatment discontinuation or non-compliance was 
observed with all nucleos(t)ide analogues.
Previous studies on the durability of nucleos(t)ide analogue induced HBeAg sero-
conversion reported contradictory results. Studies performed in Western countries 
reported HBeAg seroconversion achieved during nucleos(t)ide analogue treatment to 
be durable in 80-90% of cases (11, 13), whereas other studies, mainly performed in 
Asian countries, showed relapse of viral activity in approximately half of patients with 
nucleos(t)ide analogue induced HBeAg seroconversion.(12, 22-31) The reasons for 
these discrepancies are not clear. Explanations may be HBV genotype, different lengths 
of consolidation therapy and follow-up, as well as the use of different endpoints. Both 
Dienstag et al. (11) and Poynard et al.(13), who reported high rates of durability after 
1-3 years of follow-up, only looked at HBeAg seroconversion itself. Although the fi rst 
study mentioned that 22 of 30 patients with a durable HBeAg seroconversion had 
undetectable HBV DNA, it should be noticed that an insensitive HBV DNA assay was 
used, and that fi ve patients did not demonstrate a biochemical remission at the end 
of follow-up. Moreover, a potential selection bias exists in this study, as only patients 
with a durable HBeAg seroconversion for at least 12-16 weeks after cessation of LAM 
treatment, were included in the analysis. The second study was only published as an 
abstract.13 In contrast, studies that reported higher relapse rates also included serum 
HBV DNA in their defi nition of relapse, which is an important and reliable marker of 
viral activity and progression of liver disease.(17-18) In our study, both serological and 
virological recurrence after HBeAg seroconversion were considered and long follow-
up was present. A durable remission after HBeAg seroconversion, whether on- or 
off-treatment, was only achieved in a minority of patients, as approximately 70% of 
patients demonstrated either serological or virological recurrence.
Current international guidelines suggest that treatment with nucleos(t)ide analogues 
can be discontinued after 6-12 months of consolidation therapy following HBeAg 
seroconversion. (9-10) In agreement with these recommendations, nine of our patients 
discontinued nucleos(t)ide analogue therapy after HBeAg seroconversion and at least 
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6 months of consolidation treatment. However, during long-term follow-up only two 
patients demonstrated a sustained off-treatment response, and remained HBeAg 
negative with HBV DNA levels < 10,000 copies/mL in absence of therapy.
HBsAg loss results in a more stable remission of chronic HBV infection compared to 
HBeAg loss or seroconversion. In our study, four of 132 patients developed HBsAg 
loss during nucleos(t)ide analogue therapy. All four patients demonstrated sustained 
HBsAg negativity after treatment discontinuation. These results might indicate that 
HBsAg loss is probably a more suitable end point instead of HBeAg loss or seroconver-
sion, and should be one of our primary treatment goals in patients with HBeAg-positive 
disease treated with oral antivirals as well.(32)
A limitation of our study is that the majority of patients in our study was treated with 
LAM monotherapy, and developed recurrence before treatment was discontinued. 
Only a limited number of patients were treated with either TDF or ETV monotherapy, 
which are nowadays considered to be our fi rst-choice nucleos(t)ide analogues, and 
conclusions on these newer compounds should be made with caution. As a signifi cant 
proportion of on-treatment recurrence was related to the emergence of antiviral drug 
resistance, which was only observed in patients treated with LAM monotherapy, one 
might expect that nucleos(t)ide analogues with a good resistance profi le will result in 
lower on-treatment recurrence. Yet, this observation may also point out that when the 
suppressive effect of an oral antiviral agent is omitted, whether by discontinuation of 
therapy or by development of resistance, recurrence is likely to occur. Indeed, recur-
rence was observed with all nucleos(t)ide analogue once treatment was discontinued 
or the patient was regarded to be non-compliant. Our data, therefore, might suggest 
that the occurrence of high recurrence rates after HBeAg seroconversion is not limited 
to LAM-treated patients but applies to treatment with newer agents as well.
In conclusion, the current study showed that induction of HBeAg seroconversion by 
nucleos(t)ide analogues is temporary in most patients with chronic HBV infection. 
These fi ndings indicate that HBeAg seroconversion, in contrast to what current guide-
lines suggest, is an imperfect endpoint in assessing nucleos(t)ide analogue therapy. 
Therefore, long-term continuation of nucleos(t)ide analogue treatment, irrespective of 
the occurrence of HBeAg seroconversion, appears to be necessary.
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ABSTRACT
Background
We aimed to investigate serum hepatitis B surface antigen (HBsAg) levels in patients 
with chronic hepatitis B virus (HBV) infection during peginterferon (PEG-IFN) and ente-
cavir (ETV) monotherapy.
Methods
HBsAg was quantifi ed (Abbott ARCHITECT) at baseline and during antiviral therapy 
(weeks 12, 24, 36, 48) in hepatitis B e antigen (HBeAg-)positive patients treated with 
ETV (N=33) or PEG-IFN (N=61) and in HBeAg-negative patients treated with ETV (N=37) 
or PEG-IFN (N=69).
Results
Within the HBeAg-positive population, the degree of HBsAg decline did not differ sig-
nifi cantly between patients treated with PEG-IFN and ETV (mean decline 0.94 versus 
0.38 log IU/mL at week 48, p=0.15). HBeAg clearance occurred more often in patients 
treated with PEG-IFN compared to ETV, and HBsAg decline was larger in those who 
became HBeAg negative, irrespective of treatment regimen. A decline of HBsAg was 
confi ned to ETV-treated patients with elevated baseline alanine aminotransferase (ALT) 
levels, whereas HBsAg decline was not associated with baseline ALT in patients treated 
with PEG-IFN. Within the HBeAg-negative population, PEG-IFN induced a signifi cant 
HBsAg decline, while HBsAg did not decrease in ETV-treated patients (0.56 versus 
-0.10 log IU/mL, p<0.001). Both in HBeAg-positive and HBeAg-negative patients, 
decline of serum HBV DNA was larger in patients who received ETV compared with 
PEG-IFN.
Conclusions
In HBeAg-positive patients, decline of serum HBsAg is largely confi ned to patients who 
clear HBeAg, either induced by PEG-IFN or ETV. In HBeAg-negative patients, PEG-IFN 
therapy resulted in a signifi cant reduction in HBsAg levels, whereas HBsAg did not 
decrease in ETV-treated patients.
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INTRODUCTION
Chronic hepatitis B (CHB) can be controlled in most patients with the currently avail-
able treatment options, but complete eradication of the hepatitis B virus (HBV) is rarely 
achieved. HBV covalently closed circular DNA (cccDNA) plays a major role in viral per-
sistence and its clearance is thought to be the limiting factor in eliminating infection (1). 
Previous studies demonstrated that both (pegylated) interferon (IFN) and nucleos(t)ide 
analogue (NA) therapy result in a reduction of intrahepatic cccDNA (2-4). In addition, 
intrahepatic cccDNA was shown to be a strong predictor of sustained off-treatment 
virological response (5). Serum hepatitis B surface antigen (HBsAg) levels are known 
to refl ect cccDNA in the liver, and reduction of HBsAg levels correlates well with that 
of cccDNA (2-4).
HBsAg clearance from serum approximates clinical cure and is associated with 
improved survival (6). The kinetics of HBsAg decline have recently been described in 
patients treated with standard IFN, PEG-IFN, lamivudine (LAM), and adefovir (ADV) 
monotherapy (2, 7-8). It was demonstrated that measurement of the serum HBsAg 
concentration during therapy may allow the identifi cation of sustained responders to 
PEG-IFN more reliably than serum HBV DNA (9). However, the effect of potent NA such 
as entecavir (ETV) and tenofovir (TDF) on serum HBsAg levels is unknown. Further-
more, the effi cacy of PEG-IFN in terms of HBsAg decline was only compared to inferior 
oral agents such as LAM and ADV. The aim of our study was (1) to assess on-treatment 
serum HBsAg kinetics in hepatitis B e antigen (HBeAg-)positive and HBeAg-negative 
CHB patients treated with PEG-IFN or ETV monotherapy, (2) to compare the effi cacy of 
PEG-IFN and ETV monotherapy in terms of HBsAg decline, and (3) to identify baseline 
factors associated with HBsAg decline after 48 weeks of antiviral therapy.
METHODS AND MATERIALS
Study population
We studied all consecutive HBV-monoinfected patients treated with ETV monotherapy 
for at least 48 weeks between January 2005 and May 2008 at the Erasmus MC Uni-
versity Medical Center Rotterdam. Patients treated with PEG-IFN monotherapy were 
derived from two randomized controlled trials (total treatment duration 48 and 52 
weeks) (10-11). The studies conformed to the ethical guidelines of the Declaration of 
Helsinki. Informed consent was obtained from all patients.
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Laboratory tests
Patients attended the outpatient clinic at least every 12 weeks for routine examinations 
and laboratory assessments. Serum alanine aminotransferase (ALT) levels were mea-
sured using automated techniques and are expressed as values representing a ratio 
to the upper limit of the normal range (ULN). Determination of HBeAg and antibody 
against HBeAg (anti-HBe) status was performed using commercially available enzyme 
immunoassays. Serum HBsAg was quantifi ed at baseline and during antiviral therapy 
(weeks 12, 24, 36 and 48) using the ARCHITECT HBsAg assay (Abbott laboratories; 
range 0.05-250 IU/mL). Serum HBV DNA levels were measured using commercial 
TaqMan polymerase chain reaction (PCR) assays (Roche Molecular Systems; lower 
limit of detection 70 copies/mL), except for the HBeAg-positive patients treated with 
PEG-IFN for whom an in-house-developed TaqMan PCR assay based on the EuroHep 
standard was used (lower limit of detection 400 copies/mL) (12). It has previously been 
demonstrated that there is an excellent correlation between these assays (13).
Statistical analysis
Group-matching between the ETV and PEG-IFN groups was performed by their base-
line HBV DNA concentration and aimed at a 2:1 ratio in order to increase power, as 
described by Pocock (14). Baseline HBV DNA was selected, because this factor was 
previously found to be associated with the degree of HBsAg decline during PEG-IFN 
therapy (7).
Serum HBsAg and HBV DNA levels were logarithmically transformed for analysis. Con-
tinuous variables are presented as mean (standard deviation) or median (interquartile 
range), where appropriate. The lower limit of detection of 400 copies/mL of the in-
house PCR assay was applied to all HBV DNA results to allow comparison between the 
treatment groups. Continuous variables were compared using the t-test or the Mann-
Whitney test. Categorical variables were compared using the Chi-square or Fisher’s 
exact test. The association between baseline factors and the degree of HBsAg decline 
was assessed by linear regression analyses applying mixed modelling techniques with 
a random intercept and a random slope per subject, and with a covariance structure 
depending on the treatment regimen. Statistical analyses were performed using SPSS 
version 15.0 (SPSS Inc., Chicago, IL, USA) and the SAS 9.2 program (SAS Institute 
Inc., Cary, NC, USA). All statistical tests were two-sided and were evaluated at the 0.05 
level of signifi cance.
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RESULTS
Baseline characteristics
At total of 200 HBV-infected patients were included. The HBeAg-positive population 
consisted of 61 patients treated with PEG-IFN and 33 patients treated with ETV. The 
HBeAg-negative population consisted of 69 patients treated with PEG-IFN and 37 
ETV-treated patients (Fig.1). Baseline characteristics are presented in Table 1. HBeAg-
positive patients treated with PEG-IFN and ETV were comparable at baseline except 
for serum ALT level, distribution of HBV genotypes and prevalence of liver cirrhosis 
(Table 1). Within the HBeAg-negative population, the treatment groups were balanced 
except for ethnicity, distribution of HBV genotypes and prevalence of liver cirrhosis 
(Table 1). HBeAg-positive patients tended to be younger (38 versus 41 years, p=0.10) 
and had higher baseline serum HBV DNA and HBsAg levels compared with HBeAg-
negative patients (8.4 versus 6.8 log copies/mL for HBV DNA and 4.2 versus 3.8 log 
IU/mL for HBsAg, p<0.001 for both comparisons), while median ALT levels were similar 
(2.3 versus 2.5 ULN, p=0.42). Baseline serum HBsAg and HBV DNA levels showed 
a signifi cant positive correlation in HBeAg-positive patients (R=0.54, p<0.001), while 
HBsAg and HBV DNA were not correlated in HBeAg-negative patients (R=0.09, p=0.36).
HBeAg positive HBeAg negative
ETV
N=33
ETV
N=37
PEG-IFN alfa-2b
HBeAg-positive study
N=266
PEG-IFN alfa-2a
HBeAg-negative study
N=133
PEG-IFN + LAM
N=130
PEG-IFN
N=136
PEG-IFN
N=69
PEG-IFN + RBV
N=64
ETV*
N=70
PEG-IFN†
N=61
PEG-IFN†
N=69
Figure 1 Study profi le. *All consecutive patients treated with ETV monotherapy for at least 48 
weeks were included; †Patients treated with PEG-IFN monotherapy were randomly selected from 
two randomized controlled trials [10,11], the PEG-IFN and ETV groups were group-matched ac-
cording to their baseline HBV DNA level. RBV: ribavirin.
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HBeAg-positive patients
Virological and biochemical response rates
Within the HBeAg-positive population, PEG-IFN therapy resulted in a higher rate of 
HBeAg clearance at week 48 compared to ETV (21 (34%) versus 3 (9%) patients, 
p=0.007; Table 2). HBsAg loss (HBsAg <0.05 IU/mL) occurred in 6 (10%) patients in the 
PEG-IFN group, but was not achieved in patients treated with ETV (p=0.09; Table 2). 
In contrast, the proportion of patients with HBV DNA <400 copies/mL at week 48 was 
higher in the ETV group (17 (52%) versus 10 (16%) patients in the ETV and PEG-IFN 
group, respectively; p<0.001; Table 2).
On-treatment HBsAg and HBV DNA decline
The decline of serum HBsAg during 48 weeks of monotherapy with PEG-IFN and ETV 
in HBeAg-positive patients is displayed in Figure 2A. HBsAg decreased signifi cantly 
during PEG-IFN therapy (mean decline 0.94 log IU/mL at week 48, p<0.001) and to a 
lesser extent in ETV-treated patients (0.38 log IU/mL, p=0.07). The difference in HBsAg 
decline was not signifi cant between these two groups (p=0.15). Figure 2B shows the 
decline of serum HBV DNA for the two treatment groups. HBV DNA levels decreased 
signifi cantly during PEG-IFN and ETV therapy (p<0.001 compared to baseline in 
both groups). In contrast to HBsAg, suppression of HBV DNA was stronger in the 
Table 1 Baseline characteristics
HBeAg positive HBeAg negative
Characteristics
PEG-IFN
(N=61)
ETV
(N=33)
p
PEG-IFN
(N=69)
ETV
(N=37)
p
Mean (SD) age, years 38 (13) 38 (15) 0.93 42 (10) 40 (12) 0.59
Sex, male (%) 51 (84%) 27 (82%) 0.83 54 (78%) 28 (76%) 0.76
Race (%) 0.12 <0.001
Caucasian 44 (72%) 22 (67%) 66 (96%) 19 (51%)
Asian 15 (25%) 6 (18%) 1 (1%) 9 (24%)
Other 2 (3%) 5 (15%) 2 (3%) 9 (24%)
Median (IQR) ALT* 3.2 (2.3-5.4) 1.5 (1.1-2.4) <0.001 2.4 (1.7-4.1) 2.2 (1.5-3.3) 0.26
Mean (SD) HBV DNA,
log copies/mL
8.6 (1.1) 8.0 (2.1) 0.09 6.9 (1.2) 6.7 (1.7) 0.67
Mean (SD) HBsAg, log IU/mL 4.2 (0.8) 4.3 (0.7) 0.51 3.8 (0.6) 3.7 (0.7) 0.41
HBV Genotype (%) 0.04 <0.001
A 29 (48%) 13 (39%) 7 (10%) 5 (14%)
B 0 4 (12%) 0 3 (8%)
C 11 (18%) 2 (6%) 1 (1%) 8 (22%)
D 14 (23%) 10 (30%) 58 (84%) 20 (54%)
Other/mixed 7 (12%) 4 (12%) 3 (4%) 1 (3%)
Presence of cirrhosis (%) 9 (15%) 12 (36%) 0.02 2 (3%) 9 (24%) 0.002
*Multiples of upper limit of the normal range
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ETV-treated patients (mean decline 4.5 versus 2.2 log copies/mL at week 48 in the ETV 
and PEG-IFN group, respectively; p<0.001).
Baseline factors associated with HBsAg decline
By univariate analysis, the baseline factors age, serum ALT level, serum HBV DNA level 
and HBV genotype (A versus non-A) were signifi cantly associated with HBsAg decline. 
Patients treated with PEG-IFN tended to have a steeper HBsAg decline compared to 
patients treated with ETV (p=0.07). After correction of the model for each of these fac-
tors in multivariate analysis, a higher HBsAg decline in patients treated with PEG-IFN 
compared to ETV remained, yet this difference did not reach the level of signifi cance 
(all p<0.17). Interestingly, HBsAg levels only decreased in ETV-treated patients with 
Table 2 Rates of virological and biochemical response
HBeAg positive HBeAg negative
Response at week 48
PEG-IFN
(N=61)
ETV
(N=33)
p
PEG-IFN
(N=69)
ETV
(N=37)
p
HBV DNA <400 copies/mL 10 (16%) 17 (52%) <0.001 36 (52%) 31 (84%) 0.001
HBeAg clearance 21 (34%) 3 (9%) 0.007 - - -
HBeAg seroconversion 16 (26%) 3 (9%) 0.05 - - -
HBsAg clearance 6 (10%) 0 0.09 0 0 -
HBsAg seroconversion 4 (7%) 0 0.29 0 0 -
ALT normalization 21 (34%) 16 (48%) 0.18 28 (41%) 27 (73%) 0.001
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(Chapter 2)
Figure 2 Mean change compared to baseline for (A) HBsAg and (B) HBV DNA levels in HBeAg-
positive patients and for (C) HBsAg and (D) HBV DNA levels in HBeAg-negative patients treated 
with PEG-IFN and ETV.
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elevated ALT levels at baseline (mean decline -0.03 log IU/mL for ALT ≤2 ULN versus 
1.03 for ALT >2 ULN at week 48, p=0.007), whereas HBsAg decline was comparable in 
both ALT categories in HBeAg-positive patients treated with PEG-IFN (Fig. 3). Although 
the initial decline of HBsAg was more pronounced in the PEG-IFN group with ALT >2 
ULN and ETV group with ALT >2 ULN compared with the PEG-IFN group with ALT ≤2 
ULN (mean decline 0.67 and 0.73 versus 0.42 log IU/mL at week 24, respectively), this 
difference was not signifi cant, potentially due to the limited number of patients treated 
with PEG-IFN who had baseline ALT ≤2 ULN (p=0.61).
Association between HBsAg decline and HBeAg loss at week 48
The magnitude of HBsAg decline was larger in the 24 patients who lost HBeAg com-
pared to patients who remained HBeAg positive after 48 weeks of therapy (mean decline 
1.98 versus 0.36 log IU/mL at week 48, p=0.006; Fig. 4). Interestingly, the magnitude 
of HBsAg decline in the patients who achieved HBeAg loss was not associated with 
treatment regimen (1.94 and 2.29 log IU/mL for PEG-IFN and ETV, respectively, p=0.85; 
Fig. 4). The decline of HBV DNA was also associated with HBeAg loss at week 48 (4.6 
versus 2.6 log copies/mL for patients who were HBeAg negative at week 48 compared 
to patients who remained HBeAg positive, p<0.001), irrespective of treatment regimen 
(4.6 versus 4.9 log copies/mL for PEG-IFN and ETV, respectively, p=0.77).
0.90
-0.03
0.94
1.03
1
M
ea
n
H
Bs
Ag
de
cl
in
e
at
 w
ee
k 
48
 
(lo
g I
U/
mL
)
0.5
0
ALT 2 ULN
ALT >2 ULN
P=0.96
P=0.007
PEG-IFN ETV
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Figure 3 Degree of HBsAg decline after 48 weeks of PEG-IFN and ETV therapy for HBeAg-
positive patients according to the categories of baseline ALT ≤2 ULN and >2 ULN. Within the 
HBeAg-negative population, decline of HBsAg was only related to treatment regimen and not to 
baseline ALT or any other baseline variable.
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HBeAg-negative patients
Virological and biochemical response rates
Within the HBeAg-negative population, the number of patients with HBV DNA <400 
copies/mL at week 48 was higher in the ETV group as well (31 (84%) versus 36 (52%) 
patients, p=0.001; Table 2). Neither in the PEG-IFN nor in the ETV group HBsAg clear-
ance was observed.
On-treatment HBsAg and HBV DNA decline
The decline of serum HBsAg in HBeAg-negative patients is shown in Figure 2C. Serum 
HBsAg consistently decreased in the PEG-IFN group (p<0.001 compared to baseline), 
while HBsAg levels did not change during ETV therapy (mean decline 0.56 versus -0.10 
log IU/mL at week 48, p<0.001). Figure 2D shows the decline of serum HBV DNA for 
the PEG-IFN and ETV group. HBV DNA levels decreased signifi cantly in both treatment 
groups (p<0.001 compared to baseline), but viral suppression tended to be stronger 
in the ETV group (mean decline 4.2 for ETV versus 3.7 log copies/mL for PEG-IFN at 
week 48, p=0.13).
Baseline factors associated with HBsAg decline
Multivariate analysis showed that the decline of HBsAg was only related to treatment 
regimen (p<0.001) and not to any other baseline variable.
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Figure 4 Degree of HBsAg decline at week 48 of PEG-IFN and ETV therapy for HBeAg-positive 
patients according to the achievement of HBeAg loss after 48 weeks of treatment.
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DISCUSSION
This is the fi rst detailed study comparing on-treatment serum HBsAg kinetics in 
patients with both HBeAg-positive and HBeAg-negative CHB receiving either PEG-IFN 
or ETV monotherapy. In HBeAg-positive patients, decline of HBsAg was signifi cantly 
associated with HBeAg loss, and, subsequently, HBsAg decline tended to be higher 
in PEG-IFN treated subjects compared to ETV-treated subjects (p=0.15). Interestingly, 
patients who achieved HBeAg loss during either PEG-IFN or ETV therapy demonstrated 
a similar reduction in HBsAg levels. In contrast, in HBeAg-negative patients, only treat-
ment with PEG-IFN resulted in a signifi cant HBsAg decline, whereas HBeAg-negative 
patients treated with ETV demonstrated no HBsAg reduction at all.
In HBeAg-positive patients, previous studies suggested that serum HBsAg levels 
gradually decrease during LAM and ADV therapy (2, 15). Our study indicates that a 
decline of HBsAg in HBeAg-positive CHB is primarily confi ned to ETV-treated patients 
with a baseline serum ALT >2 ULN, and can be attributed to a large extent to patients 
achieving HBeAg loss. This fi nding suggests that the presence of an active preexisting 
immune response against HBV is required to lower HBsAg levels for patients treated 
with ETV. In contrast to ETV, PEG-IFN is able to modulate immune reactivity itself (16), 
which is underlined by our observation that PEG-IFN therapy reduced serum HBsAg 
levels irrespective of baseline ALT level, yet was also mostly confi ned to patients who 
demonstrated HBeAg loss after one year of therapy. Even more interesting is that a 
similar decline of HBsAg was observed in patients who achieved HBeAg loss during 
either PEG-IFN or ETV therapy.
With regard to our fi ndings in HBeAg-negative patients, it has recently been demon-
strated by Brunetto et al. that serum HBsAg levels do not decrease during 48 weeks of 
LAM therapy (7). Despite the higher antiviral potency of ETV compared with LAM, ETV 
therapy for 48 weeks did also not result in a reduction of serum HBsAg in HBeAg-neg-
ative patients in our study. However, a study from Greece suggested that HBsAg levels 
decrease in HBeAg-negative patients during long-term LAM monotherapy, although at 
a signifi cantly slower rate compared with IFN (8). Thus, a longer duration of NA therapy 
may be required to reduce HBsAg levels in HBeAg-negative CHB. The study from 
Brunetto et al. also demonstrated a signifi cant on-treatment HBsAg decline of 0.71 log 
IU/mL in HBeAg-negative patients treated with PEG-IFN monotherapy for 48 weeks, 
which is somewhat higher compared with our study (0.56 log IU/mL) (7). This difference 
may be caused by the predominance of HBV genotypes B and C in their study popula-
tion. HBV genotype D was predominant among the HBeAg-negative patients treated 
with PEG-IFN in our study, therefore a direct comparison between different genotypes 
was not possible. However, the degree of HBsAg decline induced by PEG-IFN appears 
to be less pronounced in genotype D compared with other genotypes (7).
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Quantitative HBsAg in serum refl ects the cccDNA concentration in the liver, which 
plays a major role in viral persistence (2-4). It has been shown that ADV monotherapy 
is able to decrease intrahepatic cccDNA. Yet, when ADV was combined with PEG-
IFN, clearance of cccDNA was enhanced, and in contrast to ADV monotherapy, it also 
resulted in a strong reduction of HBs-antigen- and HBc-antigen-positive hepatocytes 
(3). Our study, in fact, confi rms previous observations that immune modulation is of 
vital importance to completely eradicate HBV. First, PEG-IFN resulted in higher HBeAg 
loss rates compared to ETV, and in signifi cant HBsAg decline in both HBeAg-negative 
and HBeAg-positive patients. Second, although ETV demonstrated to be an potent 
inhibitor of viral replication, a signifi cant decline of HBsAg was only observed in those 
patients with preexisting immune activity, refl ected by high baseline ALT levels, and 
in those patients who achieved HBeAg loss after one year of therapy. Moreover, in 
HBeAg-negative patients, ETV therapy did not even result in HBsAg decline at all.
Our study is limited by the suboptimal study design, which lacked the possibility to 
randomize at baseline, and therefore led to somewhat different patient characteristics 
between the two treatment groups at baseline. The higher rate of HBeAg loss among 
HBeAg-positive patients treated with PEG-IFN compared with ETV may partially be 
caused by the higher baseline ALT level and the slightly unbalanced distribution of HBV 
genotypes. However, for the analysis of HBsAg decline in HBeAg-positive patients we 
corrected for confounders such as HBV genotype, HBV DNA and age using multivari-
ate analysis, and performed a stratifi ed analysis for baseline ALT. Cirrhosis was not 
associated with HBsAg decline. Furthermore, it should be noted that the predictors 
of HBsAg decline in our study are exactly the same as the predictors of HBeAg loss 
identifi ed in previous studies, which only supports our fi nding that in HBeAg-positive 
patients reduction in HBsAg levels is largely confi ned to those patients achieving 
HBeAg loss during antiviral therapy (17-19). Within the HBeAg-negative population, 
the only independent factor that was associated with HBsAg decline was treatment 
regimen. No other baseline factors were related to HBsAg decline, and therefore have 
not infl uenced the study results.
In summary, in HBeAg-positive patients decline of serum HBsAg is largely confi ned 
to those patients that achieved HBeAg loss during antiviral therapy, either induced by 
PEG-IFN or ETV therapy. In HBeAg-negative patients PEG-IFN resulted in a signifi cant 
reduction in HBsAg levels, whereas ETV resulted in no HBsAg decline at all. No other 
factors were related to HBsAg decline in HBeAg-negative patients.
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ABSTRACT
Background
Flares in chronic hepatitis B are often detrimental but sometimes lead to sustained 
immune control and disease remission. The aim of this study was to estimate the 
frequency of hepatitis fl ares which occur during and/or after cessation of nucleos(t)ide 
analogue (NA) therapy, and to assess their outcomes.
Methods
In a single center cohort study we investigated 227 patients who received a total of 
351 NA treatment courses. NA therapy was discontinued after 149 treatment courses.
Results
In total, 27 fl ares were observed during 9,779 on-treatment patient-months. The 
frequency was estimated as 3.2 per 100 person-years (95% CI 2.2-4.7). Lamivudine-
treated patients demonstrated the highest frequency (4.9/100 person-years, 95% CI 
3.2-7.4). Twenty (74%) of 27 on-therapy fl ares were associated with development of 
genotypic resistance, which all occurred during lamivudine therapy. NA withdrawal 
fl ares occurred after a median post-treatment follow-up of 3.5 months in seventeen 
(11%) of 149 treatment discontinuations. No fl ares were observed in patients who 
switched to another antiviral agent (n=51). None of the on-therapy and withdrawal 
fl ares related to NA therapy were associated with sustained disease remission, and 
seven fl ares resulted in decompensated liver disease. Multivariate analysis demon-
strated a high baseline viral load to be an independent risk factor of on-treatment 
fl ares during NA therapy (RR 1.78; 95% CI 1.22-2.60; p = 0.004). No predictors for 
withdrawal fl ares could be indentifi ed.
Conclusions
In this study, fl ares related to NA therapy never led to immune control and sustained 
disease remission, and sometimes resulted in decompensated liver disease.
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INTRODUCTION
Exacerbation episodes of disease accompanied with abrupt elevation of serum amino-
transferase levels are commonly observed during the natural course of chronic hepa-
titis B (CHB). (1-2) These so-called hepatitis fl ares, refl ecting immune-mediated lysis 
of infected hepatocytes, may be followed by HBeAg seroconversion.(3-5) However, 
most fl ares only result in transient decreases in serum HBV DNA levels without loss of 
HBeAg. The frequency and severity of these fl ares are associated with an increased 
risk of progression to cirrhosis and hepatocellular carcinoma.(4, 6-7)
Similar exacerbation episodes are also observed during anti-HBV therapies, which 
include (pegylated) interferon (IFN) and nucleos(t)ide analogues (NA). IFN-induced 
fl ares affect 25-40% of patients and have been explained by the immunostimulatory 
properties of this drug, which increases the T cell cytolytic activity and natural killer 
cell function.(8) Typically, this kind of fl are occurs during the second to third month of 
treatment and may precede HBeAg-seroconversion in HBeAg-positive patients.(9-11) 
Furthermore, fl ares related to peginterferon therapy can be divided in host-induced, 
characterized by decrease in viral load and strongly associated with treatment 
response, and virus-induced fl ares, which are preceded by an increase in viral load 
and less often followed by treatment response.
Flares during NA therapy are primarily reported as results of emergence of therapy-
resistant HBV mutants.(12-16) After discontinuation of lamivudine (LAM) monotherapy 
hepatitis fl ares are observed in 10-20% of patients,(17-18) which can be associated 
with decompensated liver disease and fatal outcome.(18-20) However, the knowledge 
on NA-therapy related fl ares and their outcome is limited. The aim of this study was to 
estimate the frequency of hepatitis fl ares which occur during and/or after cessation of 
NA treatment, and to assess their clinical outcomes.
MATERIALS AND METHODS
Study population
In this single-centre cohort study, all consecutive adult chronic HBV patients who had 
received NA therapy for at least three months between 1993 and 2008 were included 
in this analysis. Patients were excluded if they (1) had received NA therapy combined 
with (pegylated) IFN, (2) received immunosuppressive medication, (3) had co-infection 
with hepatitis C, hepatitis D, or human immunodefi ciency virus, or (4) had other causes 
of liver disease.
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Follow-up
All subjects were monitored every 3-6 months. At every visit routine examination with 
biochemical (ALT, bilirubin, albumin, creatinin) and virologic (HBV DNA level, HBeAg, 
anti-HBe) assessments took place. Genotypic analysis was done in case of virologic 
breakthrough, defi ned as an increase in serum HBV DNA level > 1 log10 (10-fold) above 
nadir after initial virologic response. HBV genotype was determined in all patients.
End points
A fl are was defi ned as an abrupt elevation of serum ALT levels over 10 times the upper 
limit of normal (ULN) and at least twice the ALT level just prior to the occurrence of 
the fl are.(21) It was categorized as on-therapy fl ares (occurring during treatment) or 
withdrawal fl ares (occurring within 6 months after discontinuation of NA agents). To 
classify the outcome of a fl are, the following end points were considered: HBsAg loss 
and seroconversion, HBeAg loss and seroconversion for HBeAg-positive patients, ALT 
normalization, undetectable HBV DNA, and decompensation of liver disease. Decom-
pensated liver disease was defi ned as any of the following signs newly developed: 
(1) ascites, (2) persistent jaundice (serum bilirubin > 34 µmol/l, no normalization after 
serum ALT normalized), (3) hypoalbuminemia (serum albumin < 28 g/l), (4) international 
normalized ratio (INR) > 2.2, (5) encephalopathy and/or (6) variceal bleeding.(21) An 
end point was considered to be related to a fl are, if it occurred within 6 months after 
the start of the fl are.
Laboratory tests
Serum alanine aminotransferase (ALT) was measured using automated techniques. 
Hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and anti-body 
against HBeAg (anti-HBe) were determined using commercially available enzyme 
immunoassays. Serum HBV DNA levels were measured using a previously described 
in house developed quantitative real-time polymerase chain reaction (PCR).(22-23) 
Currently, this assay is multiplexed without compromising the lower limit of detection 
(373 copies/mL) with an internal control (pHHV) in order to control the process from 
DNA isolation through PCR.(24) HBV DNA was extracted from serum samples using 
the MagnaPureLC (Roche Applied Science, Almere, The Netherlands) as described 
before.(22) HBV genotypes were assessed by sequence alignment of the overlapping 
hepatitis B surface antigen with HBV sequences derived from GenBank. Presence of 
HBV polymerase gene mutations was determined using InnoLiPA DR2 and DR3 line 
probe assay (Innogenetics, Gent, Belgium).
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Statistical analysis
Continuous variables are expressed as means ± SD or median (range) where appropri-
ate. We calculated the incidence rate of fl ares per person-year overall to measure the 
frequency. In calculations of incidence rates, patients could be included in multiple 
time periods, and could contribute more than one fl are in each time period. Pois-
son regression model was used to estimate and compare the incidence rate(25). All 
statistical testing was two-tailed at the 5% level. In order to determine independent 
predictors for the risk of fl ares, the baseline characteristics such as age, race, sex, 
pre-existing cirrhosis, ALT, log10 HBV DNA, HBV genotype, treatment regimen were 
included in the univariate analysis. All tested variables with a p value < 0.15 were 
entered in the multivariate regression analysis assuming a Poisson distribution. The 
analysis softwares used were the Statistical Package for Social Science (SPSS, version 
14.0, SPSS Inc. Chicago, Ill., USA) and Science Analysis Software (SAS, version 9.13; 
SAS Institute Inc., Cary, NC, USA).
RESULTS
Study population
Overall, 227 patients received a total of 351 nucleos(t)ide analogues (NA) treatment 
courses (136 LAM monotherapy; 96 adefovir dipivoxil (ADV); 22 tenofovir disiproxil 
fumarate (TDF); 77 entecavir (ETV); 4 LAM-ADV and 16 LAM-TDF combination therapy) 
and were included in this study. Median duration of every single treatment period was 
19 months (range 3-113). Of the 227 patients, 173 (76%) were male, and the mean 
age at baseline was 39±14 years. The most common virus genotypes were A (27%) 
and D (36%) (table 1). Therapy was discontinued or changed to another type of agent 
214 times within 149 patients. Sixty-one percent of them changed to another type 
of regimen because of development of resistance to the drug. The reason of therapy 
discontinuation/switch did not show a relation with off-therapy fl are occurrence (p = 
0.542). In fi ve subjects, there was no six months of follow-up available, two patients 
stopped treatment because of HBsAg seroconversion, and seven patients died at the 
end of treatment course. Hence, 200 courses (LAM 126, ADV 60, ETV 3, TDF 11, 
LAM+ADV 1) after which therapy was discontinued (n=149) or changed to another type 
of agent (n=51) were available to explore the frequency and outcome of withdrawal 
fl ares.
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Frequency of fl ares
In 23 (7%) of 351 treatment courses (9,779 on-treatment patient-months) at least one 
fl are was observed. During three treatment courses multiple fl ares occurred, resulting 
in a total of 27 (8%) on-therapy fl ares. Figure 1 shows the frequency of on-therapy 
fl are, which was 27/9,779 on-treatment patient-months, and was estimated as 3.2 
per 100 person-years (95% CI 2.2-4.7). Patients treated with LAM demonstrated the 
highest frequency (22/5,501 on-treatment patient-months: 4.9/100 person-years, 95% 
CI 3.2-7.4). The lowest frequency was observed in ADV-treated patients (1/2,913 on-
treatment patient-months: 0.4/100 person-years, 95% CI 0.06-3.0). Median peak ALT 
level was 20 x ULN (range 10-125 x ULN). Twenty (74%) of 27 on-therapy fl ares were 
associated with development of genotypic resistance, which all occurred during LAM 
therapy.
Outcomes of fl ares
The outcome of fl ares is presented in table 2. Undetectable HBV DNA and/or HBeAg 
loss was not achieved after any of the fl ares. In contrast, three of six patients who 
Table 1 Baseline characteristics
Number of patients 227
Mean age (yr) 39±14
Male – no. (%) 173 (76)
Race – no. (%)
 Asian 67 (30)
 Caucasian 128 (56)
 Other 30 (13)
Viral genotype – no. (%)
 A 61 (27)
 B 38 (17)
 C 33 (15)
 D 81 (36)a
 Other 13 (6)
Number of treatment courses 351
Courses of NAb therapy – no. (%)
Lamivudine 136 (39)
Adefovir dipivoxil 96 (27)
Tenofovir 22 (6.3)
Entecavir 77 (22)
Lamivudine + adefovir dipivoxil 4 (1.1)
Lamivudine + tenofovir 16 (4.6)
a One patient was co-infected with genotype G.
b NA, nucleos(t)ide analogues
Jurrien BW.indd   48 19-Oct-10   11:34:44 AM
Frequency and clinical outcome of nucleos(t)ide analogue-related fl ares 49
achieved HBeAg seroconversion before a fl are had HBeAg reversion during the fl are. 
Twelve fl ares were followed by ALT normalization which was sustained for at least six 
months. Four fl ares were associated with an episode of decompensation, and two 
patients died subsequently of liver failure.
Rate of on-therapy flare
4.9
0.4
2.6
3.2
0
1
2
3
4
5
6
LAM ADV ETV&TDF&COMB OVERALL
p = 0.26
p = 0.016
number of flare      22                          1              4                           27
patient years 412                        238                         151 801
(on treatment)
Figure 1 Frequency of on-therapy fl are for different type of nucleos(t)ide analogue treatment. pys, 
person-years. Other, nucleos(t)ide analogue treatments with low resistance profi le which consist 
of ETV, TDF, combination of LAM and ADV and combination of LAM and TDF.
Table 2 Characteristics of fl ares
On-therapy Withdrawal
Number of fl aresa 27 17
Number of patientsa 23 16
Median peak ALT level (x ULN) 20 (10-125) 17 (11-81)
Genotypic resistance (%) 20 (74.1) NA
HBeAg loss before fl aresb 6/21 7/16
Outcome of fl ares
 HBeAg reversion during fl aresb 3/6 5/7
 HBeAg loss after fl aresb 0/18 0c/14
 Undetectable HBV DNA (<373 c/mL) 0/27 0c/17
 Sustained serum ALT normalization 12/27 4/17
 Decompensation of liver disease 4d/27 3/17
 Death 2d/27 0/17
a Some patients experienced multiple fl ares during the same treatment period.
b 21 and 16 patients had positive HBeAg at the start of treatment. In some patients HBeAg loss 
occurred before a fl are, but HBeAg reappeared during a fl are.
c Only patients who restarted antiviral therapy demonstrated HBeAg loss and/or undetectable 
HBV DNA.
d Two patients had an episode of decompensation, and died subsequently of liver failure.
NA= not applicable
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Withdrawal fl are
Frequency of fl ares
After 149 treatment courses in which antiviral therapy was discontinued, seventeen 
(11%) withdrawal fl ares (16 after discontinuation of LAM, 1 after ADV) occurred after 
a median follow-up of 3.5 (range 1- 7.3) months. No fl ares were observed in patients 
who switched to another antiviral agent (n=51). The frequency of withdrawal fl are was 
17/852 follow-up patient-months, which was estimated as 24 per 100 person-years 
(95% CI 16-38). The highest frequency was observed in patients who discontinued 
LAM monotherapy (16/610 follow-up patient-months: 32 per 100 person-years, 95% 
CI 19.5-51.5) (Figure 2).
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Figure 2 Frequency of withdrawal fl ares among patients who discontinued nucleos(t)ide analogue 
therapy.
Outcomes of fl ares
Rescue treatment was started within ±1 month after 11 (65%) of 17 withdrawal fl ares. 
None of the fl ares resulted in HBeAg loss or undetectable HBV DNA, and only four 
fl ares were followed by ALT normalization which was sustained for at least 6 months 
in the absence of antiviral therapy. HBeAg reversion occurred during a fl are among 5/7 
(71%) patients who had achieved HBeAg loss before the exacerbation episode. Fur-
thermore, an episode of mild jaundice was observed during three (18%) fl ares. (table 2)
Risk factor of fl ares
Most on-therapy fl ares were associated with the development of genotypic resistance 
to NA regimens. The relative risk was estimated as 9.05 (resistance vs. non-resistance, 
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95% CI: 3.65-22.42, p<0.001). Multivariate analysis demonstrated that on-therapy 
fl ares occurred more often amongst patients who had a high baseline HBV DNA (RR 
1.78; 95% CI 1.22-2.60; p = 0.004) and were treated by LAM compared to ADV (RR 
0.09; 95% CI 0.01–0.64; p = 0.016) (table 3). Higher baseline viral load and an inferior 
genotypic barrier to resistance profi le of NA agents were also predictors for risk of 
genotypic resistance in Poisson regression analysis, which further confi rmed them to 
be predictors of on-therapy fl ares. No predictors for withdrawal fl ares could be indenti-
fi ed. Neither an association between on-therapy and withdrawal fl ares was found.
DISCUSSION
This is the fi rst study which extensively evaluated the characteristics and outcome of 
hepatitis fl ares related to NA therapy in chronic hepatitis B. In our study, the frequency 
of on-therapy fl ares was 3.2% per year, and 11% of patients who discontinued NA 
therapy, experienced a withdrawal fl are. The highest frequency of on-therapy fl ares was 
observed in LAM-treated subjects, and the majority of on-therapy fl ares were associ-
ated with the development of antiviral drug resistance. Similarly, the highest frequency 
of withdrawal fl ares was observed in patients who discontinued LAM monotherapy as 
well. None of the on-therapy and withdrawal fl ares related to NA therapy were associ-
ated with a benefi cial outcome. High baseline viral load was an independent risk factor 
of on-treatment fl ares. No predictors for withdrawal fl ares could be identifi ed.
Prospective studies on the natural history estimated the incidence of spontaneous 
fl ares for chronic HBV infection 10-27% per year.(26) HBeAg-seroconversion is 
often preceded by these hepatitis fl ares; however, most fl ares only result in transient 
decreases in serum HBV DNA levels without loss of HBeAg.(3) Previous studies indi-
cated that IFN-induced fl ares affect 25–40% of HBeAg-positive patients. Furthermore, 
it was demonstrated that especially host-induced fl ares, characterized by a decrease 
in viral load, were associated with treatment response, and can herald HBeAg loss or 
even HBsAg loss.(9-11) In our study, the frequency of fl ares during NA therapy was 
estimated as 3.2% per year, which is lower than the frequency observed in studies on 
Table 3 Risk factors of on-therapy fl ares
Parameters aRR (95%CI) p-value
HBeAg positivity 1.01 (0.27 - 2.79) 0.98
Baseline HBV DNA (per log10 increase) 1.78 (1.22 - 2.60) 0.003
Baseline ALT (>2×ULN vs. <2×ULN) 1.84 (0.81 - 4.14) 0.14
Treatment regimen
 LAM 1.00 reference
 ADV 0.11 (0.01 - 0.80) 0.03
 ETV/TDF/COMB 0.74 (0.25 - 2.22) 0.59
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the natural history and studies in which (pegylated) IFN was used. The majority of these 
on-therapy fl ares were associated with the development of antiviral drug resistance 
and thus also associated with LAM therapy. In contrast to IFN-induced fl ares, on-
treatment fl ares during NA therapy in our study appeared to be mostly virus-induced 
and none of them were associated with a benefi cial outcome. Four fl ares resulted in an 
episode of hepatic decompensation.
Withdrawal fl ares have been observed after cessation of both peginterferon and LAM 
monotherapy.(18-20, 27) It occurred in 22% of patients after discontinuation of pegin-
terferon monotherapy, and only few of them resulted in virologic response.(27) After 
cessation of lamivudine monotherapy, 10-20% of patients experienced withdrawal 
fl ares, which have been associated with decompensated liver disease and fatal out-
come.(18-20) In our study, 11% of patients developed a fl are after cessation of NA 
therapy. Flares were more often seen after discontinuation of LAM monotherapy com-
pared to other anti-HBV agents, although this is probably related to recent guidelines 
which indicate when and in which patient it is safe to stop antiviral therapy.(28-29) In 
contrast, no fl ares were observed if patients were directly switched to another antiviral 
agent. None of the fl ares resulted in sustained disease remission, and three fl ares 
were accompanied by an episode of mild jaundice. As all these fl ares seemed to have 
a detrimental outcome, close monitoring of patients who for any reason discontinue 
NA therapy is warranted, and rapid re-initiation of antiviral therapy is recommended. 
Furthermore, the importance of treatment compliance should be stressed to all HBV 
patients on oral anti-HBV agents.
A limitation of our study is that most patients were treated with LAM monotherapy. One 
might hypothesize that the frequency of on-therapy fl ares will be lower during ETV or 
TDF monotherapy due to their excellent resistance profi les.(30-31) Furthermore, the 
frequency of withdrawal fl ares may also be somewhat overestimated, as the current 
guidelines recommend, that in HBeAg-positive patients treatment can only be stopped 
after HBeAg-seroconversion with at least six months of consolidation treatment. In 
HBeAg-negative patients discontinuation may only be possible after HBsAg clearance.
(28-29)
In conclusion, the frequency of fl ares during NA therapy was approximately 3% per 
year. As the majority of on-therapy fl ares was associated with the development of 
antiviral drug resistance, the frequency will probably decrease when anti-HBV agents 
with good resistance profi les are used. A withdrawal fl are was observed in 11% of 
patients who discontinued NA therapy. In this study, fl ares associated with NA therapy 
appeared to be virus-induced, never led to sustained disease remission, and even 
resulted sometimes in decompensated liver disease. Therefore, close monitoring of 
patients who discontinue NA therapy is warranted, and the importance of treatment 
compliance should be stressed to all HBV patients on oral anti-HBV agents.
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ABSTRACT
Background
We investigated the long-term effi cacy and renal safety of tenofovir disoproxil fumarate 
(TDF), administered to patients co-infected with HIV and hepatitis B virus (HBV) as a 
part of anti-retroviral therapy.
Methods
We performed a multicenter, prospective cohort study of 102 patients co-infected with 
HIV and HBV who were treated with TDF.
Results
At baseline, 80% of patients had a detectable viral load (HBV DNA>20 IU/mL). Among 
patients positive for hepatitis B e antigen (HBeAg, n=67), 92% had a virologic response 
(HBV DNA < 20 IU/mL) after 5 years of treatment. There was no difference between 
patients with or without lamivudine-resistance at baseline (P=0.39). Loss rates of 
HBeAg and hepatitis B s antigen (HBsAg) were 46% and 12%, respectively. Among 
HBeAg-negative patients (n=15), 100% had a virologic response after 4 years of 
treatment and 2 (13%) lost HBsAg. Twenty subjects (20%, all HBeAg-negative) had 
undetectable HBV DNA at baseline; during a median follow-up of 52 months (41–63 
months), 19 (95%) maintained a virologic response and 2 (10%) lost HBsAg. Overall, 
one patient acquired a combination of resistance mutations for anti-HBV drugs and 
experienced a virologic breakthrough. Three (3%) patients discontinued TDF because 
of increased serum levels of creatinin. The estimated decrease in renal function after 
5 years of TDF therapy was 9.8 mL/min/1.73m2, which was most pronounced shortly 
after TDF therapy was initiated.
Conclusions
TDF, administered as part of anti-retroviral therapy, is a potent anti-HBV agent with 
a good resistance profi le throughout 5 years of therapy. Only small, non-progressive 
decreases in renal function were observed.
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INTRODUCTION
Tenofovir disoproxil fumarate (TDF) was licensed for the treatment of human immu-
nodefi ciency virus (HIV) infection in 2001, and plays since then a pivotal role in HIV 
management. Currently, the combination of TDF and emtricitabine is the most widely 
prescribed nucleos(t)ide analogue reverse transcriptase inhibitor (NRTI) backbone in 
Europe. Because HIV and hepatitis B virus (HBV) share similar routes of transmission, 
prevalence of HBsAg-carriership is more than fi ve-fold higher among HIV-infected 
patients compared to the general population.(1-2) Furthermore, HIV/HBV co-infected 
patients are at increased risk for development of cirrhosis and hepatocellular carci-
noma, and have higher overall mortality rates compared to HIV monoinfected patients.
(3-6)
The effi cacy of TDF in HBV therapy was fi rst described in studies including mainly 
patients with HIV-1 co-infection.(7-11) Recent data showed the effi cacy of TDF in the 
treatment of chronically HBV-monoinfected patients as well.(12) TDF was superior to 
adefovir dipivoxil in both nucleos(t)ide-naïve HBeAg-positive and HBeAg-negative 
HBV patients, and appeared to be one of the most potent anti-HBV agents so far. 
Several reports showed that TDF was also effective in the nucleos(t)ide-experienced 
population, although confl icting results have been presented concerning patients with 
genotypic resistance to adefovir dipivoxil.(13-16) Moreover, TDF has a good resistance 
profi le, and no convincing proof of HBV-resistant mutants to TDF has been presented 
so far.(17)
Long-term therapy is indicated for all HIV/HBV co-infected and most HBV mono-
infected patients treated with oral nucleos(t)ide analogues, as a sustained response 
after cessation of therapy is rare.(18-19) However, follow-up in studies investigating 
the effi cacy of TDF in HIV/HBV-coinfected and HBV-monoinfected patients is limited to 
only two years. In addition, there are concerns about the risk of renal toxicity with TDF.
(20-25) We investigated the long-term effi cacy and renal safety of TDF administered as 
a part of anti-retroviral therapy in a large cohort of HIV/HBV-coinfected patients.
MATERIALS AND METHODS
Study population
Six Dutch centers specialised in HIV management participated in this multicenter 
cohort study. From 2001 to July 2006 all consecutive adult HIV-infected patients posi-
tive for hepatitis B surface antigen (HBsAg) for more than six months, and treated with 
TDF as a part of anti-retroviral therapy for at least six months were included. Patients 
were excluded if they had hepatitis C or hepatitis delta co-infections, or received 
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concomitant treatment with (pegylated) interferon during the on-treatment follow-up 
period. Patients were categorized to those with or without the presence of detectable 
HBV-DNA at baseline
Follow-up
Virologic, haematological and biochemical parameters were recorded at least at 
6-month intervals in the fi rst two years of follow-up and at yearly intervals thereafter. 
At every visit routine examination with measurement of serum alanine aminotransfer-
ase (ALT), creatinin, CD4 cell count, serum HIV RNA, serum HBV DNA, HBeAg, and 
anti-HBe took place. HBsAg status was measured in case of the combined presence 
of undetectable HBV DNA and negative HBeAg. A mutation analysis was done (a) 
at baseline in all lamivudine (LAM)-experienced HBV patients, (b) in case of virologic 
breakthrough, defi ned as an increase in serum HBV DNA level > 1 log10 (10-fold) above 
nadir on at least two occasions after initial virologic response, or (c) in case of serum 
HBV DNA > 200 IU/mL at the end of follow-up. HBV genotype was determined at 
baseline. At baseline, the diagnosis of cirrhosis was based on the treating physician’s 
judgment. Abdominal ultrasound was performed if there was clinical suspicion of pro-
gression to cirrhosis, development of decompensated liver disease or hepatocellular 
carcinoma.
Endpoints
The primary outcome was virologic response (VR), defi ned as serum HBV DNA levels < 
20 IU/mL during the on-treatment follow-up period. Secondary endpoints were HBsAg 
loss, HBeAg loss for HBeAg-positive patients, ALT normalization, and emergence of 
antiviral resistant mutations. Progression to cirrhosis was defi ned on clinical grounds, 
that is, albumin level < 3,5 g/dL, platelet count < 100,000 mm3, clinical decompen-
sation, and ultrasound demonstration of surface nodularity, splenomegaly, and > 
15-mm portal vein diameter. Clinical decompensation was defi ned as development 
of ascites, encephalopathy, jaundice, or gastro-intestinal bleeding, defi ned to interna-
tionally agreed criteria.(26) Renal function was assessed by monitoring the estimated 
glomerular fi ltration rate (eGFR) in mL/min/1.73 m2, which was calculated using the 
Modifi cation in Diet in Renal Disease (MDRD) equation, based on the serum creatinin, 
age, sex and race.
Laboratory tests
Serum alanine aminotransferase (ALT), and creatinin levels were measured using 
automated techniques. Absolute numbers of CD4 T lymphocytes were assessed 
on whole blood by fl owcytometry. Hepatitis B surface antigen (HBsAg), hepatitis B 
e antigen (HBeAg), and antibody against HBeAg (anti-HBe) were determined using 
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commercially available enzyme immunoassays. HIV-RNA was quantitatively assessed 
with the Cobas Ampliprep/Cobas Amplicor version 1.5 (Lower limit of detection: 50 
copies/mL; Roche Molecular Systems, Penzberg, Germany). HBV DNA was quantifi ed 
in serum as previously described.(27-28) The lower limit of this assay was recently 
determined at 20 IU/mL by probit analysis (M. Schutten, unpublished results). HBV 
genotype was determined by Sanger sequencing on a 752 basepair fragment in the 
S gene as previously described.(29) Antiviral resistance associated mutations were 
determined using the Inno-LIPA HBV DR v2 (Innogenetics NV, Zwijnaarde, Belgium) 
for highly sensitive detection of mutant species and by Sanger sequencing of the HBV 
reverse transcriptase gene to detect mutations not present on the Inno-LIPA HBV DR 
v2 (rtT184, rtA194, rtS202, rtI233, rtM250).
Statistical analysis
Continuous variables are expressed as means ± standard deviation or median (inter-
quartile range) where appropriate. Continuous variables were compared using the 
t-test or the Mann-Whitney test. Categorical variables were compared using the Chi-
square or Fisher’s exact test. Follow-up times were calculated from the date of TDF 
treatment initiation to the date of event or censorship. The cumulative probabilities of 
virologic response, HBeAg loss and HBsAg loss during treatment were calculated by 
the Kaplan-Meier method. Survival analysis with Cox regression model was used to 
analyze which baseline factors were associated with virologic response in patients with 
a detectable HBV DNA at baseline (n=82). Changes in creatinin during treatment were 
analyzed with a repeated measurement model estimating an overall smooth quadratic 
decline while allowing for a random intercept and a decline per patient. All statistical 
tests are two-sided, and a p-value < 0.05 was considered to be statistically signifi cant. 
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) and SAS version 9.2 (SAS Institute 
Inc., Cary, NC, USA) were used for all statistical analysis.
RESULTS
Baseline characteristics of the study population are presented in table 1. A total of 
102 patients were included in this analysis. Ninety-two (90%) subjects were men and 
the mean age was 42±8.9 years. The treatment regimens that were used in addition to 
TDF were for most patients either a NRTI and a non-NRTI regimen (64%) or a NRTI and 
ritonavir boosted protease inhibitor regimen (24%). During the on-treatment follow-up 
all patients received concomitant treatment with either LAM or emtricitabine. Median 
follow-up of the whole study population was 55 (42-64) months.
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Virologic response in patients with detectable HBV DNA at baseline
Of 82 patients with detectable HBV DNA at baseline, 67 (82%) subjects were HBeAg-
positive at the initiation of TDF, and the mean HBV DNA was 7.0±2.1 log10 IU/mL. Fifty 
(61%) patients were previously treated with LAM for a median duration of 42 (22-74) 
months. TDF was added to LAM therapy as a second anti-HBV drug in 45 (90%) of 
50 patients and in 5 patients LAM was reintroduced in combination with TDF. In 33 
(66%) subjects LAM-resistant mutations could be detected at the initiation of TDF. 
During a median follow-up of 56 (43-64) months, 72 (88%) patients achieved VR. For 
HBeAg-positive patients (n=67), the cumulative probability of achieving VR at 1, 2, 3, 4 
and 5 years of treatment was 31%, 70%, 83%, 88%, and 92%, respectively (fi gure 1). 
Table 1 Baseline characteristics
Detectable HBV 
DNA
Undetectable HBV 
DNA
P - value
N=82 N=20
Age 42±8.7 43±10 0.68
Gender (male %) 77 (94%) 15 (75%) 0.02
Race 0.04
 Caucasian 54 (66%) 8 (40%)
 Black 18 (22%) 10 (50%)
 Other 10 (12%) 2 (10%)
BMI 23±5.2 25±3.4 0.31
ALT (xULN) 1.6 (1.0-2.7) 0.7 (0.4-1.0) < 0.001
HBV DNA (Log10 IU/ml) 7.0±2.1 UD* < 0.001
HBeAg-positive 67 (82%) 0 (0%) < 0.001
Genotype (N=81) 0.15
 A 47 (62%) 5 (100%)
 other 29 (38%) 0 (0%)
Presence cirrhosis 12 (15%) 2 (10%) 0.66
CD4 count 285 (120-473) 320 (155-460) 0.68
HIV RNA (Log10 copies/mL) 3.1±1.6 2.0±1.3 0.002
Creatinin (mg/dL) 0.86±0.17 0.88±0.19 0.66
eGFR (mL/minute) 106±31 102±30 0.62
Treatment regimen 0.41
 2 NRTI + 1 NNRTI 50 (61%) 15 (75%)
 2 NRTI + PI/r 20 (24%) 4 (20%)
 Other 12 (16%) 1 (5%)
Concomitant anti-HBV therapy 0.26
 Lamivudine 77 (94%) 20 (100%)
 Emtricitabine 5 (6%) 0 (0%)
Previous anti-HBV therapy
 LAM-experienced 50 (61%) 18 (90%) 0.02
 LAM-resistance at baseline 33 (40%) 0 (0%) < 0.001
 Duration of LAM therapy# 42 (22-74) 45 (24-64) 0.73
*Undetectable; # Months
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There was no signifi cant difference between patients with or without LAM-resistance 
at baseline (p = 0.39) (fi gure 2). In univariate analysis only HBeAg negativity at base-
line demonstrated a trend towards a higher chance of achieving undetectable HBV 
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Figure 1 Kaplan-Meier curve for the cumulative probabilities of achieving virologic response, 
defi ned as HBV DNA < 20 IU/mL, for HBeAg-positive (n = 67) and HBeAg-negative (n = 15) HIV/
HBV with patients with detectable HBV DNA at baseline (n = 82).
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Figure 2 Kaplan-Meier curve for the cumulative probabilities of achieving virologic response, defi ned 
as HBV DNA < 20 IU/mL, for HIV/HBV patients with detectable HBV DNA at baseline (n = 82) with 
lamivudine-resistant (n = 33) or no lamivudine-resistant mutations (n = 49) at the initiation of TDF.
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DNA (p = 0.09). Loss rates of HBeAg and HBsAg were 46% and 12%, respectively, 
after 5 years of TDF therapy. For HBeAg-negative patients (n=15), the cumulative 
probability of achieving VR at 1, 2, 3 and 4 years of treatment was 47%, 85%, 85% 
and 100%, respectively (fi gure 1). During follow-up 2 (13%) of 15 HBeAg-negative 
patients achieved HBsAg loss. Of 59 patients with elevated ALT levels at baseline, 46 
(78%) demonstrated ALT normalization at the end of follow-up. Three (4%) patients 
experienced a virologic breakthrough during the observation period. In two subjects 
no genotypic resistance could be detected; one patient demonstrated the combined 
presence of rtM204I, rtL80I, rtL180M, and rtA181V in the HBV polymerase gene (fi gure 
3B).
Virologic response in patients with undetectable HBV DNA at baseline
Twenty patients (100% HBeAg-) had undetectable HBV DNA at baseline. Two patients 
were treatment-naïve; 18 patients were pretreated with LAM for a median duration 
of 38 (24-64) months, in whom all TDF was added as a second anti-HBV drug per 
internal protocol. During a median follow-up of 52 (41-63) months 19 (95%) subjects 
maintained virologic response, and two (10%) patients showed HBsAg loss. One (5%) 
subject experienced a virologic breakthrough after which a hepatocellular carcinoma 
was diagnosed. No genotypic resistance could be detected.
HBV resistance surveillance
During a median follow-up of 55 (42-64) months nine of 67 (13%) HBeAg-positive 
and one of 15 (7%) HBeAg-negative patients with a detectable HBV DNA at base-
line did not achieve virologic response. Of these ten subjects, three experienced a 
virologic breakthrough as well. One of 20 patients with undetectable HBV DNA at 
baseline demonstrated a virologic breakthrough. None of the subjects with a virologic 
breakthrough demonstrated LAM-resistant mutations at baseline. In two patients 
non-adherence was suspected, as a simultaneous rebound HIV RNA was observed. 
A hepatocellular carcinoma was diagnosed in the other two patients, of whom one 
Figure 3 Clinical course of three patients who developed hepatocellular carcinoma throughout 
follow-up. Two patients demonstrated a virologic breakthrough as well.
A. #: MRI abdomen demonstrated diffuse hepatocellular carcinoma in segment 4-8, with infi ltra-
tion of the portal vein. In addition, there was a focal lesion in segment 2 with a diameter of 8mm, 
suspicious for hepatocellular carcinoma. *: Mutation analysis demonstrated wild-type hepatitis B 
virus
B. #: MRI abdomen demonstrated a focal lesion in segment 4a, suspicious for hepatocellular 
carcinoma with a diameter of 3.3 cm, for which he received treatment with radio-frequent abla-
tion. After 36 months recurrent hepatocellular carcinoma was diagnosed.
C. #: MRI abdomen demonstrated a focal lesion in segment 8, suspicious for hepatocellular carci-
noma, with a diameter of 13 cm. Two other focal lesions, suspicious for hepatocellular carcinoma 
were observed in segment 2 and 3, with a diameter
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subject also demonstrated multiple anti-HBV drug-resistant mutations (rtM204I, 
rtL80I, rtL180M, and rtA181V). Of the patients with a detectable viral load at the end 
of follow-up without fulfi lling the criteria of virologic breakthrough (n=7), four subjects 
showed LAM-resistance at baseline, and in one patient these substitutions persisted 
throughout the observation period. No therapy-resistant mutations were observed in 
the other patients at the end of follow-up.
Progression of hepatitis B and survival
Of the 14 cirrhotic patients at baseline, 3 developed de novo hepatocellular carci-
noma after 10-32 months (fi gure 3), and two subjects decompensated liver disease 
after 42 and 48 months of follow-up, respectively. In total, four patients died due to 
hepatocellular carcinoma progression (n=3) or complications related to end-stage liver 
disease (n=1). Of the 88 non-cirrhotic patients, none progressed clinically to cirrhosis 
or developed de novo hepatocellular carcinoma. Three patients died because of HBV-
unrelated causes.
Entecavir as rescue therapy in patients with persisting HBV replication
In four patients who demonstrated persistent HBV replication during antiviral therapy, 
entecavir (ETV) (dosed at 1 mg once daily) was added to the treatment regimen as 
rescue therapy (table 2). Patients were compliant with the treatment regimen, which is 
supported by the undetectable HIV RNA levels in these four patients at the moment 
ETV was added. The addition of ETV resulted in undetectable HBV DNA in all subjects 
after 3-15 months of follow-up; one patient also achieved HBeAg loss.
HIV RNA and CD4 cell count changes
At the initiation of TDF, the mean HIV RNA was 2.9±1.6 log10 copies/mL, and 51 
patients (50%) demonstrated serum HIV RNA < 50 copies/mL. At the end of follow up a 
signifi cantly increased proportion of patients (84%; p < 0.001) demonstrated undetect-
able HIV RNA. The median CD4 cell count increased from 293 (138-470) cells/mm3 at 
baseline to 455 (340-643) cells/mm3 at the end of follow-up (p < 0.001).
Renal safety
Two patients (2%) experienced an increase in serum creatinin > 0.5 mg/dL after 5 
(peak creatinin level: 1.5 mg/dL; eGFR: 54 mL/min) and 16 (peak creatinin level: 2.2 
mg/dL; eGFR: 32 mL/min) months of follow-up, respectively. In both patients TDF was 
stopped, after which serum creatinin levels stabilized, but did not return to normal in 
both patients. One additional subject TDF was discontinued after 45 months because 
of an increase in serum creatinin of 0.38 mg/dL from baseline. The mean eGFR at 
baseline was 105±30 mL/min/1.73m2. The estimated decrease after fi ve years of TDF 
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therapy was 9.8 (95%CI: 5.4 – 14.2) mL/min/1.73m2. The major part of decline in renal 
function occurred shortly after initiation of TDF therapy (p = 0.02), and was observed 
especially in those subjects with a baseline eGFR > 100 mL/min/1.73m2 (p < 0.001). 
The use of ritonavir-boosted protease inhibitors was not related to decline in eGFR. (p 
= 0.60).
DISCUSSION
This is the fi rst study to assess the long-term effi cacy of TDF administered as part of 
anti-retroviral therapy in a large cohort of HIV/HBV-coinfected patients. Previous stud-
ies on the effi cacy of TDF in both HIV/HBV-coinfected and HBV-monoinfected patients 
were limited by a relatively short follow-up period for up to two years.(7-8, 12, 14) In 
our study, there is a median follow-up of almost fi ve years, and, moreover, it presents 
the largest cohort of HIV/HBV-coinfected patients treated with TDF so far. It is shown 
that after fi ve years of follow-up, approximately 90% of patients achieved undetectable 
Table 2 Summary of patients with persistent HBV replication in whom entecavir was added as 
rescue therapy
Patient 1 Patient 2 Patient 3 Patient 4
Age (years) 26 43 41 37
Gender male male male male
Previous therapy with LAM no yes yes no
At start of tenofovir
 HBeAg status positive positive positive positive
 HBV DNA (log10 IU/mL) 8.9 7.3 7.8 8.2
 HIV RNA (log10 copies/mL) 4.6 3.5 UD 3.5
 HBV Genotype A A A A
 Concomitant anti-HBV therapy LAM LAM LAM FTC
Virologic breakthrough no no no no
At time of initiation of entecavir
 Month of follow-up 42 48 48 15
 HBV DNA (log10 IU/ml) 5.3 3.3 4.2 4.2
 HBeAg status positive positive positive positive
 HIV RNA (log10 copies/mL) UD UD UD UD
 Mutation analysis wild-type wild-type wild-type wild-type
 Non-compliance no no no no
Response to salvage therapy
Salvage therapy
Addition of 
ETV
Addition of 
ETV
Addition of 
ETV
Addition of 
ETV
Follow-up (months) 15 27 15 12
 HBV DNA (log10 IU/mL) at last F/U UD UD UD UD
 HBeAg status at last F/U positive negative positive positive
UD = Undetectable; F/U = Follow-up
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HBV DNA (< 20 IU/mL), almost 50% of HBeAg-positive patients demonstrated HBeAg 
loss, and HBsAg loss was even observed in approximately 10% of subjects. There was 
no signifi cant difference between patients with or without LAM-resistance at baseline. 
More importantly, only one patient demonstrated a combination of known anti-HBV 
drug-resistant mutations, and experienced a virologic breakthrough thereafter. In three 
patients TDF was discontinued because of increases of serum creatinin levels. The 
estimated decrease in renal function after at fi ve years of TDF therapy was approxi-
mately 10 mL/min/1.73m2, and was most pronounced directly after initiation of TDF 
therapy.
The widespread use of highly active anti-retroviral therapy (HAART) has signifi cantly 
increased the life expectancy of HIV-infected patients, and liver disease has now 
emerged as a signifi cant cause of non-AIDS-related death.(3, 5) A large prospective 
cohort study demonstrated active HBV infection to be strongly associated with liver-
related mortality.(3) Current guidelines recommend, therefore, inclusion of HBV-active 
agents within the HAART regimen, and to initiate HAART early if an indication to treat 
HBV infection exists.(30) However, the benefi ts of long-term treatment may be negated 
by the development of anti-HBV drug resistance, which can lead to reversion of virologic 
and histological improvement. In two recently performed randomized clinical trials in 
HBV-mono-infected patients, TDF resulted in HBV DNA levels lower than 400 copies/
mL in 76% and 93% of HBeAg-positive and HBeAg-negative patients, respectively.(12) 
Continued therapy produced additional viral suppression, HBeAg- and HBsAg-loss 
at week 72 and 96.(31-32) Our study now shows TDF, combined with either LAM or 
emtricitabine, to be an effective anti-HBV agent through fi ve years of therapy with 90% 
of HIV/HBV co-infected subjects achieving undetectable HBV DNA.
In the phase III trials in HBV-mono-infected patients no evidence of TDF-resistance 
was shown up to 72 weeks of treatment despite extensive resistance surveillance.(17) 
Until now TDF resistance has only been described in two HIV-HBV co-infected patients 
demonstrating the A194T mutation in addition to LAM-resistance (33), yet the associa-
tion between this mutation and TDF resistance was not confi rmed in another study.
(34) In our study, four subjects experienced a virologic breakthrough. In two patients 
this was explained by non-compliance and only one patient demonstrated a combina-
tion of LAM- and adefovir (ADV)-resistant mutations in the HBV polymerase gene. The 
rtA194T mutation was not observed. An interesting phenomenon was that two virologic 
breakthroughs occurred in association with the development of hepatocellular carci-
noma. A satisfactory explanation for this relation could not be found. There are many 
reports which demonstrate an association between development of resistance and the 
risk of hepatocellular carcinoma, which is largely explained by the recurrence of viral 
replication; only one report noted that signifi cantly more hepatocellular carcinomas 
were observed shortly after development of LAM resistance.(35)
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The recently published EASL guidelines on the management of hepatitis B state that 
“in patients receiving entecavir or tenofovir with a partial virologic response at week 
48, some experts would suggest adding the other drug in order to prevent resistance in 
the long term.”(36) In agreement with the follow-up data of the two large phase III trials 
in HBV-monoinfected patients(12), our study shows that most patients are still able 
to achieve undetectable HBV DNA in the second year without changing the treatment 
regimen. Moreover, this is also the fi rst report which demonstrates that adding ETV to 
existing TDF therapy is still effective after at least 15 months of treatment, and resulted 
in undetectable HBV DNA in all patients. Our study, therefore, suggests that one can 
probably wait at least 24 months before adding ETV in patients who are viremic on a 
TDF-containing treatment regimen.
There have been concerns about the risk of renal toxicity with TDF due to an associa-
tion between related compounds such as ADV and nephrotoxicity.(37-38) In our study, 
a small but signifi cant increase in serum creatinin levels was observed after fi ve years 
of treatment. Yet, only 3% of patients developed serum creatinin elevations which 
necessitated the discontinuation of TDF. Furthermore, serum creatinin elevations 
usually occurred early, which suggests that frequent monitoring of renal function is 
necessary shortly after initiation of TDF treatment, but that thereafter, monitoring can 
probably decreased.(22) Overall, this study supports the renal safety of TDF as a part 
of anti-retroviral therapy through fi ve years of treatment.
To date, no confi rmed genotypic substitutions in the HBV polymerase gene associated 
with decreased sensitivity to TDF have been identifi ed. Although direct sequencing 
does allow for all mutations to be identifi ed, in vitro phenotypic confi rmatory assays 
are mandatory to detect new substitutions. A limitation of our study is therefore, that 
we were only able to search for known anti-HBV drug-resistant mutations. In addition, 
no liver biopsies were available during follow-up in all our patients, and abdominal 
ultrasound was only performed if there was clinical suspicion of progression to cir-
rhosis, decompensated liver disease, or hepatocellular carcinoma. The frequency of 
progression of hepatitis B, and more specifi cally, the development of cirrhosis and 
hepatocellular carcinoma, may therefore be underestimated in our study.
In conclusion, TDF administered as part of anti-retroviral therapy, demonstrated to be a 
potent anti-HBV agent with a good resistance profi le throughout fi ve years of therapy. 
The antiviral effi cacy of TDF was not infl uenced by presence of LAM resistance. Fur-
thermore, this study supports the renal safety of TDF through fi ve years of treatment, 
as only a small, non-progressive decline in renal function was observed. Nevertheless, 
close monitoring of renal function is still indicated. Adding ETV to the treatment regi-
men resulted in achievement of undetectable HBV DNA in patients who demonstrate 
persistent HBV replication during a TDF-containing treatment regimen.
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ABSTRACT
Background
Entecavir is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve 
chronic hepatitis B patients, but data on the effi cacy in NA-experienced subjects is 
limited.
Methods
In a multi-center cohort study we investigated 161 chronic hepatitis B patients (34% 
NA-experienced) treated with entecavir monotherapy.
Results
During a median follow-up of 11 (3-23) months, 82 (79%) of 104 NA-naïve patients 
achieved virologic response (VR), defi ned as HBV DNA < 80 IU/mL, and none of the 
patients (0%) developed genotypic entecavir-resistance. VR was demonstrated in 31 
(54%) of 57 NA-experienced patients during a median follow-up of 12 (3-31) months. 
Patients with lamivudine-resistant mutations at the start of entecavir monotherapy had 
a reduced probability of achieving VR compared to lamivudine-naïve patients (HR 0.14; 
95%CI 0.04-0.58; p = 0.007). Antiviral effi cacy was not decreased by prior treatment 
with lamivudine in case lamivudine-resistance had never developed (HR 0.81; 95%CI 
0.43-1.52; p = 0.52). Prior adefovir therapy without development of adefovir-resistance 
(HR 0.84; 95%CI 0.43-1.64; p = 0.61) and presence of adefovir-resistance (HR 0.86; 
95%CI 0.27-2.71; p = 0.80) did not infl uence antiviral response to entecavir. Switching 
to a tenofovir-containing treatment regimen resulted in viral load decline in patients 
with entecavir-resistance associated mutations.
Conclusions
Entecavir proved to be effi cacious in NA-naïve patients. The antiviral effi cacy of entecavir 
was not infl uenced by prior treatment with adefovir or presence of adefovir-resistance. 
Entecavir should not be used in patients with previous lamivudine-resistance, yet it 
may still be an option in lamivudine-experienced patients in case lamivudine-resistance 
never developed.
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INTRODUCTION
Nucleos(t)ide analogues (NA) target the reverse transcriptase of hepatitis B virus (HBV), 
and are potent inhibitors of viral replication. In the absence of antiviral drug resistance 
continued NA therapy is able to suppress viral replication over prolonged periods, 
and can result in delay or even prevention of clinical progression to liver cirrhosis and 
hepatocellular carcinoma.(1)
Entecavir (ETV) is a cyclopentyl guanosine analogue, and a potent and selective inhibi-
tor of HBV replication in vitro.(2) In the phase III registration trials it resulted in superior 
virologic, biochemical and histological effi cacy after one year of therapy compared to 
lamivudine (LAM) in both HBeAg-positive and HBeAg-negative chronic HBV patients.
(3, 4) Moreover, ETV proved to have a high genetic barrier to resistance with only 1.2% 
of NA-naïve HBV patients demonstrating genotypic resistance to ETV after fi ve years 
of ETV monotherapy.(5) In LAM-refractory chronic HBV patients ETV appeared to be 
less potent and the frequency of resistance was increased.(6, 7) After fi ve years of 
treatment 51% of LAM-refractory patients showed genotypic ETV resistance, and in 
43% a virologic breakthrough was observed as well.(8) However, study populations 
of registration trials consist of selected groups of HBV patients, and results can not 
always be translated to clinical practice. Furthermore, as the increasing number of 
patients who experienced treatment failure to different NA treatment regimens poses a 
growing problem for the clinician, data on the effi cacy of ETV in these NA-experienced 
patient groups is warranted.
The aim of this cohort study was to asses the effi cacy of ETV in both NA- naïve and 
–experienced chronic hepatitis B patients, and to explore baseline factors associated 
with virologic reponse (VR) to ETV.
MATERIALS AND METHODS
Study population
In this investigator-initiated cohort study within the European network of excellence for 
Vigilance against Viral Resistance (VIRGIL), all consecutive adult chronic HBV patients 
treated with ETV monotherapy between 2005 and May 2008 in 7 large European referral 
centers were included. Further eligibility criteria were: a viral load of at least 2000 IU/ 
mL at the initiation of ETV monotherapy, and duration of ETV monotherapy for at least 
3 months. Patients were excluded if they had co-infections (HIV, HCV, HDV). In total, 
220 HBV-infected patients treated with ETV monotherapy were identifi ed. Fifty-nine 
patients did not fulfi ll the entry criteria and were excluded from analysis: 33 subjects 
had been treated with ETV monotherapy for less than three months, 19 patients had 
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a baseline HBV DNA of less than 2000 IU/mL, six patients were co-infected with HCV, 
and one patient was co-infected with HDV. Thus, a total of 161 patients were eligible 
for this analysis.
Follow-up
All subjects were prospectively monitored at least every three months. At every visit 
routine examination with biochemical (ALT, bilirubin, albumin) and virologic (HBV DNA 
level, HBeAg, anti-HBe) assessments took place. Genotypic analysis was done (a) at 
baseline in all NA-experienced HBV patients, (b) in case of virologic breakthrough, 
defi ned as an increase in serum HBV DNA level > 1 log10 (10-fold) above nadir on 
at least two occasions after initial virologic response, or (c) in case of serum HBV 
DNA > 200 IU/mL at the end of follow-up. If ETV-resistant mutations were detected 
during follow-up, genotypic analysis was performed at baseline in NA-naïve subjects. 
In NA-experienced patients, genotypic resistance was also assessed in stored serum 
samples obtained at the end of all previously given NA-treatment regimes. HBV geno-
type was determined at baseline.
Endpoints
The primary outcome was virologic response (VR), defi ned as serum HBV DNA levels 
< 80 IU/mL (approximately 400 copies/mL) during the on-treatment follow-up period. 
Secondary endpoints were HBsAg loss and seroconversion, HBeAg loss and serocon-
version for HBeAg-positive patients, ALT normalization, and emergence of ETV-related 
mutations.
Laboratory tests
Serum alanine aminotransferase (ALT), bilirubin, albumin levels and international ratio 
of prothrombin time were measured using automated techniques. Hepatitis B surface 
antigen (HBsAg), antibody against HBsAg (anti-HBs), hepatitis B e antigen (HBeAg), 
and antibody against HBeAg (anti-HBe) were determined using commercially available 
enzyme immunoassays in all centers. Serum HBV DNA levels were measured using a 
quantitative real-time polymerase chain reaction assay, the COBAS AmpliPrep-COBAS 
TaqMan HBV test (CAP-CTM; Roche Molecular Systems, Inc., Branchburg, NJ, USA), 
with a lower limit of detection of 12 IU/mL, in six of seven centers. In one center serum 
HBV DNA was measured using Roche Amplicor (linear dynamic range, 400 to 200,000 
copies/mL; Roche Diagnostic Systems, Branchburg, NJ, USA). A conversion factor 
of 5.26 copies/IU was used for conversion of copies/mL to IU/mL. Presence of HBV 
polymerase gene mutations was determined by direct sequencing. HBV genotypes 
were assessed by sequence alignment of the overlapping hepatitis B surface antigen 
with HBV sequences derived from GenBank.
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Statistical analysis
Continuous variables are expressed as means ± SD or median (range) where appro-
priate. Follow-up times were calculated from the date of ETV treatment initiation to 
the date of event or censorship. Cumulative probabilities of different endpoints were 
estimated by Kaplan-Meier analysis. Survival analysis with Cox regression model was 
used to analyze which of the following baseline factors were associated with viro-
logic response to ETV monotherapy: Age, gender, race, body mass index (BMI), HBV 
genotype, HBeAg status, viral load, ALT level, presence of cirrhosis, prior treatment 
with LAM, prior history of LAM resistance, presence of LAM resistance at baseline, 
duration of LAM therapy, prior treatment with adefovir dipivoxil (ADV), prior history of 
ADV resistance, prior treatment with (peg)interferon, dosage, and treatment centre. 
Factors that correlated highly with each other were compared in separate models with 
each collinear variable by using the Akaike information criterion method. To estimate 
the infl uence of prior treatment with LAM and prior treatment with ADV on the virologic 
response to ETV, hazard ratios were calculated in a multivariate Cox PH model, and 
adjusted for other confounding effects of other baseline characteristics (HBeAg status, 
viral load, ALT level, and prior treatment with LAM). Interaction terms in Cox regression 
model were used to test for the statistical signifi cance of effect modifi cation by base-
line HBV DNA on the effi cacy of ETV. We applied a dichotomous cut point of HBV DNA 
> 7 log10 IU/mL based on published data.(6) The estimated curves of probability of 
achieving VR were calculated according to Cox regression model that adjusted for the 
infl uence of signifi cant variables (fi gure 3 and 4).(9) All statistical tests are two-sided, 
and a p-value < 0.05 was considered to be statistically signifi cant. SPSS version 15.0 
was used for all statistical analysis (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics of the study population are presented in table 1. Sixty-eight 
(42%) patients were HBeAg-positive, median ALT was 1.8 (0.3-75) xULN, and mean 
HBV DNA was 6.3±1.7 log10 IU/mL. NA-experienced patients were more often HBeAg-
positive (p < 0.001) at baseline compared to NA-naïve patients. Median follow-up of 
the whole study population was 12 (3-31) months.
Effi cacy of ETV in NA-naïve patients with chronic HBV infection
In total, 104 (66%) patients were NA-naïve, of whom all were treated with ETV 0.5 mg 
(table 1). Eighty-two (79%) patients achieved VR after a median follow-up of 4 (1-23) 
months (table 2). For HBeAg-positive patients (n=32), the cumulative probability of 
achieving VR at 3, 6, and 12 months was 13, 23, and 55%, respectively (fi gure 1). 
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Six (19%) of thirty-two HBeAg-positive patients lost HBeAg after a median treatment 
duration of 12 (10-22) months, of whom four patients also seroconverted to anti-HBe. 
For HBeAg-negative patients (n=72), the cumulative probability of achieving VR at 3, 
6, and 12 months was 40, 65, and 92%, respectively (fi gure 1). In none of the patients 
HBsAg loss was observed. Two (2%) patients experienced a virologic breakthrough 
during follow-up, but in none of the subjects genotypic resistance to ETV could be 
detected (table 2).
Effi cacy of ETV in NA-experienced chronic HBV patients
VR was demonstrated in 31 (54%) of 57 NA-experienced patients during a median 
follow-up of 12 (3-31) months. Fifteen (26%) patients were treated with 0.5 mg, of 
whom ten patients were LAM-experienced and one patient had a prior history of 
Table 1 Baseline characteristics
All patients NA-naïve NA-experienced
N=161 N=104 N=57 p-value
Age 43±14 44±14 40±14 0.12
Gender (male %) 118 (73%) 74 (71%) 44 (77%) 0.41
Race
 Caucasian 108 (67%) 68 (65%) 40 (70%) 0.83
 Asian 31 (19%) 21 (20%) 10 (18%)
 Other 22 (14%) 15 (14%) 7 (12%)
BMI 25±4.2 25±3.4 25±5.3 0.37
ALT (xULN) 1.8 (0.3-75) 2.1 (0.4-75) 1.6 (0.3-47) 0.18
HBV DNA (Log10 IU/ml) 6.3±1.7 6.3±1.6 6.2±1.8 0.86
HBeAg-positive 68 (42%) 32 (31%) 36 (63%) < 0.001
Genotype (N=148)
 A 30 (20%) 18 (20%) 12 (21%) 0.48
 B 10 (7%) 6 (7%) 4 (7%)
 C 19 (13%) 12 (13%) 7 (12%)
 D 80 (54%) 52 (57%) 28 (49%)
 Other 9 (6%) 3 (3%) 6 (11%)
Dosage entecavir (0.5 mg %) 119 (74%) 104 (100%) 15 (26%) < 0.001
Presence of cirrhosis 44 (27%) 25 (24%) 19 (33%) 0.21
Previous treatment with (peg)ifn 51 (32%) 30 (29%) 21 (37%) 0.30
Previous treatment with LAM
 LAM-experienced 43 (27%) 43 (75%)
 Prior history of LAM resistance 23 (14%) 23 (40%)
 LAM-resistance at baseline 9 (6%) 9 (16%)
Previous treatment with ADV
 ADV-experienced 42 (26%) 42 (74%)
 Prior history of ADV resistance 12 (8%) 12 (21%)
 ADV resistance at baseline 11 (7%) 11 (19%)
Previous treatment with TDF 3 (2%) 3 (5%)
Previous treatment with LdT 1 (1%) 1 (2%)
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LAM-resistance. There were no centre differences (p = 0.23). Forty-three (75%) subjects 
were directly switched to ETV monotherapy after failure to preceding NA-therapy. In 
the remaining 14 patients, the median time between the end of previous NA treatment 
and the start of ETV monotherapy was 46 (5-132) months.
Lamivudine
Forty-three (27%) patients had received prior treatment with LAM for a median duration 
of 20 (3-64) months (fi gure 2). Twenty-three (53%) subjects developed LAM resistance, 
of whom in 9 (21%) subjects LAM-resistant mutations could still be detected at the 
initiation of ETV monotherapy. Median duration between the end of LAM treatment and 
the start of ETV treatment was 23 (0-114) months. Table 2 shows the effi cacy of ETV 
in different subgroups of LAM-experienced patients. Adjusted for baseline viral load, 
HBeAg status and ALT level, only presence of LAM-resistant mutations at the start of 
ETV monotherapy was signifi cantly associated with a reduced probability of achieving 
VR compared to LAM-naïve patients (HR 0.14; 95% CI 0.04-0.58; p = 0.007). Previous 
treatment with LAM without development of LAM resistance (HR 0.81; 95% CI 0.43-
1.52; p = 0.52) and a prior history of LAM resistance (HR 0.59; 95% CI 0.26-1.34; p 
= 0.21) did not infl uence the antiviral response to ETV (fi gure 3). A test for interaction 
among baseline HBV DNA, LAM-naïve and different subgroups of LAM-experienced 
patients, and virologic response was not signifi cant (p = 0.63), suggesting that the 
Table 2 Virologic and biochemical response to entecavir
NA-naïve 
patients 
(N=104)
LAM-experienced patients
(N=43)
ADV-experienced 
patients* (N=36)
No LAM-
resistance 
(N=20)
Prior 
history of 
LAM-
resistance 
(N=14)
LAM-
resistance 
at baseline
(N=9)
LAM-
experienced 
(N=24)
LAM-naïve 
(N=12)
Baseline HBV DNA 6.3±1.7 6.3±2.0 6.6±1.5 6.0±1.9 6.1±1.8 5.7±2.0
Median follow-up 
(month)
11 (3-23) 9 (4-24) 15 (4-31) 12 (3-26) 12 (3-31) 14 (6-25)
Virologic response 82/104 
(79%)
12/20 
(60%)
7/14 (50%) 2/9 (22%) 10/24 (42%) 9/12 
(75%)
Virologic 
breakthrough
2/104 (2%) 0/20 (0)% 4/14 (29%) 2/9 (22%) 5/24 (21%) 0/12 (0%)
Genotypic ETV 
resistance
0/104 (0%) 0/20 (0%) 3/14 (21%) 2/9 (22%) 4/24 (17%) 0/12 (0%)
ALT normalization 58/83 (70%) 6/14 (43%) 7/9 (78%) 3/5 (60%) 6/13 (46%) 10/10 
(100%)
HBeAg loss 6/32 (19%) 0/12 (0%) 1/10 (10%) 1/5 (20%) 1/19 (5%) 1/7 (14%)
HBsAg loss 0/104 (0%) 0/20 (0%) 0/14 (0%) 0/9 (0%) 0/24 (0%) 0/12 (0%)
* To explore the role of ETV as rescue therapy for ADV-treated patients, the antiviral effect of ETV 
is described for those subjects, who were directly switched to ETV monotherapy (n = 36 (86%)).
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Number of patients without responsea
HBeAg-positive patients
HBeAg-negative patients
Total number of patientsb
in follow-up
32 32 27 21 17 9 8
72 66 33 24 20 9 4
0 2 4 6 8 10 12
0
20
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104 104 98 89 77 56 42
Figure 1 Kaplan-Meier curve for the cumulative probabilities of achieving virologic response, 
defi ned as HBV DNA < 80 IU/mL, for HBeAg-positive and HBeAg-negative NA-naïve hepatitis 
B patients. (a) Number of patients who have not achieved virologic response and are still in 
follow-up. (b) Number of patients who are still in follow-up, whether or not they have achieved 
virologic response.
LAM 
monotherapy
(N=14)
Sequential 
LAM-ADV therapy
(N=20)*
LAM-ADV
add-on therapy
(N=6)
Sequential LAM-
TDF-ADV therapy
(N=3)**
ADV
monotherapy
(N=13)
LdT
monotherapy
(N=1)
LAM-experienced
(N=43) #
ADV-experienced
(N=42)
TDF-experienced
(N=3)
LdT-experienced
(N=1)
No LAM-
resistance
(N=20)
Prior history of 
LAM-resistance
(N=14)
LAM-resistance
at baseline
(N=9)
No direct 
switch to ETV 
(N=6)
Direct 
switch to ETV
(N=36) #
LAM-
experienced 
(N=24)
LAM-
naive 
(N=12)
Figure 2 Overview of NA patients (N=57): treatment schedules prior to ETV monotherapy
* Two patients received sequential ADV-LAM therapy; ** One patient received sequential LAM-
ADV-TDF therapy; # Patients described in table 2
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infl uence of previous treatment with LAM on the antiviral response to ETV, is similar 
in patients with a high viral load (>7 log10 IU/mL) and patients with a low viral load (≤7 
log10 IU/mL) at the institution of ETV (fi gure 4). Of the fourteen patients with a prior 
history of LAM-resistance, four (29%) subjects developed a virologic breakthrough 
during follow-up, and in three (22%) patients genotypic resistance to ETV could be 
detected (table 2).
Adefovir
Forty-two (26%) patients had received prior treatment with ADV (fi gure 2). Six (14%) 
subjects were not directly switched to ETV monotherapy, of whom three patients 
initially received LAM monotherapy as rescue therapy, one subject was fi rst treated 
with tenofovir (TDF) monotherapy, and two other patients stopped antiviral therapy 
after two and twelve months of ADV monotherapy, respectively. To explore the role of 
ETV as rescue therapy for ADV-treated patients, the antiviral effect of ETV is described 
in table 2 for those subjects, who were directly switched to ETV monotherapy (n = 
36 (86%)). Median ADV treatment duration was 19 (3-55) months. In 10 (28%) of 36 
patients genotypic resistance to ADV (rtN236T/ rtA181V/T) could be detected at the 
initiation of ETV monotherapy, of whom nine subjects were LAM-experienced. Adjusted 
for previous LAM treatment, baseline viral load, HBeAg status, and ALT level, antiviral 
P = 0.007
LAM-naïve 
LAM-experienced without development of LAM-resistance 
LAM-experienced with a prior history of LAM-resistance
LAM-experienced with LAM-resistant mutations at baseline 
Treatment month
%
 
Cu
m
ul
at
ed
 re
sp
on
se
P = 0.52
P = 0.21
Figure 3 Adjusted estimated survival curve for the cumulative probability of achieving virologic re-
sponse, defi ned as HBV DNA < 80 IU/mL, for LAM-naïve and different subsets of LAM-experienced 
hepatitis B patients, based on the Cox’s model for mean values of baseline HBV DNA, ALT level 
and HBeAg status.
Jurrien BW.indd   79 19-Oct-10   11:35:04 AM
C
ha
p
te
r 
5
80
response to ETV was neither infl uenced by prior ADV therapy without development 
of ADV resistance (HR 0.84; 95% CI 0.43-1.64; p = 0.61) nor by presence of ADV 
resistance at the start of ETV monotherapy (HR 0.86; 95% CI 0.27-2.71; p = 0.80).
Predictors of virologic response
Table 3 shows predictors of VR. Increased probabilities of VR were seen in HBV 
patients with HBeAg negativity at baseline (HR 1.95; 95%CI 1.25-3.06; p = 0.004), 
high baseline ALT levels (HR 1.06; 95% CI 1.03-1.09; p < 0.001), low baseline HBV 
DNA levels (HR 0.67; 95% CI 0.59-0.77; p < 0.001), and absence of LAM-resistant 
Table 3 Baseline predictors of virological response: time-to-event analysis
Parameters Multivariate Cox PH model
HR (95%CI) p-value
HBeAg negativity 1.95 (1.25-3.06) 0.004
Baseline HBV DNA (per log10 increase) 0.67 (0.59-0.77) < 0.001
Baseline ALT (per 1*ULN increase) 1.06 (1.03-1.09) < 0.001
Lamivudine resistance at baseline 0.16 (0.04-0.64) 0.01
LAM-naïve 
LAM-experienced without development of LAM-resistance 
LAM-experienced with a prior history of LAM-resistance
LAM-experienced with LAM-resistant mutations at baseline 
Treatment month
%
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A
B C
HBV DNA = 5 log10 IU/mL
HBV DNA = 7 log10 IU/mL HBV DNA = 9 log10 IU/mL
(Chapter 5)
Figure 4 Adjusted estimated survival curves for the cumulative probability of achieving viro-
logic response, defi ned as HBV DNA < 80 IU/mL, for LAM-naïve and different subsets of LAM-
experienced hepatitis B patients, based on the Cox’s model for mean values of baseline ALT level, 
HBeAg status, and HBV DNA = 5 log10 IU/mL (A), HBV DNA = 7 log10 IU/mL (B), and HBV DNA = 
9 log10 IU/mL (C).
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mutations at baseline (HR 0.16; 95% CI 0.04-0.64; p = 0.01). There was no signifi cant 
difference in antiviral response between the participating centers (p = 0.13). Due to a 
short follow-up period and a low number of patients developing mutations related to 
ETV resistance, no predictors of resistance could be identifi ed.
Resistance surveillance
During a median follow-up of 12 (3-31) months eight (5%) patients experienced a 
virologic breakthrough (table 4). Six patients had a prior history of LAM-resistance, of 
whom in two subjects LAM-resistant mutations could still be detected at the start of 
ETV monotherapy. Two NA-naïve patients experienced a virologic breakthrough, but 
non-adherence was suspected in both subjects. In three patients only LAM-resistant 
substitutions were seen; two patients demonstrated additional mutations related to 
ETV-resistance. Only one of fi ve patients who developed genotypic resistance, had 
achieved virologic response. A TDF containing treatment regimen was initiated in fi ve 
patients, and a subsequent decline in HBV DNA was observed in four of fi ve patients. 
No mutations associated with decreased sensitivity to ETV were observed in patients 
with a viral load > 200 IU/mL at the end of follow-up.
DISCUSSION
This study explores the infl uence of previous exposure to nucleos(t)ide analogues on 
the effi cacy of ETV, and identifi es which factors predict virologic response to ETV. It was 
shown that in patients with LAM-resistant mutations at baseline ETV is less potent, but 
that antiviral effi cacy was not decreased by prior LAM treatment without development 
of LAM-resistance. Previous treatment with ADV and presence of ADV-resistant muta-
tions did both not infl uence the potency of ETV as well. Baseline HBeAg-negativity, 
high serum ALT, low serum HBV DNA levels, and absence of LAM-resistant mutations 
were independent predictors of VR for ETV monotherapy. ETV was shown to be a 
potent antiviral with a favorable resistance profi le in NA-naïve chronic HBV patients.
Currently, the increasing number of patients who experienced treatment failure to dif-
ferent NA treatment regimens poses a growing problem in daily clinical practice. Nev-
ertheless, data on the effi cacy of different anti-HBV agents in these NA-experienced 
patient groups are scarce. In accordance with the studies by Sherman et al. (6, 7), 
we showed that antiviral effi cacy of ETV is signifi cantly decreased in patients with 
LAM-resistant mutations at the start of ETV monotherapy. No difference in potency 
was seen compared to NA-naïve patients in subjects who were previously treated 
with LAM without development of resistance to LAM, or patients with a prior history 
of LAM-resistance but in whom these mutations could not be detected at baseline. 
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However, in the latter group 4 of 14 patients experienced a virologic breakthrough, and 
in 3 subjects mutations related to ETV-resistance were detected. In the fi rst group no 
virologic breakthroughs were seen. Furthermore, the effect of previous treatment with 
LAM on the effi cacy of ETV was not infl uenced by baseline HBV DNA, which suggests 
that also in patients with LAM-resistant mutations and a viral load less than 7 log10 
IU/mL at baseline, the antiviral response to ETV was reduced. This challenges earlier 
experience in a small number (n=11) of LAM-resistant HBV patients.(6) Based on these 
results, ETV should not be used as rescue option for patients with a prior history of 
LAM-resistance. ETV may still be used in LAM-experienced patients in case LAM-
resistance never developed, although longer follow-up is required to confi rm these 
initial observations.
Until now, only small case reports have described the in vivo effi cacy of ETV in HBV 
patients previously treated with ADV and/ or patients with ADV-resistant HBV.(10-12) 
In vitro studies showed that ADV-resistant HBV strains remain completely sensitive to 
ETV, or only demonstrate a slightly decreased susceptibility.(13-17) Consistent with 
these in vitro and limited in vivo data, antiviral effi cacy of ETV was not infl uenced by 
prior treatment with ADV or presence of ADV resistance. A subset of these patients with 
a poor virologic response to ADV has been described previously by us,(18) in which 
ETV monotherapy resulted in a limited virologic response. The contrasting outcome 
might be related to selection of patients who respond poorly to NA in general instead 
of previous ADV therapy itself. Furthermore, in this study we were able to control for 
confounding factors such as baseline HBeAg-status, HBV DNA and ALT levels, and 
prior exposure to LAM.
The antiviral effect of ETV in NA-naïve patients in our study is consistent with results 
demonstrated in the large phase III registration trials.(3, 4) Our study, therefore, con-
fi rms ETV to be a highly potent antiviral agent with a good resistance profi le within this 
population. Furthermore, we demonstrate that patients who are the initiation of ETV 
HBeAg-negative, have low HBV DNA levels, and high ALT levels, are the most likely to 
respond. These baseline predictors of VR were also found in patients treated with other 
NA.(10-12) Due to a short follow-up period and a low number of patients developing 
ETV-resistance associated mutations, no predictors of resistance could be identifi ed.
In total, eight virologic breakthroughs were observed during the follow-up period, after 
which in fi ve subjects mutations associated with ETV resistance could be detected. 
In three LAM-experienced patients, only LAM-resistant substitutions were present 
at the moment of virologic breakthrough. Minor populations (< 20%) existing within 
the quasispecies with additional ETV-resistant mutations can not be ruled out, but 
it confi rms that LAM-resistant mutations are maintained or can reappear during ETV 
monotherapy.(19-21) To our knowledge no patient with a virologic breakthrough during 
ETV monotherapy with just an rtM204I and an rtL80F mutation has been described 
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before.(22) In vitro studies suggest TDF and ADV to remain susceptible to LAM- and 
ETV-resistant HBV mutants.(21, 23) In our study, fi ve patients were switched to a TDF-
containing regimen, resulting in decline of HBV DNA levels in four of them.
Limitations of our study include the observational design and the heterogeneous group 
of patients. Nevertheless, Kaplan-Meier analysis was used to address the variability of 
treatment duration, and the infl uence of prior NA therapy on the antiviral response to 
ETV monotherapy, was estimated in a multivariate model, and adjusted for confounding 
effects of other baseline characteristics. Indeed, results from our study are consistent 
with results from previous in vitro and in vivo studies, including phase III random-
ized clinical trials, and the concordance in results between the different participating 
centers underlines the reliability of the data.
In conclusion, in NA-experienced patients, ETV should not be used as rescue therapy 
in patients with a prior history with LAM-resistance, even when LAM-resistant muta-
tions can not be detected at baseline. Also in patients with LAM-resistance and a low 
viral load at baseline, response to ETV appears suboptimal. ETV may still be used 
in LAM-experienced patients in case LAM-resistance never developed, yet longer 
follow-up is required to confi rm these initial observations. The antiviral effi cacy of ETV 
was not infl uenced by prior treatment with ADV or presence of ADV resistance. In 
NA-naïve HBV patients ETV proved to be highly effi cacious. Switching to TDF, whether 
in mono- or in combination therapy, resulted in decline of viral load in patients with 
ETV-resistance associated mutations.
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ABSTRACT
Background
We investigated the effi cacy of entecavir in lamivudine-experienced and -naïve patients 
with persistently high HBV DNA during adefovir treatment.
Methods
Fourteen chronic hepatitis B patients (57% lamivudine-experienced) with a viral load 
above 5log10 copies/mL after twelve months of adefovir therapy and thereafter were 
treated with entecavir 1 mg daily.
Results
During a median follow-up of 15 months (range: 8-23 months) one of six lamivudine-
naïve and none of the eight lamivudine-experienced patients achieved undetectable 
HBV DNA (< 373 copies/mL). HBeAg loss occurred in none of the subjects. Two lami-
vudine-experienced patients demonstrated the rtM204I mutation; no other entecavir-
resistant substitutions were detected (rtI169, rtT184, rtS202, rtM250). Two of three 
patients with genotypic adefovir resistance at baseline demonstrated a rapid virologic 
response to entecavir, but undetectable HBV DNA was not achieved. To achieve a 
better antiviral response the dosage of entecavir was increased to 2 mg daily in two 
patients, resulting in further viral load decline for both of them.
Conclusions
Entecavir monotherapy dosed at 1 mg resulted in a slow reduction of viral load in both 
lamivudine-experienced and -naïve patients with persistently high HBV DNA during 
adefovir therapy. Increasing the dosage of entecavir led to further HBV DNA decline.
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INTRODUCTION
Treatment of patients with chronic hepatitis B virus (HBV) infection remains an impor-
tant challenge. With the currently approved treatment options the main goal of treat-
ment is complete suppression of viral replication, because persistent HBV viraemia 
is associated with development of liver cirrhosis and hepatocellular carcinoma.(1, 2) 
Furthermore, a rapid virologic response after initiation of nucleos(t)ide analogue treat-
ment is associated with lower rates of antiviral drug resistance in the long term.(3-5)
Adefovir dipivoxil (ADV) is an oral prodrug of adefovir, a phosphonate acyclic nucleotide 
analogue of adenosine monophosphate.(6) Previous studies demonstrated its effi cacy 
in both patients with HBeAg-positive and patients with HBeAg-negative chronic HBV 
infection, showing signifi cant virologic, biochemical, and histological improvement 
after 48 weeks of treatment.(7, 8) However, after fi ve years of treatment resistance 
rates can be up to 29%.(9) Furthermore, ADV demonstrates a relatively high rate of 
primary nonresponse, probably due to its suboptimal dosage.(10, 11) In the treatment 
of lamivudine (LAM)-resistant HBV infection, switching to ADV monotherapy resulted 
in signifi cant HBV DNA decline, but several case series reported increased resistance 
rates compared to LAM-naïve patients.(12, 13)
Entecavir (ETV) is a cyclopentyl guanosine analogue, and a potent and selective inhibi-
tor of viral replication in vitro.(14) A large phase III study demonstrated its effi cacy in 
nucleoside-naïve patients with HBeAg-positive chronic HBV infection. After 48 weeks 
of treatment with ETV a greater reduction in viral load was achieved compared to 
LAM (6.9log10 vs. 5.4log10).(15) In LAM-refractory patients ETV is less effective, and 
results in a 5.1log10 HBV DNA decline after 48 weeks of treatment.(16) It has yet not 
been evaluated in patients with a partial virologic response to ADV therapy. Here we 
describe 8 LAM-experienced and 6 LAM-naïve patients with chronic HBV infection and 
a persistently high level of viral replication after twelve months of treatment with ADV, 
who were switched to ETV monotherapy.
MATERIALS AND METHODS
Study population
All adult patients with chronic hepatitis B, referred to the Erasmus Medical Center 
Rotterdam from September 2005 till February 2007 who had a persistently high viral 
load during ADV treatment and subsequently received rescue therapy with ETV 1 
mg daily for at least six months were included. A persistently high viral load during 
ADV treatment was defi ned as presence of HBV DNA levels greater than 5log10 cop-
ies/mL after twelve months of treatment and thereafter. All patients had repeatedly 
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self-reported good compliance to ADV and ETV treatment. The study conformed to the 
ethical guidelines of the 1975 Declaration of Helsinki. Informed consent was obtained 
from all patients.
Follow-up
All subjects were monitored at least every three months. At every visit routine examina-
tion with biochemical (ALT, bilirubin, albumin, creatinin) and virologic (HBV DNA level, 
HBeAg, anti-HBe) assessments took place. Genotypic resistance was assessed by 
the InnoLiPA DR2 and DR3 line probe assay (Innogenetics, Gent, Belgium), and was 
done (a) at baseline (start of ETV treatment) in all subjects, (b) in case of virologic 
breakthrough, defi ned as an increase in serum HBV DNA level > 1log10 (10-fold) above 
nadir on at least two occasions after initial virologic response, or (c) in case of serum 
HBV DNA > 3log10 copies/mL at the end of follow-up. If ETV-resistant mutations were 
detected at the end of follow-up, genotypic analysis was retrospectively performed 
at six and twelve months of treatment. Genotypic LAM- and ADV resistance was 
assessed using the InnoLiPA DR2 line probe assay in stored serum samples obtained 
at the end of LAM and/ or ADV treatment. HBV genotype was determined at baseline 
in all patients.
Treatment schedules prior to application of entecavir
Lamivudine-naïve patients with high HBV DNA during adefovir therapy
Six patients were LAM-naïve and received ADV treatment for at least twelve months, 
demonstrating a viral load of more than 5log10 copies/mL after 12 months of therapy 
and thereafter (fi gure 1a and 2a). The median duration of ADV treatment was 17 (12-31) 
months. At the start of ADV therapy, all patients were HBeAg-positive, and median 
HBV DNA was 9.0 (6.5-9.9) log10 copies/mL. After twelve months of treatment the 
median viral load decreased to 7.1 (6.1-10.1) log10 copies/mL. In none of the subjects 
HBeAg loss was observed. ALT levels normalized before switching to ETV in one of fi ve 
patients with initially elevated ALT. No ADV-resistant mutations could be detected at 
the end of ADV therapy.
Lamivudine-experienced patients with high HBV DNA during adefovir therapy
Eight patients had received prior treatment with LAM for a median duration of 20 
(12-70) months. Six (75%) subjects developed LAM resistance. After detection of 
resistance, LAM was discontinued in fi ve patients. One patient was directly switched 
to ADV, another patient continued LAM, while ADV was added. All patients received 
ADV treatment for at least twelve months, demonstrating a viral load of more than 
5log10 copies/mL after 12 months of therapy and thereafter (fi gure 1b and 2b). Median 
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duration of ADV therapy was 20 (12-30) months. Seven (88%) patients were HBeAg-
positive and median HBV DNA was 8.3 (6.3-10.0) log10 copies/mL at the start of ADV 
treatment. After twelve months of treatment median HBV DNA levels decreased to 6.8 
(5.8-9.5) log10 copies/mL. HBeAg loss occurred in none of the subjects. All patients 
had increased serum ALT levels at the start of ADV therapy; of these, one had ALT 
normalization prior to switching to ETV monotherapy. At the end of ADV treatment 
three (38%) patients demonstrated genotypic ADV resistance (rtN236T ± rtA181V/T), 
and in the one patient in whom LAM was continued after detection of LAM-resistance, 
the rtM204I mutation could also be detected (table1).
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Figure 1 Median serum HBV DNA and ALT levels during adefovir and consecutive entecavir 
therapy in lamivudine-naïve (A) and lamivudine-experienced patients (B). The dashed line repre-
sents the lower limit of detection of the HBV DNA assay.
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Laboratory tests
Serum alanine aminotransferase (ALT) levels were measured using automated tech-
niques. Hepatitis B surface antigen (HBsAg), antibody against HBsAg (anti-HBs), hepa-
titis B e antigen (HBeAg), and antibody against HBeAg (anti-HBe) were determined 
using a Microparticle Enzyme Immune Assay (MEIA, Abbott, Chicago, IL). Serum 
HBV DNA levels were measured using a previously described in house developed 
quantitative real-time polymerase chain reaction (PCR).(17, 18) Currently, this assay 
is multiplexed without compromising the lower limit of detection (373 copies/mL or 
< 69 IU/mL) with an internal control (pHHV) in order to control the process from DNA 
isolation through PCR.(19) HBV DNA was extracted from serum samples using the 
MagnaPureLC (Roche Applied Science, Almere, The Netherlands) as described before.
(17) Presence of HBV polymerase gene mutations was determined using the InnoLiPA 
DR2 and DR3 line probe assay (Innogenetics, Gent, Belgium).
Clonal analysis
To determine the kinetics of ADV resistant mutants during ETV treatment a clonal 
sequence analysis was performed. HBV DNA was isolated using the MagnaPureLC 
and part of RT (domain B, C and D) was amplifi ed using primers S1 (5’-GTATGTT-
GCCCGTTTGTCCTC’-3’) and YMDD2tripple (a combination of three primers to ensure 
the amplifi cation of all genotypes, 5’-ACCCCATCTTTTTGTTTT-3’ + 5’-ACCCCAAC-
GTTTGGTTTTATTAGG-3’ + 5’- ACCCCATCTTTTTGTTTTGTTAGG-3’).(17) These prim-
ers amplify a PCR product of 403 bp (nt position 461 to 863). If a product of correct size 
was observed on agarose gel, it was ligated into PCR2.1 vector and transformed into 
competent E.coli bacteria according to manufacturer’s protocol (Invitrogen, Breda, NL). 
White colonies were picked and colony PCR was performed using the same primers 
as described above. Sequencing was performed on the PCR products of the colony 
PCR using the same primers as describes above with Big Dye terminator V3.1 cycle 
sequencing kit (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) and a 
ABI3100 instrument (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). 
Subsequently, sequence analysis was performed using Sequence Navigator software 
sequencer (Applied Biosystems), Lasergene v7 (DNASTAR, Madison, WI) and BioEdit 
Software (v7.05).
Statistical analysis
HBV DNA levels were logarithmically transformed for analysis. To correct for differ-
ences in reference between males and females, ALT levels are expressed as values 
representing a ratio to the local upper limit of normal (xULN). Continuous variables are 
expressed as median (range). To compare two continuous variables the Mann-Whitney 
U test was used. Comparisons of categorical endpoints were assessed by the Chi2 
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test. SPSS version 14.0 was used for all statistical analysis (SPSS Inc., Chicago, IL, 
USA).
RESULTS
Baseline characteristics of all 14 patients who met inclusion criteria are listed in table 
1. Eleven (79%) patients were men and the median age was 40 (range: 23-73) years. 
Thirteen (93%) patients were HBeAg-positive, median ALT was 1.6 (0.9-5.8) x ULN, 
and median HBV DNA was 7.8 (5.2-10.1) log10 copies/mL.
Lamivudine-naïve patients with high HBV DNA during adefovir therapy
Serum HBV DNA levels and ALT levels of these six patients throughout the clinical 
course of ETV treatment are shown in fi gure 1a and 2a, and table 2. After 6 and 12 
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Figure 2 Individual courses of HBV DNA (■) and ALT (▲) levels during ADV and consecutive ETV 
treatment in six lamivudine-naïve (A) and eight lamivudine-experienced (B) HBV-infected subjects 
with a persistently high level of viral replication during ADV treatment. The dashed line represents 
the lower limit of detection of the HBV DNA assay.
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months of treatment the median decline of viral load was 2.9 (2.4-5.9) and 3.4 (2.4-5.8) 
log10 copies/mL, respectively. At the end of the observation period (median 16 months, 
range 12-20 months) the median decrease of HBV DNA was 3.6 (2.5-5.8) log10 copies/
mL. Only one patient achieved HBV DNA levels below the detection limit after twelve 
months of ETV treatment. HBeAg loss occurred in none of the patients. All patients with 
serum ALT levels above the normal range prior to switching to ETV (n=5) demonstrated 
ALT normalization at the last visit. No virologic breakthroughs were observed during 
ETV treatment, and in none of the patients ETV-resistant mutations were detected at 
the end of follow-up.
Lamivudine-experienced patients with high HBV DNA during adefovir 
therapy
Eight patients had received prior treatment with LAM for a median duration of 20 (12-
70) months. Six (75%) subjects developed LAM resistance. Median duration between 
the end of LAM treatment and the start of ETV treatment was 40 (0-74) months, and 
in one patient LAM-resistant mutations (rtM204I) could be detected at the start of 
ETV treatment. Serum HBV DNA levels and ALT levels of the patients throughout the 
clinical course of ETV treatment are shown in fi gure 1b and 2b, and table 2. None of 
the patients achieved HBV DNA levels below the detection limit during follow-up. Con-
cerning virologic response to ETV, no signifi cant differences were observed between 
LAM-experienced and LAM-naïve subjects. At the end of the ETV observation period 
two (25%) patients demonstrated the rtM204I mutation, but no other ETV-resistant 
substitutions were detected (rtI169, rtT184, rtS202, rtM250). In patient 7 this mutation 
could already be detected at baseline, and persisted throughout the follow-up period. 
Table 2 Virologic and biochemical response to entecavir
All patients (n=14)
History of LAM therapy
Present (n=8) Absent (n=6) p-value
Follow-up 15 (8-23) 14 (8-23) 16 (12-20) 0.44
HBV DNA
 Baseline 7.8 (5.2-10.1) 7.8 (5.8-9.7) 7.6 (5.2-10.1) 1.0
 Month 6 4.0 (2.8-6.4) 4.0 (3.0-5.5) 3.9 (2.8-6.4) 0.90
 Month 12 3.7 (2.3-5.7) 3.3 (2.8-5.2) 4.0 (2.3-5.7) 0.79
 End of follow-up 3.8 (2.3-5.2) 3.8 (2.8-5.2) 4.0 (2.3-5.1) 0.90
HBV DNA decline
 Month 6 2.9 (1.9-5.9) 3.2 (1.9-5.7) 2.9 (2.4-5.9) 0.70
 Month 12 3.6 (2.3-6.6) 3.9 (2.3-6.6) 3.4 (2.4-5.8) 0.52
 End of follow-up 3.9 (2.3-5.8) 4.3 (2.3-5.4) 3.6 (2.5-5.8) 1.0
Undetectable HBV DNA 1/14 0/8 1/6
HBeAg loss 0/14 0/8 0/6
HBsAg loss 0/14 0/8 0/6
ALT normalization 8/12 3/7 5/5 0.08
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Patient 10 developed a virologic breakthrough subsequently, after which tenofovir 
(TDF) was added to treatment. The mutation could not be detected at baseline, or 
after six and twelve months of treatment. Both subjects had a prior history of LAM 
resistance.
Patients with genotypic adefovir resistance at baseline
Of eight LAM-experienced subjects, three (38%) patients developed ADV-resistant 
mutations during ADV treatment, after which treatment was changed to ETV mono-
therapy. Figure 3 shows the clinical response to ETV of these patients. No signifi cant 
differences were observed between patients with and without ADV-resistant mutations 
at baseline (data not shown). Clonal sequence analysis of follow-up samples with 
serum HBV DNA levels > 1000 copies/mL was performed to examine the evolution 
of ADV-resistant mutations during ETV treatment. In patient 7 the LiPA assay showed 
rtM204I and rtN236T substitutions at baseline. Yet, in all 27 clones only wild-type 
sequence was found. After six months of treatment serum HBV DNA levels decreased 
to 4.1 log10 copies/mL, and stayed at that level. In follow-up samples at month 3, 6 
and 15 the rtM204I substitution was detected in all clones. No other mutations were 
selected (fi g 3a). RtN236T and rtA181V mutations were demonstrated in all clones at 
baseline in patient 8. Serum HBV DNA levels decreased to only 5.2 log10 copies/mL 
after 12 months of treatment, and at month 12 all clones still harbored the ADV-resistant 
substitutions (fi g 3b). At baseline patient 9 had rtN236T and rtA181V mutations in all 
52 clones. HBV DNA decreased to 3.6 log10 copies/mL after three months of treatment 
and remained at that level. Due to low viral load clonal analysis was not successful in 
subsequent blood samples (fi g 3c).
Effi cacy and safety of entecavir 2 mg daily
In an attempt to gain an increased antiviral response the dosage of ETV was enhanced 
to 2 mg daily in two patients. Figure 4 shows HBV DNA and ALT kinetics in these 
patients during treatment with ADV 10 mg, ETV 1 mg, and ETV 2 mg. Both patients 
demonstrated a persistently high viral load during treatment with ETV 1 mg, showing a 
viral load greater than 5 log10 copies/mL after twelve and fi fteen months of treatment, 
respectively. No ETV-resistant mutations could be detected at the moment the dosage 
of ETV was increased to 2 mg daily. In patient 8 serum HBV DNA levels decreased 
from 5.2 to 3.4 log10 copies/mL within ten months of treatment. In patient 4 HBV DNA 
decreased from 5.1 to 3.9 log10 copies/mL after eight months of treatment. ETV 2 mg 
daily was well tolerated by both patients.
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Figure 3 Clinical course and cloning results under entecavir monotherapy of three lamivudine-
experienced patients who had genotypic adefovir resistance (InnoLiPA) at the start of entecavir 
treatment. No signifi cant differences were observed between patients with and without ADV-
resistant mutations at baseline.
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DISCUSSION
This is the fi rst study to describe the effi cacy of ETV as rescue therapy for patients with 
a persistently high viral load during ADV treatment. We showed that ETV monotherapy 
resulted in a limited HBV DNA decline in both LAM-experienced and -naïve patients 
with persistently high HBV DNA during ADV treatment. Only one of fourteen patients 
achieved undetectable HBV DNA levels (< 373 copies/mL), and none of the patients 
showed HBeAg loss or seroconversion. Two LAM-experienced patients demonstrated 
the presence of the rtM204I mutation, but no other ETV-resistant mutations were 
detected at the end of follow-up. Increasing the dosage of ETV to 2 mg daily resulted 
in a further decline in viral load, and was tolerated well. Furthermore, ADV-resistant 
substitutions persisted during ETV monotherapy.
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Figure 4 Clinical course of two patients during sequential treatment with adefovir 10 mg, entecavir 
1 mg, and entecavir 2 mg.
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Non-compliance to either ADV or ETV was unlikely for several reasons. First, all patients 
repeatedly confi rmed their adherence in all outpatient clinic visits. Second, all patients 
demonstrated a continuous HBV DNA decline and no unexpected virologic rebounds 
were observed. Third, the two patients who were switched to 2 mg demonstrated 
further viral load reduction. We did not perform random sampling of entecavir plasma 
levels, because it is still of limited value to assess adherence. Due to the relatively low 
accumulation index for ETV identifi cation of “white coat” adherence is not feasible. In 
addition, the long terminal elimination phase makes it diffi cult to reliably distinguish 
between a sample taken 24-hours after the last dose and a sample taken 2-4 days after 
the last dose. Therefore, only a sample with no detectable drug would assure you that 
a patient had not taken any ETV for a period of at least several weeks.(20)
A general host and/ or pharmacological effect, which results in the inability to achieve 
suffi cient intracellular concentrations of the active moiety of nucleoside analogues, 
could be an explanation for the poor virologic response to both treatment regimens. 
One could therefore postulate that the selected group of patients in our study might be 
in fact “underdosed”. Indeed, two patients with a limited virologic response to ETV 1 
mg daily demonstrated further HBV DNA decline after increasing the dosage to 2 mg 
daily. This observation suggests that increasing a drug to its maximum tolerated dose 
may provide a reasonable option to maximize antiviral activity besides switching to or 
adding another drug.
Another possible explanation might be the presence of HBV strains with reduced sus-
ceptibility to ETV at baseline. In vitro studies demonstrated that LAM-resistance asso-
ciated mutations induce a decrease in susceptibility to ETV, and it is also suggested 
that ETV exhibits a positive selective pressure on LAM-resistant mutants in vivo.(21, 
22) In our study, no signifi cant differences were observed between LAM-experienced 
and LAM-naïve patients, which may be related to the large interval period (median 40 
months; range 0-74 months) between the end of LAM treatment and the start of ETV 
monotherapy. Yet, both subjects in whom the rtM204I mutation could be detected at 
the end of follow-up were in fact previously treated with LAM. In contrast to LAM, ADV-
resistant mutations are expected to remain sensitive to ETV. Therefore, an unexpected 
fi nding was that rtN236T and rtA181V mutations persisted during ETV therapy, which 
may indicate a selective advantage for these HBV variants. In vitro studies showed, 
however, that the rtN236T mutant remains sensitive to ETV with <3-fold change in IC50.
(23-25) A recent study reported that rtA181V/T mutations remain completely sensitive 
to ETV as well (26), although other studies demonstrated a slightly decreased suscep-
tibility. (23-25, 27) Nevertheless, the higher antiviral potency of ETV may overcome 
this potential weak decrease in susceptibility. In our study, two of three patients with 
genotypic ADV resistance at baseline demonstrated a rapid virologic response to ETV, 
although undetectable HBV DNA levels were not achieved.
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In accordance with previous studies (16), our study shows that ETV monotherapy may 
not be the best rescue option for LAM-experienced patients. However, our study also 
shows that ETV resulted in a limited virologic response in LAM-naïve patients with 
a persistently high level of viral replication during ADV treatment. In contrast, TDF 
resulted in undetectable HBV DNA levels in nineteen of twenty LAM-refractory patients 
with high HBV DNA levels during ADV treatment after a median time of 3.5 months.
(28) In another study, 81% of patients (57% LAM-experienced) with an incomplete 
response to ADV achieved undetectable HBV DNA levels (< 400 copies/mL) after 48 
weeks of TDF monotherapy.(29) However, it should be noted that the median baseline 
viral load was considerably lower in both these studies compared to our study (6.4 
log10 and 6.1 log10 vs. 7.8 log10). Furthermore, the median HBV DNA decline after 
twelve months of treatment (3.8 log10) in the study by Van Bommel et al. was actually 
comparable to the observed reduction in our study.(28) Therefore, TDF monotherapy 
proved to be effective in both LAM-experienced and –naïve patients with low viral load 
at baseline, but its effi cacy has still to be demonstrated in highly viraemic HBV patients 
with a poor response to ADV. As TDF and ETV are the most potent antiviral drugs 
that are currently approved, our data suggest that combination therapy may be more 
benefi cial in this subset of patients.
In conclusion, in both LAM-experienced and –naïve patients with a persistently high 
level of viral replication during ADV treatment, switching to ETV monotherapy resulted 
in a limited virologic response. During treatment only one of fourteen patients achieved 
undetectable HBV DNA, which indicates the need for close monitoring for development 
of ETV resistance, especially in the lamivudine-experienced population. Furthermore, 
ADV-resistant mutations persisted during ETV monotherapy, which may suggest a 
selective advantage for these HBV variants, and highlights the importance of potential 
presence of cross-resistance among nucleos(t)ide analogues. Increasing the dosage 
of ETV to 2 mg daily resulted in a further decline in viral load and was tolerated well.
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ABSTRACT
Background
Patients with chronic hepatitis B (CHB) who will and who will not respond to adefovir 
(ADV) monotherapy need to be identifi ed in an early stage in order to adjust treatment 
and prevent future development of antiviral resistance.
Methods
In a single center cohort study we investigated seventy-six CHB patients (50% HBeAg-
positive) treated with long-term ADV monotherapy.
Results
During a median follow-up of 122 (24-185) weeks 42 (55%) patients achieved virologic 
response (VR), defi ned as HBV DNA levels < 103 copies/mL, and ten patients (13%) 
developed genotypic ADV resistance. Independent baseline predictors of VR were 
HBeAg negativity (HR (hazard ratio) HR 2.98; 95%CI 1.24-7.19; p = 0.02), high ALT 
levels (HR 1.11; 95% CI 1.05-1.18; p = 0.001), and low HBV DNA levels (HR 0.56; 95% 
CI 0.41-0.75; p < 0.001). HBV DNA at week 24 demonstrated a higher predictive value 
for VR than HBV DNA at week 48. Important predictors of genotypic resistance were 
presence of cirrhosis (HR 6.54; 95% CI 1.39-30.9; p = 0.018), and not achieving VR 
during treatment (HR 6.60; 95% CI 1.35-32.4; p = 0.008). Patients without VR at week 
24 already demonstrated a trend towards the emergence of ADV resistance (p = 0.07)
Conclusion
HBV DNA at week 24 was a better on-treatment predictor of VR than HBV DNA at week 
48, and ADV-resistant mutations developed more frequently in patients without VR at 
week 24. Therefore, our study suggests that virologic response to ADV therapy can 
already be assessed at 24 weeks, instead of the generally recommended 48 weeks.
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection is still a serious global health problem with an 
estimated 350 million people chronically infected, and 0.5-1.2 million deaths a year.
(1-2) With the currently approved treatment options the major goal of treatment is HBV 
DNA suppression in order to prevent development of liver cirrhosis, end-stage liver 
disease, and hepatocellular carcinoma.
Adefovir dipivoxil (ADV) is an oral prodrug of adefovir, a phosphonate acyclic nucleotide 
analogue of adenosine monophosphate.(3) Previous studies demonstrated its effi cacy 
in patients with HBeAg-positive and HBeAg-negative chronic HBV infection, show-
ing signifi cant virologic, biochemical, and histological improvement after 48 weeks of 
treatment.(4-5) However, genotypic resistance rates are up to 29% after fi ve years 
of treatment with ADV.(6) Two mutations (rtN236T, rtA181V) have been described to 
confer resistance to ADV.(7-8) Other mutations have also been reported to be associ-
ated with reduced susceptibility to ADV, including the rtA181T and rtI233V mutations, 
but the signifi cance of these mutations remains unclear.(9-13) Furthermore, it is known 
that a signifi cant proportion of patients have slower and poor primary responses to 
ADV, probably related to the suboptimal approved dose. In one study, 25% of patients 
had a less than 2.2 log10 reduction in HBV DNA levels after 48 weeks of treatment. (14)
It is currently recommended that in HBeAg-positive patients treatment can be stopped 
after HBeAg-seroconversion with at least six months of consolidation treatment. In 
HBeAg-negative patients discontinuation may only be possible after HBsAg clearance, 
necessitating long-term therapy for a signifi cant proportion of patients.(15-17) How-
ever, development of antiviral drug resistance is a major limitation to long-term effi cacy 
of nucleos(t)ide analogues and will thus be an important factor in treatment failures.
(18) It is known that resistance only emerges when replication occurs in the presence 
of drug selection pressure, and complete suppression of viral replication allows little 
opportunity for resistance to develop.(19) Several studies have already shown that 
a rapid virologic response is associated with lower rates of antiviral drug resistance 
in HBV patients in the long term.(20-22) Therefore, antiviral therapy, once initiated, 
should aim to suppress viral replication as quickly and completely as possible, and 
patients who will or will not respond to ADV monotherapy need to be identifi ed in an 
early stage in order to adjust treatment and prevent future development of antiviral 
drug resistance.
The primary aim of our observational study was to assess virologic response to ADV 
in patients with chronic hepatitis B virus infection, and to identify baseline and on-
treatment factors associated with virologic response in the setting of clinical practice. 
Secondary aims were to evaluate rates of HBeAg loss, and genotypic resistance rates, 
and to explore associated baseline and on-treatment parameters.
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METHODS AND MATERIALS
Study population
In this retrospective cohort study, all adult HBV patients with compensated liver disease 
and a viral load of at least 4 log10 copies/ mL referred to the Erasmus Medical Center 
Rotterdam from August 2003 to March 2006, who had received ADV monotherapy for 
at least six months, were included in the analysis. Patients were excluded if they had 
decompensated liver disease or a diagnosis of hepatocellular carcinoma at baseline, 
received immunosuppressive medication, or if they had co-infections (HIV, HCV, HDV) 
or other liver diseases.
Follow-up
All subjects were monitored every 3-4 months. At every visit routine examination with 
biochemical (ALT, bilirubin, albumin, creatinin) and virologic (HBV DNA level, HBeAg, 
anti-HBe) assessments took place. Genotypic analysis was done in case of virologic 
breakthrough, defi ned as an increase in serum HBV DNA level > 1 log10 (10-fold) above 
nadir on at least two occasions after initial virologic response, or in case of serum HBV 
DNA > 4 log10 copies/mL at the end of follow-up. HBV genotype was determined at 
baseline in all patients.
Endpoints
The primary outcome was virologic response (VR), defi ned as serum HBV DNA levels < 
3 log10 copies/mL during the on-treatment follow-up period. Secondary endpoints were 
loss of HBeAg for HBeAg-positive patients and emergence of ADV-related mutations.
Laboratory tests
Serum alanine aminotransferase (ALT) levels were measured using automated tech-
niques. Hepatitis B surface antigen (HBsAg), antibody against HBsAg (anti-HBs), hepa-
titis B e antigen (HBeAg), and antibody against HBeAg (anti-HBe) were determined 
using a Microparticle Enzyme Immune Assay (MEIA, Abbott, Chicago, IL). Serum 
HBV DNA levels were measured using a previously described in house developed 
quantitative real-time polymerase chain reaction (PCR).(23-24) Currently, this assay 
is multiplexed without compromising the lower limit of detection (373 copies/mL) 
with an internal control (pHHV) in order to control the process from DNA isolation 
through PCR.(25) To investigate resistance-associated mutations related with ADV 
treatment, HBV DNA was extracted from serum samples using the MagnaPureLC 
(Roche Applied Science, Almere, The Netherlands) as described before and part 
of the HBV polymerase reverse transcriptase (domain A, B, C, D and F) was PCR 
amplifi ed and sequenced directly, using a nested PCR.(23) The outer primers were 
Jurrien BW.indd   108 19-Oct-10   11:35:28 AM
Virologic response to adefovir can be assessed at 24 weeks 109
HT26-5 (3’-CAGGCCATGCAGTGGAA-5’) and YMDD2tripple (a combination of three 
primers to ensure the amplifi cation of all genotypes, 5’-ACCCCATCTTTTTGTTTT-3’ 
+ 5’-ACCCCAACGTTTGGTTTTATTAGG-3’ + 5’- ACCCCATCTTTTTGTTTTGTTAGG-3’) 
amplifying a PCR product of 880 bp and in the semi-nested PCR reaction the forward 
primer was replaced by HT26-2 (5’-CCTGCTGGTGGCTCCAGTTC-3’), amplifying a 
product of 806 bp. Sequencing was performed using Big Dye terminator v3.1 cycle 
sequencing kit (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) and a 
ABI3100 instrument (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). 
Subsequently, sequence analysis was performed using Sequence Navigator software 
sequencer (Applied Biosystems), Lasergene v7 (DNASTAR, Madison, WI) and BioEdit 
Software (v7.05), Ibis Therapeutics, Carlsbad, CA, USA). The same region and proce-
dure were used to determine HBV genotypes. The consensus sequences for genotypes 
A-H were obtained from the GenBank.
Statistical analysis
HBV DNA levels were logarithmically transformed for analysis. To correct for differ-
ences in reference between males and females, ALT levels are expressed as values 
representing a ratio to the local upper limit of normal (xULN). Continuous variables 
are expressed as means ± SD or median (range). Follow-up times were calculated 
from the date of ADV treatment initiation to the date of event or censorship. Cumula-
tive probabilities of different endpoints were estimated by Kaplan-Meier analysis. The 
relative risk of several baseline and on-treatment parameters was estimated as an 
hazard ratio (HR) in an univariate and multivariate Cox’s proportional hazards model 
and presented with a 95 percent confi dence interval (95%CI). Multivariate analysis 
was performed with all variables with a p-value < 0.2 in univariate analysis. As the 
low number of patients achieving both secondary endpoints did not provide enough 
power to include multiple variables, only univariate analysis was performed to assess 
baseline and on-treatment predictors. All statistical tests are two-sided, and a p-value 
< 0.05 was considered to be statistically signifi cant. SPSS version 14.0 was used for 
all statistical analysis (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics of the study population are presented in table 1. A total of 76 
patients treated with ADV monotherapy in our hospital were included in this analysis. 
Eighteen patients were excluded. Fourteen patients had a baseline HBV DNA < 4 log10 
copies/mL, of whom eight subjects were switched from a tenofovir (TDF)-containing 
regimen. One patient had coexisting auto-immune hepatitis, two patients were 
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co-infected with HIV, and one patient was co-infected with HDV. Of the 76 patients, 
fi fty-seven (75%) subjects were men and the mean age was 46±14 years. Thirty-eight 
(50%) patients were HBeAg-positive, mean ALT was 3.8±4.2 xULN, and mean HBV 
DNA was 7.5±1.6 log10 copies/mL. The most common genotypes were A (32%), B 
(16%), C (12%), and D (34%). Thirty (40%) subjects had a diagnosis of cirrhosis at 
baseline. Thirty-two (42%) patients received adefovir monotherapy as de novo treat-
ment, while 27 (36%) and 42 (55%) patients were previously treated with (pegylated) 
interferon or lamivudine (LAM), respectively. Twenty-fi ve (33%) patients had a prior his-
tory of LAM resistance. In fourteen (18%) patients LAM-resistant mutations could still 
be detected at the start of ADV treatment. Median follow-up was 122 (24-185) weeks.
Virologic response to adefovir
Overall, 42 (55%) patients achieved VR after a median follow-up of 23 (4-173) weeks, 
of whom 30 subjects (71%) maintained it throughout the on-treatment follow-up. In 8 
additional patients (19%) serum HBV DNA levels remained below 4 log10 copies/mL. 
The cumulative probability of achieving VR at 12, 24, 48, and 96 weeks was 11, 28, 
39, and 49%, respectively (fi gure 1). Undetectable HBV DNA (<373 copies/mL) was 
demonstrated by only 19 (25%) patients during follow-up. Table 2 shows predictors 
of virologic response. Using multivariate analysis increased probabilities of VR were 
seen in HBV patients with HBeAg negativity at baseline (HR 2.98; 95%CI 1.24-7.19; 
Table 1 Baseline characteristics (N=76)
Age 46 ± 14
Gender (male %) 57 (75%)
Race
 Caucasian 44 (58%)
 Asian 19 (25%)
 Other 13 (17%)
BMI 25 ± 4.1
ALT (*ULN) 3.8 ± 4.2
HBV DNA (log10 copies/ml) 7.5 ± 1.6
HBeAg-positive 38 (50%)
Genotype
 A 24 (32%)
 B 12 (16%)
 C 9 (12%)
 D 26 (34%)
 Other 5 (7%)
Cirrhosis 30 (40%)
Previous treatment with peginterferon 27 (36%)
Previous treatment with lamivudine 42 (55%)
Patients with LAM resistance at baseline 14 (18%)
Patients with a prior history of LAM resistance 25 (33%)
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p = 0.02), high baseline ALT levels (HR 1.11; 95% CI 1.05-1.18; p = 0.001), and low 
baseline HBV DNA levels (HR 0.56; 95% CI 0.41-0.75; p < 0.001). In univariate analysis 
HBV DNA levels at week 24 and 48 of ADV treatment were associated with VR as 
well, but both parameters did not reach statistical signifi cance in multivariate analysis. 
Nevertheless, HBV DNA at week 24 demonstrated a higher predictive value for VR 
than HBV DNA at week 48. Clear cut off points for both ALT and HBV DNA levels 
could not be found. Initial virologic response, defi ned as serum HBV DNA levels < 4 
log10 copies/mL after 24 weeks of treatment (26), was achieved in 35 (46%) patients, 
of whom 86% reached VR subsequently. Of the 41 patients who did not achieve initial 
virologic response, VR was found before week 48 and at the end of follow-up in two 
(5%) and twelve patients (29%), respectively. Seventeen patients (22%) demonstrated 
primary nonresponse, defi ned as a decrease in serum HBV DNA of less than 2 log10 
after 24 weeks of treatment (16), of whom four subjects (24%) showed VR at the end of 
follow-up. Of the patients with an HBV DNA decline of more than 2 log10 after 24 weeks 
(59 subjects), only 64% achieved VR during follow-up.
Serological response to adefovir
In total, eight of thirty-eight HBeAg-positive patients (21%) lost HBeAg during follow-
up. Six patients also seroconverted to anti-HBe. The cumulative probability of HBeAg 
loss during ADV treatment was 10% after 48 weeks and 19% after 96 weeks of treat-
ment. In none of the patients ADV was discontinued after HBeAg loss. One patient 
demonstrated a seroreversion during follow-up. In the univariate analysis, HBeAg loss 
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Figure 1 Kaplan-Meier curve for the cumulative probabilities of achieving virologic response, 
defi ned as HBV DNA < 103 copies/mL.
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was only associated with high baseline serum ALT levels (HR 1.15; 95% CI 1.02-1.31; 
p = 0.029).
Development of genotypic resistance to adefovir
Ten patients (13%) developed genotypic ADV resistance during a median follow-up 
of 122 (24-185) weeks of treatment. The cumulative probability of developing ADV-
resistant mutations was 3% and 8% after 48 and 96 weeks of treatment, respectively. 
In the univariate analysis, predictors of genotypic resistance were female gender (HR 
4.99; 95% CI 1.40-17.8; p = 0.013), a higher BMI (HR 1.18; 95% CI 1.02-1.37; p = 
0.026), presence of cirrhosis (HR 6.54; 95% CI 1.39-30.9; p = 0.018), and not achieving 
VR during treatment (HR 6.60; 95% CI 1.35-32.4; p = 0.008). Furthermore, HBeAg 
positivity at baseline (HR 3.09; 95% 0.79-12.0; p = 0.10), and HBV DNA levels above 
Table 2 Baseline and on-treatment predictors of virological response: time-to-event analysis
Parameters Univariate Cox PH model Multivariate Cox PH model
HR (95%CI) p-value HR (95%CI) p-value
Gender 0.70 (0.32-1.51) 0.36 - - -
Age (per 1 year increase) 1.02 (1.0-1.05) 0.05 - - -
Race
 Caucasian 1.00 reference - - -
 Asian 1.92 (0.97-3.82) 0.06 - - -
 Other 1.14 (0.46-2.83) 0.78 - - -
BMI (per 1 unit increase) 0.96 (0.89-1.05) 0.38 - - -
Genotype
 A 1.00 reference - - -
 B 2.78 (1.18-6.58) 0.02 - - -
 C 0.56 (0.16-1.95) 0.36 - - -
 D 0.91 (0.43-1.94) 0.80 - - -
 Other 1.06 (0.24-4.74) 0.94 - - -
HBeAg negativity 7.55 (3.39-16.8) < 0.001 2.98 (1.24-7.19) 0.02
Baseline HBV DNA (per log10 increase) 0.50 (0.40-0.64) < 0.001 0.56 (0.41-0.75) < 0.001
Baseline ALT (per 1*ULN increase) 1.06 (1.00-1.13) 0.05 1.11 (1.05-1.18) 0.001
Previous treatment
 None 1.00 reference - - -
 (PEG) IFN 0.96 (0.13-7.29) 0.97 - - -
 Lamivudine 0.76 (0.34-1.71) 0.51 - - -
 (PEG) IFN/ Lamivudine 0.81 (0.39-1.65) 0.55
Lamivudine resistance at baseline 1.33 (0.63-2.81) 0.46 - - -
Prior history of lamivudine resistance 0.78 (0.40-1.55) 0.49 - - -
Viral load during ADV treatment
  HBV DNA (per log10 increase) at 
week 24 0.48 (0.32-0.72) < 0.001 0.70 (0.47-1.03) 0.07
  HBV DNA (per log10 increase) at 
week 48 0.33 (0.13-0.82) 0.02 - - -
Cirrhosis 0.73 (0.38-1.38) 0.33 - - -
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3 log10 copies/mL after 24 and 48 weeks of treatment exhibited a trend towards the 
emergence of ADV-resistant mutations (table 3). No patients with genotype B or C 
developed genotypic ADV resistance.
Clinical outcome of patients with genotypic resistance
Table 4 shows a summary of the ten patients developing genotypic resistance during 
follow-up. Of these ten patients only three patients were initially switched to ADV after 
LAM breakthrough. At baseline, seven patients were HBeAg positive, median serum 
HBV DNA level was 8.4 (5.2-9.4) log10 copies/mL, and median serum ALT level was 2.5 
(1.2-10.6) xULN. Eight patients had a diagnosis of cirrhosis. Median maximal viral sup-
pression was 3.9 log10 copies/mL. ADV-resistant mutations were detected at a median 
of 98 (36-177) weeks after treatment was initiated. At time of ADV resistance, median 
serum HBV DNA level was 5.1 (3.9-8.1) log10 copies/mL, and median serum ALT level 
was 1.2 (0.6-2.5) xULN. Two patients had an episode of decompensation, and one 
of these patients died subsequently of liver failure. Specifi c ADV-resistant mutations 
included rtN236T and rtA181V (two patients), rtN236T (two patients), rtA181V/T (four 
patients), and rtV214A, rtQ215S/P (two patients). After detection of resistance, ADV 
was discontinued in fi ve patients, and four of these subjects were switched to entecavir 
Table 3 Predictors of development of genotypic adefovir resistance: time-to-event analysis (uni-
variate Cox’s proportional hazards model)
Parameters HR (95%CI) p-value
Gender (female vs. male) 4.99 (1.40-17.8) 0.013
Age (per 1 year increase) 1.03 (0.98-1.09) 0.24
Race
 Caucasian 1.00 reference
 Other 0.44 (0.09-2.12) 0.30
BMI (per 1 unit increase) 1.18 (1.02-1.37) 0.026
Genotype
 A 1.00 reference
 D 3.51 (0.70-17.6) 0.13
 Other 1.53 (0.20-11.5) 0.68
HBeAg positivity 3.09 (0.79-12.0) 0.10
Baseline HBV DNA (per log10 increase) 1.09 (0.71-1.66) 0.70
Baseline ALT (per 1*ULN increase) 0.93 (0.79-1.10) 0.41
Prior exposure to lamivudine 2.55 (0.53-12.3) 0.24
Lamivudine resistance at baseline 0.94 (0.19-4.82) 0.94
Prior history of lamivudine resistance 2.51 (0.66-9.63) 0.18
Cirrhosis 6.54 (1.39-30.9) 0.018
Not achieving VR 6.60 (1.35-32.4) 0.008
Viral load during ADV treatment
 HBV DNA > 3log10 c/mL at week 24 7.15 (0.89-57.6) 0.07
 HBV DNA > 3log10 c/mL at week 48 3.69 (0.76-17.8) 0.07
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(ETV). In one patient TDF/ LAM combination treatment was started. Two patients con-
tinued ADV and LAM was added. One patient did not receive salvage therapy. In this 
patient serum HBV DNA levels decreased and stabilized between 3-4 log10 copies/
mL; ALT levels remained normal at continued ADV therapy. At the last follow-up visit 
ADV-resistant mutations could not be detected.
DISCUSSION
In our study, 55% of patients demonstrated virologic response defi ned as serum HBV 
DNA levels < 3 log10 copies/mL, 21% of HBeAg-positive patients lost HBeAg, and 
13% of patients developed ADV resistance during a median follow-up of 122 (24-185) 
weeks. HBeAg-negativity at baseline, high baseline serum ALT, and low baseline serum 
HBV DNA levels were independent predictors of VR. HBV DNA at week 24 was a better 
on-treatment predictor of VR than HBV DNA at week 48. A diagnosis of cirrhosis at 
baseline and not achieving VR were the most important predictors of occurrence of 
ADV-resistant mutations.
It is known that a signifi cant proportion of patients have slower and poor primary 
responses to ADV, probably related to the suboptimal approved dose.(14). As dem-
onstrated by our and other studies in ADV- and LAM-treated populations, the most 
important baseline predictors of achieving VR are HBeAg-negativity, higher ALT, and 
lower HBV DNA levels.(26-29) Clear cut-off points for both ALT and HBV DNA levels 
could not be found in this study.
In contrast to the treatment of chronic hepatitis C virus infection, current offi cial guide-
lines on the management of chronic HBV infection provides only few recommenda-
tions on on-treatment evaluation.(16) Recently, a new strategy in the treatment with 
nucleos(t)ide analogues, the roadmap concept, was proposed. It was recommended 
that virologic response to ADV should be assessed at week 48 for both HBeAg-positive 
and HBeAg-negative patients, as ADV has a delayed antiviral effect.(30) Indeed, Locar-
nini et al. showed that absolute HBV DNA levels above 3 log10 copies/mL after one 
year of therapy were predictors of ADV resistance at three years.(21) In our study, 
development of genotypic resistance also occurred more frequently in patients with 
HBV DNA levels above 3 log10 copies/mL after 48 weeks treatment. Probably due to 
the low number of patients with ADV resistance this association did not reach statistical 
signifi cance (P=0.07). However, even more interesting is that this trend could already 
be found using absolute HBV DNA levels at week 24. In addition, viral load at week 24 
demonstrated a higher predictive value for VR than HBV DNA levels at week 48, and 
only two patients who did not show initial virologic response at week 24, responded 
before week 48. Yet, it should be mentioned that baseline parameters of VR were far 
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more important predictors of VR than on-treatment HBV DNA levels, as viral load at 
week 24 only demonstrated a trend and viral load at week 48 was not associated with 
VR at all in multivariate analysis. Nevertheless, our study suggests that on-treatment 
assessment of the effi cacy of ADV can be done at an earlier stage than the usually 
recommended 48 weeks, thereby further optimizing the HBV roadmap concept.
Our study demonstrated that continued viral replication during treatment with an antivi-
ral drug and presence of cirrhosis at baseline signifi cantly increased the risk of antiviral 
resistance. Therefore, patients with cirrhosis might be a specifi c population for whom 
potent antiviral agents with high genetic barriers or even de novo combination therapy 
should be considered, as viral and biochemical breakthrough can result in severe 
exacerbations, decompensation, and death.(31) The reason why development of ADV 
resistance occurred more frequently in patients with cirrhosis remains unclear. Another 
unexpected fi nding was that prior lamivudine resistance was not signifi cantly associ-
ated with the emergence of ADV-resistant mutations, as previous studies reported 
increased ADV-resistance rates in lamivudine-resistant HBV patients.(32) However, in 
our study 6 of 25 (24%) patients with a prior history of LAM-resistance showed ADV-
resistant mutations during follow-up, which concurs with previously reported rates.(26, 
33) This suggests that the low number of patients with ADV-resistance did not allow 
demonstrating a signifi cant relation between a prior history of LAM-resistance and 
development of ADV resistant mutations during ADV monotherapy.
Four patients who developed genotypic ADV resistance received entecavir mono-
therapy as salvage therapy, of whom three showed a rapid virologic response. In two 
patients LAM was added, and one patient was switched to TDF/LAM combination 
therapy. In vitro studies indicate that ADV-resistant HBV strains remain susceptible 
to ETV and TDF.(8, 34-37) These results were confi rmed by anecdotal clinical reports.
(26, 37-38) In contrast, substitutions at rtA181 associated with ADV-resistance may 
also induce a decreased susceptibility to LAM.(36-37) The optimal antiviral salvage 
strategy for patients with ADV-resistant HBV remains, however, unclear and needs 
further investigation.
Limitations of our study include the retrospective-observational design and the het-
erogeneous group of patients. Although this is may be considered a disadvantage, it 
probably also refl ects the real situation of CHB clinical practice in the western world. 
Undetectable HBV DNA levels (< 300 copies/mL) may be a more precise defi nition 
of VR. However, as only few patients achieved undetectable HBV DNA, we decided 
to set the defi nition of VR at 103 copies/mL to be able to determine baseline and on-
treatment predictive factors for achieving VR. In addition, using Kaplan-Meier analysis 
response rates can be overestimated. A basic assumption of this approach is that 
a patient will retain the measured outcome whether or not they remain in the study. 
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However, relapse of HBV DNA levels above 103 copies/mL and seroreversion during 
treatment is known to occur in chronic HBV patients.(39)
In conclusion, after two years of ADV treatment VR is achieved in approximately half 
of chronic HBV patients. HBV DNA levels at week 24 demonstrated a higher predictive 
value for VR than HBV DNA levels at week 48. In addition, emergence of ADV-resistant 
mutations occurred more frequently in patients with a viral load > 3 log10 copies/mL 
at week 24. Therefore, our study suggests that virologic response to ADV can already 
be assessed at week 24, instead of the generally recommended 48 weeks. Presence 
of cirrhosis at baseline and not achieving virologic response were important predictors 
of the occurrence of ADV-resistance associated mutations. Patients with cirrhosis at 
baseline might be a specifi c population for whom more potent antiviral agents with 
higher genetic barriers or even de novo combination therapy should be considered.
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Long-term therapy with oral nucleos(t)ide analogues is nowadays used in most patients 
with chronic hepatitis B virus (HBV) infection. Three nucleoside analogues, lamivudine 
(LAM), entecavir (ETV), telbivudine (LdT), and two nucleotide analogues, adefovir dip-
ivoxil (ADV), and tenofovir disiproxil (TDF), are currently approved for the treatment of 
chronic HBV infection.
All nucleos(t)ide analgues are competitive inhibitors of the viral polymerase by compet-
ing with the incorporation of natural intracellular nucleotides in viral DNA. As they lack 
a hydroxyl group, incorporation prevents the formation of a covalent bond with the 
adjacent nucleotide, resulting in chain termination. Although all nucleos(t)ide analogues 
act on HBV polymerase, there are different mechanisms of action. In that perspective, 
three classes of nucleos(t)ide analogues can be identifi ed.(1) L-nucleosides include 
LAM and LdT. LAM is mainly an inhibitor of viral minus strand DNA synthesis, that 
is reverse transcriptase activity, while LdT is supposed to inhibit all the enzymatic 
activities, including priming of reverse transcription, reverse transcriptase activity, and 
synthesis and elongation of viral plus strand. Acyclic phosphonates include TDF and 
ADV, which both are active on the priming of reverse transcription as well as elongation 
of viral minus strand.(2) ETV is the only compound which belongs to the cyclopentane 
group, and acts at all three stages of the viral replication cycle.(3)
Treatment end points and durability of response
With the currently approved treatment options the ultimate goal is to prevent the devel-
opment of long-term sequelae of chronic liver disease. As these clinical outcomes 
arise only after decades of infection, short-term surrogate endpoints are needed to 
determine the success of hepatitis B treatment. As a result, permanent and complete 
suppression of viral replication (at least below 2.000 IU/mL) is our main goal, for per-
sistent HBV viraemia is the most important predictor of progression to liver cirrhosis, 
hepatic failure, and development of hepatocellular carcinoma.(4-5) HBeAg seroconver-
sion remains another important endpoint in HBeAg-positive HBV infection, because 
it is usually associated with sustained remission and very low risk for cirrhosis and 
hepatocellular carcinoma.(6-7)
In general, HBeAg seroconversion rates are approximately 20% after one year of 
nucleos(t)ide analogue treatment, and these rates increase with prolonged therapy.
(8-15) International guidelines on the therapy of hepatitis B suggest that fi nite dura-
tion of treatment with nucleos(t)ide analogues is a reasonable option, and recommend 
that treatment can be stopped after HBeAg seroconversion and an additional 6 to 12 
months of consolidation therapy.(16-17) However, the long-term durability of HBeAg 
seroconversion induced by nucleos(t)ide analogues is controversial, as several studies 
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have reported contradictory results. Whereas some authors reported nucleos(t)ide 
analogue-induced HBeAg seroconversion to be durable in up to 90%, others reported 
relapse rates as high as 70%.(18-20) In chapter two, the long-term durability of 
nucleos(t)ide analogue-induced HBeAg seroconversion is explored. During a median 
follow-up of fi ve years after the development of nucleos(t)ide analogue induced HBeAg 
seroconversion, only 31% of patients demonstrated a durable remission, defi ned as 
HBeAg negativity and HBV DNA levels less than 10,000 copies/mL (~ 2.000 IU/mL). 
Moreover, sustained response was demonstrated in just two of nine patients who 
discontinued therapy after a consolidation therapy of at least 6 months. Disease recur-
rence in patients that continued therapy after HBeAg seroconversion was preceded 
by the development of resistance (80% of these patients); resistance only occurred 
in subjects given lamivudine monotherapy. In contrast, recurrence after treatment 
discontinuation or non-compliance was observed in all patients given nucleos(t)ide 
analogues. These fi ndings indicate that HBeAg seroconversion, in contrast to what 
current guidelines suggest, is an imperfect endpoint in assessing nucleos(t)ide ana-
logue therapy. Therefore, long-term continuation of nucleos(t)ide analogue treatment, 
irrespective of the occurrence of HBeAg seroconversion, appears to be necessary in 
most patients.
In contrast to nucleos(t)ide analogue therapy, treatment with (pegylated) interferon 
results in a more durable response once treatment is discontinued in patients with 
chronic hepatitis B.(21-22) Intrahepatic covalently closed circular DNA (cccDNA), 
which plays a major role in viral persistence, is a strong predictor of sustained off-
treatment virological response.(23) Serum hepatitis B surface antigen (HBsAg) levels 
are known to refl ect cccDNA in the liver, and reduction of HBsAg levels correlates 
well with that of cccDNA.(24-26) In chapter 3, on-treatment serum HBsAg kinetics in 
patients with both HBeAg-positive and HBeAg-negative chronic hepatitis B receiving 
either pegylated interferon or ETV monotherapy, are compared. In HBeAg-positive 
patients, decline of HBsAg was signifi cantly associated with HBeAg loss, and, sub-
sequently, HBsAg decline tended to be higher in pegylated interferon treated subjects 
compared to ETV-treated subjects. Interestingly, patients who achieved HBeAg loss 
during either pegylated interferon or ETV therapy demonstrated a similar reduction in 
HBsAg levels. In contrast, in HBeAg-negative patients, only treatment with pegylated 
interferon resulted in a signifi cant HBsAg decline, whereas HBeAg-negative patients 
treated with ETV demonstrated no HBsAg reduction at all. This study confi rms 
previous observations that immune modulation is of vital importance to completely 
eradicate HBV.(25-26) First, pegylated interferon resulted in higher HBeAg loss rates 
compared to ETV, and in signifi cant HBsAg decline in both HBeAg-negative and 
HBeAg-positive patients. Second, although ETV demonstrated to be a potent inhibitor 
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of viral replication, a signifi cant decline of HBsAg was only observed in those patients 
with preexisting immune activity, refl ected by high baseline ALT levels, and in those 
patients who achieved HBeAg loss after one year of therapy.
That nucleos(t)ide analogues relatively lack any immunomodulatory action is actually 
confi rmed in chapter 4, which explores the role and outcome of nucleos(t)ide analogue 
treatment-related hepatitis fl ares. Hepatitis fl ares are abrupt elevations of serum ami-
notransferase levels, and refl ect immune-mediated lysis of infected hepatocytes.(27-
28) It is known that during treatment with (pegylated) interferon approximately 25-40% 
of patients experience hepatitis fl ares, which are explained by the immunostimulatory 
properties of this drug, and are associated with HBeAg seroconversion and sustained 
response.(29) In our study, fl ares during (on-therapy fl ares) and after discontinuation 
(withdrawal fl ares) of nucleos(t)ide analogue therapy never led to sustained disease 
remission, and even sometimes resulted in decompensated liver disease.
Nucleos(t)ide analogue therapy in treatment-naïve patients
As a sustained off-treatment response seems only possible in a minority of patients 
treated with nucleos(t)ide analogues, nucleos(t)ide analogues probably have to be 
administered for very long periods, if not indefi nitely. Development of antiviral drug 
resistance is a major limitation to long-term effi cacy of nucleos(t)ide analogues, and 
completely negates the benefi ts obtained from treatment with oral antiviral agents.(30) 
It is therefore clear that the main barrier to long-term control in any individual will be 
drug resistance. The rapidity of emergence of these drug-resistant mutants depends 
on several factors, including two treatment-related parameters, i.e. genetic barrier and 
potency. The genetic barrier of a treatment regimen is the number of mutations needed 
to generate a virus strain with a marked decrease in susceptibility to the drug, yet 
which still is able to replicate in the presence of these primary resistance mutations. A 
high antiviral potency of a treatment regimen results in quick and complete suppres-
sion of viral replication. As resistance only emerges when replication occurs in the 
presence of the drug selection, it allows little opportunity for resistance to develop.(31)
TDF was licensed for the treatment of human immunodefi ciency virus (HIV) infection in 
2001, and plays since that time a pivotal role in HIV management. Recent data showed 
the effi cacy of TDF in the treatment of chronically HBV-monoinfected patients as well.
(13) TDF was superior to ADV in both nucleos(t)ide-naïve HBeAg-positive and HBeAg-
negative HBV patients, and appeared to be one of the most potent anti-HBV agents 
so far. In chapter 5, the long-term effi cacy and renal safety of TDF administered as a 
part of anti-retroviral therapy was explored in a largest cohort of HIV/HBV-coinfected 
patients published so far. It is shown that after fi ve years of follow-up, approximately 
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90% of patients achieved undetectable HBV DNA (< 20 IU/mL), almost 50% of HBeAg-
positive patients demonstrated HBeAg loss, and HBsAg loss was even observed in 
approximately 10% of subjects. More importantly, only one patient demonstrated a 
combination of known anti-HBV drug-resistant mutations, and experienced a virologic 
breakthrough thereafter. Furthermore, this study supports the renal safety of TDF 
through fi ve years of treatment, as only a small, non-progressive decline in renal func-
tion was observed.
ETV is a potent and selective inhibitor of HBV replication in vitro.(3) In the phase III 
registration trials it resulted in superior virologic, biochemical and histological effi cacy 
after one year of therapy compared to LAM in both HBeAg-positive and HBeAg-nega-
tive chronic HBV patients.(8, 32) Moreover, ETV proved to have a high genetic barrier to 
resistance with only 1.2% of nucleos(t)ide analogue-naïve HBV patients demonstrating 
genotypic resistance to ETV after fi ve years of ETV monotherapy.(15) In chapter 6 
the potent antiviral effect of ETV and its excellent resistance profi le in nucleos(t)ide 
analogue-naïve patients is confi rmed. It is demonstrated that 55% of HBeAg-positive 
and 92% of HBeAg-negative HBV patients achieved undetectable HBV DNA levels 
after one year of therapy, and none of the patients developed antiviral drug resistance.
In conclusion, the superior potency of TDF and ETV and their excellent resistance 
profi les in nucleos(t)ide-naïve HBV patients, which were previously demonstrated in 
large randomized controlled trials, have now been confi rmed in large scale investigator-
initiated studies with variable follow-up, organised by European research consortia.
(33) As recommended in the recent HBV treatment guidelines of EASL, TDF and ETV 
should, therefore, be prioritised as a fi rst-line treatment. LAM, ADV and LdT should 
no longer be considered as fi rst-line choice, due to their inferior resistance profi le, for 
HBV-monoinfected patients, even for those with favourable baseline characteristics 
and even when virological response will be evaluated at week 24.
Nucleos(t)ide analogue therapy in treatment-experienced patients
As mentioned before, we should use only potent nucleos(t)ide analogues with a high 
genetic barrier as monotherapy to prevent the emergence of antiviral drug resistance. 
The current guidelines recommend that in case of development of antiviral drug resis-
tance, a second antiviral drug should be added to the treatment regimen, which is not 
cross-resistant.(16-17, 31)
TDF has been shown to be effective in the nucleos(t)ide analogue-experienced 
population, although confl icting results have been presented concerning patients with 
genotypic resistance to ADV.(33) LAM demonstrates signifi cant anti-HIV activity, and 
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is commonly used as part of an anti-HIV combination treatment regimen. In chapter 
5, it is demonstrated that both preceding treatment with LAM and the presence of 
LAM-resistance did not affect the response to TDF. Furthermore, switching to TDF, 
whether in mono- or in combination therapy, resulted in decline of viral load in patients 
with ETV-resistance associated mutations (chapter 6).
Concerning the use of ETV for the nucleos(t)ide analogue-experienced population, it 
is clearly demonstrated in chapter 6 that ETV should not be used as rescue therapy in 
patients with a prior history with LAM-resistance, even when LAM-resistant mutations 
can not be detected at baseline. Also in patients with LAM-resistance and a low viral 
load at baseline, response to ETV appears suboptimal. ETV may still be used in LAM-
experienced patients in case LAM-resistance never developed, yet longer follow-up 
is required to confi rm these initial observations. The antiviral effi cacy of ETV was not 
infl uenced by prior treatment with ADV or presence of ADV resistance. Furthermore, 
in a large cohort of HIV/HBV coinfected patients, adding ETV to the treatment regi-
men resulted in achievement of undetectable HBV DNA in patients who demonstrate 
persistent HBV replication during a TDF-containing treatment regimen (chapter 5).
In the last few years management of resistance has evolved, and treatment strategies 
and clinical guidelines have been developed, mostly focusing on prevention of antiviral 
drug resistance.(16, 34) It is recommended that treatment should be adapted at an 
early stage in case of incomplete viral suppression, as several studies have already 
shown that an initial virologic response is associated with lower rates of antiviral drug 
resistance in HBV patients in the long term. The so-called roadmap concept and the 
recently published EASL guidelines on the treatment of chronic HBV infection both 
propose that virologic response should be assessed at week 12 and 24 to identify 
primary nonresponse and/or partial virologic response, respectively, and to modify 
treatment accordingly. Although it is questionable whether this concept also applies 
to the new potent drugs with low resistance rates, some experts would suggest in 
patients receiving ETV or TDF with a partial virologic response at week 48, adding the 
other drug in order to prevent resistance in the long term. However, in chapter 5, it is 
demonstrated that most patients treated with TDF are still able to achieve undetectable 
HBV DNA in the second year without changing the treatment regimen, and a similar 
observation was recently made in patients treated with ETV. In contrast, for LAM it was 
suggested that virologic response could already be assessed at four weeks to predict 
response at fi ve years of therapy (35), and that on-treatment evaluation of the effi cacy 
of ADV can also be done at an earlier stage than one year (chapter 8).
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In chapter 7, the effi cacy of ETV as rescue therapy for patients with a persistently high 
viral load during ADV treatment is described. Surprisingly, ETV monotherapy resulted 
in a limited HBV DNA decline in both LAM-experienced and -naïve patients with per-
sistently high HBV DNA during ADV treatment. Only one of fourteen patients achieved 
undetectable HBV DNA levels (< 373 copies/mL), and none of the patients showed 
HBeAg loss or seroconversion. The contrasting outcome with other studies might be 
related to selection of patients who respond poorly to nucleos(t)ide analogues in gen-
eral instead of previous ADV therapy itself. An interesting observation was, therefore, 
that two patients with a limited virologic response to ETV 1 mg daily demonstrated 
further HBV DNA decline after increasing the dosage to 2 mg daily, which suggests that 
increasing a drug to its maximum tolerated dose may provide a reasonable option to 
maximize antiviral activity besides switching to or adding another drug.
In summary, for patients who developed antiviral drug resistance, it is recommended 
that a second drug without cross-resistance should be added, meaning TDF or ETV 
should be added in subjects who developed resistance against a nucleoside or nucleo-
tide analogue, respectively. However, the necessity of the add-on strategy has recently 
been debated, as the initial results of switching to TDF or ETV monotherapy in LAM- or 
ADV-resistant HBV patients are promising. Although treatment should be adapted at 
an early stage in case of incomplete viral suppression to prevent the development of 
antiviral drug resistance, one can probably wait at least 24 months in patients treated 
with TDF or ETV monotherapy who are viremic, before switching to an alternative treat-
ment regimen, particularly in case of continued viral load decline.
Conclusion
Long-term continuation of nucleos(t)ide analogue treatment, irrespective of the 
occurrence of HBeAg seroconversion, appears to be necessary in most patients. The 
superior potency of TDF and ETV and their excellent resistance profi les in nucleos(t)
ide-naïve HBV patients have now been confi rmed in large scale investigator-initiated 
studies. TDF and ETV should, therefore, be prioritised as a fi rst-line nucleos(t)ide 
analogue treatment. One can probably wait at least 24 months in patients treated with 
TDF or ETV monotherapy who are viremic, before switching to an alternative treatment 
regimen. In the nucleos(t)ide analogue-experienced population, TDF or ETV should be 
initiated if resistance is detected to a nucleoside or nucleotide analogue, respectively. 
The necessity of the add-on strategy has recently been debated, and additional stud-
ies with longer follow-up are needed to confi rm these initial observations.
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Langdurige behandeling met nucleos(t)ide-analogen is tegenwoordig een veelvuldig 
gebruikte behandelingsmethode voor een chronische hepatitis B infectie. Op dit 
moment zijn drie nucleoside-analogen, lamivudine (LAM), telbivudine (LdT), en enteca-
vir (ETV), en twee nucleotide-analogen, adefovir dipivoxil (ADV), en tenofovir disiproxil 
(TDF), geregistreerd voor de behandeling van chronische hepatitis B.
Alle nucleos(t)ide-analogen zijn krachtige remmers van het virale enzym, DNA- poly-
merase, door middel van competitie met het natuurlijk substraat, de bouwstenen 
van het DNA. Door het ontbreken van een hydroxyl-groep, leidt incorporatie van het 
synthetische nucleoside-analogon tot voortijdige blokkering van de virale DNA-keten-
verlenging. Hoewel alle nucleos(t)ide-analogen het HBV-polymerase remmen, zijn er 
verschillende werkingsmechanismen. In totaal worden er drie klassen van nucleos(t)
ide-analogen onderscheiden.(1) LAM en LdT behoren tot de groep van L-nucleosiden. 
LAM is hoofdzakelijk een inhibitor van reverse-transcriptie van de negatieve streng 
DNA van het pregenome boodschapper-RNA, terwijl LdT alle drie functionele acti-
viteiten van het virale polymerase remt: priming van het HBV-polymerase, reverse-
transcriptie, en synthese van de positieve streng HBV DNA. De acyclische fosfonaten 
omvatten TDF en ADV, welke beide werken middels remming van synthese van de 
negatieve streng DNA en priming van het HBV-polymerase. (2) ETV is het enige middel 
dat behoort tot de groep van cyclopentanen, en remt alle drie de activiteiten van het 
HBV-polymerase. (3)
Eindpunten van behandeling en duurzaamheid van respons
Met de huidige beschikbare antivirale middelen is het uiteindelijke doel van behandeling 
het voorkomen van de lange termijnscomplicaties van chronisch leverlijden. Levercir-
rose en hepatocellulair carcinoom ontstaan echter pas tientallen jaren na besmetting, 
en derhalve zijn er surrogaat eindpunten op de korte termijn nodig, die geassocieerd 
zijn met een gunstig effect op de lange termijn. Het belangrijkste surrogaat eindpunt 
is blijvende en complete remming van virale replicatie, omdat virale load (serum HBV 
DNA) een uitstekende voorspeller is van progressie naar levercirrose of het ontwik-
kelen van hepatocellulair carcinoom. Een serum HBV DNA < 2.000 IU/mL lijkt hiervoor 
voldoende. (4-5) HBeAg seroconversie (verlies van HBeAg met ontwikkeling van anti-
HBe) is tevens een belangrijk eindpunt bij HBeAg-positieve chronische hepatitis B, 
omdat het meestal geassocieerd is met blijvende remissie van ziekte, en een laag risico 
op het ontwikkelen van levercirrose of hepatocellulair carcinoom.(6-7)
In het algemeen resulteert een jaar behandeling met een nucleos(t)ide-analogon bij 
ongeveer 20% van de patiënten in HBeAg-seroconversie, en dit percentage neemt 
toe met doorgaande therapie.(8-15) In de huidige internationale richtlijnen over de 
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behandeling van hepatitis B wordt aanbevolen dat de behandeling met nucleos(t)
ide-analogen ten minste dient te worden gecontinueerd tot het optreden van HBeAg-
seroconversie, en pas gestaakt kan worden na zes tot twaalf maanden consolidatie-
therapie.(16-17) De duurzaamheid van een door nucleos(t)ide analogen geïnduceerde 
HBeAg-seroconversie is echter onduidelijk, daar verschillende studies tegengestelde 
resultaten laten zien en het percentage van patiënten die een blijvende remissie van 
ziekte tonen na HBeAg-seroconversie uiteenloopt van 30-90%.(18-20) In hoofdstuk 
twee onderzochten wij de duurzaamheid van een door nucleos(t)ide-analogen geïndu-
ceerde HBeAg-seroconversie. Gedurende een mediane follow-up van vijf jaar na het 
optreden van HBeAg-seroconversie tijdens de behandeling met nucleos(t)ide-analogen, 
was er slechts bij 31% van de patiënten sprake van een blijvende duurzame respons, 
hetgeen gedefi nieerd werd als een combinatie van HBeAg-negativiteit en een virale 
load lager dan 10.000 kopieën/ml (~2.000 IU/ml). Daarnaast toonden zeven van de 
negen patiënten, die de behandeling staakten na een consolidatietherapie van ten min-
ste zes maanden, terugkeer van actieve ziekte. Terugval gedurende behandeling werd 
voorafgegaan door het ontstaan van antivirale resistentie bij 80% van de patiënten, en 
alleen bij de patiënten die werden behandeld met LAM monotherapie. Daarentegen 
trad terugkeer van ziekte na het bewust staken van antivirale behandeling of therapie-
ontrouw op bij alle nucleos(t)ide-analogen. Derhalve lijkt HBeAg-seroconversie een 
suboptimaal eindpunt te zijn voor de behandeling met nucleo s(t)ide-analogen en 
dient de behandeling langdurig te worden gecontinueerd, ongeacht het optreden van 
HBeAg-seroconversie bij de meeste patiënten.
Vergeleken met de behandeling met nucleos(t)ide-analogen resulteert (gepegyleerd) 
interferon in een hoger percentage patiënten met een blijvende, duurzame respons na 
het staken van therapie.(21-22) Totale eliminatie van het hepatitis B virus is vooralsnog 
niet mogelijk gebleken met de huidige behandelmogelijkheden, hetgeen samenhangt 
met het uitermate therapieresistente cccDNA (covalently closed circular DNA) dat zich 
bevindt in de hepatocyt. Eerder onderzoek toont aan dat de hoeveelheid intrahepa-
tisch cccDNA een belangrijk voorspeller is van een blijvende virologische respons na 
het staken van antivirale therapie.(23) Bovendien lijken HBsAg concentraties in het 
serum de hoeveelheid intrahepatisch cccDNA goed te weerspiegelen en is een daling 
van HBsAg-concentraties in het serum gecorreleerd met de daling van cccDNA in de 
lever.(24-26) In hoofdstuk 3 vergelijken wij de kinetiek van HBsAg concentraties in het 
serum van patiënten met chronische HBeAg-positieve en HBeAg-negatieve hepatitis 
B, die behandeld worden met gepegyleerd interferon of entecavir. In HBeAg-positieve 
hepatitis B patiënten was de daling in HBsAg concentraties sterk geassocieerd met het 
optreden van HBeAg verlies gedurende de behandeling. Aangezien behandeling met 
gepegyleerd interferon leidt tot een hoger percentage patiënten met HBeAg verlies, 
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resulteerde het in vergelijking met entecavir ook in een grotere daling van serum 
HBsAg. Indien HBeAg verlies bewerkstelligd werd, was er echter geen verschil te zien 
in de mate van HBsAg daling tussen deze twee behandelingen. Bij HBeAg-negatieve 
hepatitis B patiënten leidde alleen gepegyleerd interferon tot een daling van HBsAg 
concentraties.
Deze uitkomsten bevestigen eerdere bevindingen dat voor totale eliminatie van het 
hepatitis B virus immuunmodulatie van essentieel belang is.(25-26) Ten eerste resulteert 
gepegyleerd interferon, een antiviraal middel met immunomodulatoire eigenschappen, 
in hogere percentages patiënten met HBeAg verlies, en in signifi cante dalingen van 
HBsAg concentraties in HBeAg-positieve en HBeAg-negatieve hepatitis B patiënten. 
Daarnaast leidde ETV alleen tot HBsAg daling bij patiënten die of vooraf aan de behan-
deling immuunactiviteit toonden, hetgeen weerspiegeld werd door hogere baseline 
ALAT waarden, of HBeAg verlies bereikten gedurende de behandeling.
Dat het nucleos(t)ide-analogen ontbreekt aan immunomodulatoire eigenschappen, 
wordt in feite gesteund door de bevindingen in hoofdstuk 4, waarin de rol en uitkomst 
van hepatitis opvlammingen (‘hepatitis fl are’) gedurende behandeling met nucleo-
s(t)ide-analogen wordt onderzocht. Hepatitis fl ares zijn plotselinge toenames van serum 
transaminsase concentraties, en geven immuungemedieerde lysis van geïnfecteerde 
hepatocyten weer.(27-28) Hepatitis fl ares worden bij 25-40% van de patienten gezien 
die worden behandeld met interferon. Ze zijn geassocieerd met HBeAg-seroconversie 
en blijvende virologische respons na het staken van de therapie. In hoofdstuk vier 
wordt beschreven dat geen enkele nucleos(t)ide-analogen geassocieerde hepatitis 
fl are leidde tot een blijvende remissie van ziekte en soms zelfs resulteerde in gede-
compenseerde leverziekte.
Behandeling met nucleos(t)ide-analogen in nucleos(t)ide-naïeve patiënten
Patiënten dienen in het algemeen langdurig met nucleos(t)ide-analogen te worden 
behandeld, aangezien een blijvende respons na het staken van de behandeling slechts 
bij een beperkt aantal patiënten kan worden bereikt. Met de duur van de behandeling 
neemt de kans op het ontstaan van antivirale resistentie toe. Dit manifesteert zich door 
een stijging van het serum HBV DNA, ondanks het continueren van de behandeling, bij 
een patiënt met in eerste instantie een goede virologische respons,.(30) Het voorkomen 
van antivirale resistentie is daarom essentieel om langdurige onderdrukking van virale 
replicatie te bewerkstelligen door middels van nucleos(t)ide-analogentherapie. De snel-
heid waarmee antivirale resistentie zich ontwikkelt, wordt onder andere bepaald door 
twee therapiegerelateerde parameters: de genetische barrière en antivirale potentie. 
Met de genetische barrière wordt bedoeld het aantal mutaties dat nodig is om een HBV 
mutant te verkrijgen met verminderde gevoeligheid voor het antivirale middel, maar die 
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nog steeds in staat is te repliceren ondanks deze mutaties. Een hoge antivirale potentie 
resulteert in een snelle en complete remming van virale replicatie, hetgeen de kans op 
het ontstaan van resistentie op de lange termijn vermindert.(31)
TDF werd in 2001 geregistreerd voor de behandeling van een HIV (humaan 
immunodefi ciëntievirus)-infectie en is sindsdien een belangrijk onderdeel van HAART 
(highly active anti-retroviral therapy). Recente studies tonen tevens de effectiviteit van 
TDF aan voor de behandeling van een chronische hepatitis B virus monoinfectie.(13) 
In zowel HBeAg-positieve als HBeAg-negatieve hepatitis B patiënten werden er betere 
resultaten bereikt met TDF vergeleken met ADV. Daarnaast leek het een van de meeste 
krachtige anti-HBV middelen te zijn tot nu toe. In hoofdstuk 5 wordt de effectiviteit en 
veiligheid van TDF, als onderdeel van HAART, onderzocht in het grootste cohort van 
HIV/HBV gecoinfecteerde patiënten dat tot nog toe gepubliceerd is. Na vijf jaar behan-
deling bereikte ongeveer 90% van de patiënten een ondetecteerbaar HBV DNA (<20 
IU/ml), bijna 50% van de HBeAg-positieve patiënten toonde HBeAg verlies, en bij 10% 
van de patiënten werd zelfs HBsAg verlies gezien. In slechts een patiënt werd er een 
virologische doorbraak geobserveerd en detecteerden wij mutaties in het HBV DNA, 
die geassocieerd zijn met resistentie tegen anti-HBV middelen. Daarnaast bevestigden 
wij de renale veiligheid van TDF, aangezien er gedurende vijf jaar behandeling slechts 
een beperkte, niet-progressieve daling in nierfunctie werd geobserveerd.
In vitro studies tonen aan dat ETV een krachtige en selectieve remmer is van HBV 
replicatie. In grote gerandomiseerde klinische trials werden er na een jaar behande-
ling met ETV betere virologische, biochemische en histologische resultaten bereikt 
vergeleken met LAM bij HBeAg-positieve en HBeAg-negatieve hepatitis B patiënten.
(8, 32) Daarnaast heeft ETV een goed resistentieprofi el en werd er na vijf jaar ETV 
monotherapie bij slechts 1.2% van de nucleos(t)ide-naïeve patiënten genotypische 
resistentie aangetoond.(15) In hoofdstuk 6 wordt het krachtige antivirale effect van 
ETV en het uitstekende resistentieprofi el bij nucleos(t)ide-naïeve patiënten bevestigd in 
de klinische praktijk. Na een jaar behandeling bereikten 55% van de HBeAg-positieve 
en 92% van de HBeAg-negatieve patiënten een ondetecteerbare virale load en ontwik-
kelde geen van de patiënten resistentie tegen ETV.
De krachtige anti-HBV eigenschappen van TDF en ETV en hun uitstekende resisten-
tieprofi elen bij nucleos(t)ide-naïeve hepatitis B patiënten, welke al eerder werden 
aangetoond in klinische trials, zijn nu ook bevestigd in grootschalige, onafhankelijke 
cohort studies.(33) TDF en ETV dienen dan ook de middelen van eerste keuze te zijn, 
indien er wordt gekozen voor een behandeling met nucleos(t)ide-analogen. Dit wordt 
tevens aanbevolen in de recent verschenen richtlijnen betreffende de behandeling van 
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chronisch hepatitis B van de EASL. LAM, ADV, en LdT komen hier niet langer voor in 
aanmerking vanwege hun inferieure resistentieprofi elen en dienen ook niet te worden 
overwogen bij patiënten met voordelige baseline karakteristieken, of bij patienten bij 
wie op week 24 de virologische respons kan worden geëvalueerd.
Behandeling met nucleos(t)ide-analogen in voorbehandelde patiënten
Zoals hierboven reeds beschreven werd, dienen er alleen krachtige antivirale middelen 
te worden gebruikt met een hoge genetische barrière teneinde de ontwikkeling van 
resistentie op de lange termijn te voorkomen. De huidige richtlijnen bevelen aan dat in 
het geval van het ontstaan van resistentie, er een tweede middel moet worden toege-
voegd aan de behandeling die niet kruisresistent is.(16-17, 31)
TDF is een effectief antiviraal middel bij patiënten die al eerder zijn behandeld met 
nucleos(t)ide-analogen, hoewel studies betreffende voornamelijk ADV-resistente HBV 
patiënten tegenstrijdige resultaten laten zien.(33) LAM is een goede remmer van HIV 
replicatie en maakt regelmatig onderdeel uit van HAART. In hoofdstuk 5 wordt aange-
toond dat eerdere behandeling met LAM en/of de aanwezigheid van LAM-resistentie 
geen invloed heeft op het antivirale effect van TDF bij HIV/HBV gecoïnfecteerde patiën-
ten. Daarnaast laten wij zien dat bij patiënten met HBV mutanten die geassocieerd 
zijn met een verminderde gevoeligheid voor ETV, de omzetting naar TDF, al dan niet in 
combinatie met een ander middel, leidt tot virusdaling (hoofdstuk 6).
Omzetting naar ETV monotherapie is geen geschikte strategie voor patiënten die in 
het verleden resistentie tegen LAM hebben ontwikkeld, zelfs niet als op het moment 
van starten deze specifi eke HBV mutanten niet meer gedetecteerd kunnen worden 
of als er sprake is van een lage virale load. ETV kan daarentegen nog steeds een 
effectief middel zijn bij patiënten die eerder werden behandeld met LAM, maar bij wie 
nooit LAM-resistente mutaties zijn gedetecteerd. Er is echter een langere follow-up 
nodig om deze initiële observaties te bevestigen. Een eerdere behandeling met ADV, 
of de aanwezigheid van ADV-resistente HBV mutanten, heeft echter geen invloed op 
het antivirale effect van ETV (hoofdstuk 6). Bovendien leidde het toevoegen van ETV 
bij HIV/HBV gecoinfecteerde patiënten met persisterende HBV replicatie onder een 
TDF-bevattend behandelingsschema, tot complete virale suppressie (hoofdstuk 5).
In de laatste jaren is de behandeling van resistentie verder verfi jnd, en zijn er behan-
delingsstrategieën en richtlijnen ontwikkeld die meer gericht zijn op de preventie van 
antivirale resistentie.(16, 34) Aangezien voortgaande virale replicatie onder antivirale 
therapie geassocieerd is met een hogere kans op resistentie, wordt in de huidige 
richtlijnen aanbevolen de behandeling in een vroeg stadium aan te passen indien er 
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sprake is van incomplete virale suppressie. Het zogenoemde “roadmap” concept en 
de recent verschenen richtlijnen van de EASL geven beide aan dat de virologische 
respons op zowel week 12 als week 24 geëvalueerd dient te worden en dat in het 
geval van een zogenaamde primaire non-respons of partiële virologische respons, de 
behandeling moet worden aangepast. Hoewel het de vraag is of deze aanbevelingen 
ook van toepassing zijn op de nieuwere orale middelen met hun uitstekende resisten-
tieprofi elen, zijn sommige experts van mening dat bij incomplete virale suppressie na 
een jaar behandeling met TDF of ETV monotherapie, het andere middel moet worden 
toegevoegd om resistentie op de lange termijn te voorkomen. Data om deze aan-
bevelingen te ondersteunen, ontbreken echter op dit moment. In hoofdstuk 5 laten 
wij juist zien dat een aanzienlijk deel van de patiënten met een detecteerbare virale 
load na een jaar behandeling met TDF, in het tweede jaar van de behandeling alsnog 
complete virale suppressie bereiken. Eenzelfde observatie bij ETV monotherapie werd 
recent ook beschreven. Daarentegen werd met betrekking tot LAM monotherapie in 
een Aziatische studie aangetoond dat de virologische respons op week 4 al een goede 
voorspeller is van de uitkomst na vijf jaar behandeling.(35) Verder laten wij in hoofdstuk 
8 zien dat de respons op ADV monotherapie waarschijnlijk ook op een eerder tijdstip 
kan worden geëvalueerd dan de vaak aanbevolen 48 weken.
In hoofdstuk 7 wordt de effectiviteit van ETV beschreven bij een serie HBeAg-positieve 
HBV patiënten met een persisterend hoge virale load onder ADV monotherapie. Zowel 
bij patiënten die eerder met LAM werden behandeld als bij LAM-naïeve patiënten, 
leidde de omzetting naar ETV monotherapie tot een beperkte daling in virale load. 
Gedurende de follow-up bereikte slechts een van de veertien patiënten een onde-
tecteerbare virale load (< 373 kopieën/mL) en bij geen van de patiënten werd HBeAg 
verlies of seroconversie geobserveerd. Deze tegenstrijdige uitkomst vergeleken met 
andere studies, kan mogelijk verklaard worden door het feit dat er een selectie van 
patiënten heeft plaatsgevonden die in het algemeen slecht responderen op nucleos(t)
ide-analogen. Een interessante bevinding daarbij was dat bij twee patiënten met een 
partiele respons op ETV monotherapie (1 mg) een verdubbeling van de dosering leidde 
tot een verdere virusdaling. Dit suggereert dat voor bepaalde patiënten met een sub-
optimale virologische respons het verhogen van de dosis een alternatief kan zijn naast 
het omzetten naar of toevoegen van een nucleos(t)ide-analogon.
In het algemeen kan dus worden aanbevolen dat in het geval van antivirale resistentie 
tegen een nucleoside- of nucleotide-analogon, respectievelijk TDF of ETV moet worden 
toegevoegd aan de behandeling. Of het toevoegen van een nucleos(t)ide-analogon in 
plaats van het omzetten naar monotherapie daadwerkelijk nodig is, moeten additionele 
studies met een langere follow-up uitwijzen. De initiële resultaten van het omzetten 
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naar TDF of ETV monotherapie bij LAM- of ADV-resistente HBV patiënten zijn echter 
veelbelovend. Ter preventie van resistentie dient de antivirale behandeling in een vroeg 
stadium te worden aangepast in het geval van incomplete virale suppressie. Bij TDF 
of ETV monotherapie lijkt men hiermee echter veel langer meer te kunnen wachten, en 
waarschijnlijk tot ten minste 24 maanden behandeling.
Conclusie
Langdurige behandeling met nucleos(t)ide-analogen lijkt noodzakelijk bij de meeste 
patiënten, zelfs indien HBeAg-seroconversie gedurende de therapie optreedt. De 
krachtige anti-HBV eigenschappen van TDF en ETV en hun uitstekende resisten-
tieprofi elen bij nucleos(t)ide-naïeve hepatitis B patiënten zijn nu ook bevestigd in 
grootschalige, onafhankelijke cohort studies. TDF en ETV dienen dan ook de nucleo-
s(t)ide-analogen van eerste keuze te zijn. Bij patiënten die viremisch blijven onder 
TDF of ETV monotherapie kan men veel langer wachten dan bij LAM en ADV, voordat 
de behandeling moet worden aangepast. In het geval van antivirale resistentie tegen 
een nucleoside- of nucleotide-analogon moet respectievelijk TDF of ETV worden 
toegevoegd aan de behandeling. Of het toevoegen van een nucleos(t)ide-analogon in 
plaats van het omzetten naar monotherapie daadwerkelijk nodig is, moeten additionele 
studies met een langere follow-up uitwijzen.
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D ankwoord
Ik dacht gedurende mijn promotieonderzoek, dat als ik eenmaal was aangekomen bij 
het dankwoord, ik enorm gelukkig en ontspannen zou zijn. Ik kan echter melden dat in 
deze fase van afronding zelfs dit een opgave wordt en een deadline heeft, aangezien 
het drukken van het boekje over twee dagen moet gaan starten. Ik ben echter blij dat ik 
de afgelopen vier jaar aan dit onderzoek heb kunnen werken, en kijk nog weleens met 
weemoed terug hoe fl exibel je de dagen toen nog kon invullen.
Allereerst gaat mijn dank natuurlijk uit naar mijn promotor, prof. dr. Harry Janssen. 
Beste Harry, in 2006 kwam ik tijdens mijn oudste coschap tussen de bedrijven door 
je kamer binnenzetten met de vraag of je niet een promotieplekje voor mij had. Het 
resulteerde in een soort van sollicitatiegesprek, en binnen een week lag mijn toekomst 
voor de komende drie jaar vast. Ik denk dat je voor mij de ideale begeleider was bij ons 
onderzoek. Je geeft iemand veel verantwoordelijkheid en vrijheid om het onderzoek 
naar zijn inzichten in te vullen, en weet de onderzoeksgroep te leiden zonder te veel 
nutteloos gewauwel eromheen. Daarnaast kijk ik met bewondering hoe je ster wereld-
wijd rijzende is binnen de hepatologie, waarbij naar mijn mening Rotterdam een unieke, 
maar nog veel belangrijker, onafhankelijke positie inneemt binnen de commercie van 
het klinische onderzoek. Als ik een ding van je geleerd heb, dan is het wel dat inhoud 
op de eerste plaats staat bij een wetenschappelijk artikel, maar dat het “verkopen” van 
een artikel minstens zo belangrijk is. Alhoewel je agenda drukker en drukker wordt (en 
er in de toekomst dus maar een ding op zit, en dat is delegeren), wil ik je ontzettend 
bedanken voor de tijd die je hebt vrijgemaakt in met name het laatste jaar. Ik wens je 
heel veel succes en plezier toe de komende jaren met het verder uitbouwen van het 
Rotterdamse hepatologie-imperium. En nog even ter herinnering aan het kleine resis-
tentiecongres dat we hadden in Parijs: wij beide hebben daar in ieder geval geleerd 
dat het niet verstandig is, dat ik aan het roer van de wijnfl es zit, als we de volgende 
ochtend om 8.00h een breakfast meeting hebben. 
Daarnaast wil ik natuurlijk dr. Rob de Man, mijn huidige opleider, bedanken voor zijn 
hulp bij mijn medische carrière. Bij u kwam ik begin 2006 voor het eerst aankloppen 
voor het bespreken van mijn oudste coschap. U adviseerde me destijds om er vooral 
te zorgen dat ik promotieonderzoek ging doen. Nu, in 2010, heb ik mijn promotieonder-
zoek zo goed als afgerond, en ben ik vorig jaar gestart met de opleiding tot MDL-arts 
onder uw supervisie. Naast dr. R.A. de Man wil ik verder prof. dr. C.A.B. Boucher en 
prof. dr. J.P. Drenth bedanken voor het beoordelen van mijn proefschrift. Furthermore, 
I am honoured to have a committee in which dr. H.W. Reesink, prof. dr. G. Duscheiko, 
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and prof. dr. F. Zoulim will take place. Daarnaast gaat nog mijn speciale dank uit naar 
prof. dr. Solko Schalm. Beste Solko, als er iemand een bevlogen wetenschapper is 
en in feite de belichaming van de Nederlandse hepatologie vormt, dan bent u het. 
Alhoewel u uiteindelijk te wijs werd bevonden voor mijn kleine commissie, toonde u 
altijd enorm veel belangstelling voor mijn verrichtingen. Ik wens u veel succes met uw 
huidige projecten, en ik hoop daar zeker steentje aan bij te dragen. 
Promoveren binnen een onderzoeksgroep heeft veel voordelen: een daarvan is dat 
de meest up-to-date reviewers het manuscript in feite al hebben beoordeeld, voordat 
het gesubmit gaat worden bij een medisch tijdschrift. Erik, een organisatietalent als jij 
heb ik nog nooit eerder gezien. Ik zou willen dat ik iets van je mocht lenen, dan krijg 
jij wat van mijn fl exibiliteit ;-) Milan en Roeland, ik wens jullie heel veel succes met 
jullie verdere promotietraject. Martijn, voor een koffi e is altijd tijd. Vincent, al zijn wij 
twee totaal verschillende personen, ik denk dat onze bijna perfecte samenwerking nu 
inmiddels al zijn tweede lustrum bereikt heeft, en ik hoop dat er nog een stuk of twintig 
zullen volgen. Op het moment van de verdediging ben jij ook een van de strijders van 
het fort in Zuid: het Ikaziaatje. Daarnaast gaat nog speciale dank uit naar de leden van 
het lab, die mij een korte introductie in de wereld van het pipetteren hebben gegeven: 
Eric, Andrea, Gertine, en Marjolein (en eigenlijk ook Mark en Andre, ook al doen jullie 
iets met dat andere virus).
En dan de meest fancy statisticus die er volgens mij ter wereld bestaat, en die, totdat 
ze vertelt dat ze al twee puberende kinderen heeft, ten minste twintig jaar jonger wordt 
ingeschat: Bettina Hansen. Bettina, dankzij jou werden de artikelen weer net even naar 
een hoger plan getild. Veel leuker waren natuurlijk echter de uitjes tijdens de congres-
sen. Heel veel succes met je verdediging van je proefschrift.
Martin en Suzan, mijn steun vanuit de virologie, was ik jullie toch bijna vergeten in mijn 
dankwoord! Gelukkig kwam ik daar nog net op tijd achter, want jullie bijdrage aan dit 
boekje is substantieel. Enorm veel dank voor alle hulp bij de aanvullende bepalingen 
die moesten worden verricht voor de stukken. Mijn start van de week gaat tegenwoor-
dig een stuk trager, er gaat namelijk niets boven een duik in de vriezer op de vroege 
maandagochtend. Ook voor de andere HBV-promovendi blijkt dit een plezierig uitje te 
zijn. Milan, Roeland en Vincent zullen dan ook altijd bereid zijn alle samples weer netjes 
terugzetten. 
Moniek en Emily, mijn twee studenten die ik mocht begeleiden bij hun master’s thesis. 
Het leven zou zo veel simpeler zijn als ons project gewoon een rechttoe rechtaan 
gerandomiseerde klinische trial was. Alhoewel we in het begin niet wisten waar te 
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moeten beginnen met een eindeloze brij aan heterogene data, die soms terugvoerde 
tot begin jaren negentig, is er uiteindelijk wel de beloning gekomen met een goede 
publicatie. Moniek, ik denk dat je een uitstekende keuze hebt gemaakt door met je 
coschappen te gaan starten in Amsterdam. Heel veel succes met je verdere carrière. 
Emily, I really enjoyed our cooperation, yet remember that it is important to keep your 
paper simple and straightforward. Furthermore, I have to thank you for your invaluable 
contribution to the ARES project.
De directe collega’s. Misschien is het goed om te beginnen met onze werkplek, want 
kippen in de bio-industrie hebben het misschien zwaar, maar ik denk dat ze wel een 
toontje lager zingen als ze de dakpoli hebben gezien. Het is ongelofelijk dat onder die 
omstandigheden, er toch nog van die mooie boekjes ontstaan. Allereerst mijn kamerge-
nootjes: Koch, de heerlijke rooklucht die mij tegemoet kwam, als jij lekker je ontbijtje 
voor de overdracht zat te nuttigen, ik mis het gewoon! Femme, jij bent 24 uur per dag 
vrolijk en blijft praten, zelfs als er normaal gesproken voor twaalf uur niet veel meer 
dan zinnen van hooguit een en maximaal twee woorden uit mijn mond komen. Ik vond 
het ontzettend gaaf om bij je bruiloft te zijn, en succes met je verdere pancreasproject. 
Paulus van Putten, eigenlijk waren wij ook gewoon kamergenoten. Ik heb ontzettend 
veel bewondering hoe jij je door je promotietraject weer heen te slaan. Ik hoop dat je 
het uiteindelijk met succes zal gaan afronden. Nicoline, Desirée, Aaf, Jildou,  Leonie, 
kleine Vincent, Daphne, Jerome, Lieke, Edith, Jilling, Geert, Leonie, Margot, Robert, 
Joyce, Sarwa, de sfeer was altijd goed, dank voor alle borrels, congressen, skireizen 
etc.
Marion en Margriet, het onverslaanbare (en enig cynische) secretaresseduo van de 
Hepatologie, ik zou willen dat jullie bij mij thuis ook eens de administratie op orde 
kwamen brengen. Marion, jouw hulp bij de gang van zaken rondom de promotie en het 
submitten van artikelen, met name in het laatste jaar, was onmisbaar. 
Meiden van het clinical research bureau, en in het bijzonder Elke en Irene, dank voor 
jullie hulp bij het schrijven en indienen van protocollen, het doorploegen van de wirwar 
aan regeltjes, en het omzeilen van de bureaucratie van de METC. Jullie strijd om ervoor 
te zorgen dat alles verloopt volgens de regels is essentieel (maar…regels zijn toch altijd 
minder straks dan ze lijken…). Heleen, Cokki, Anneke, Lucille, en Melek, ’s ochtends 
besprak je met jullie het plan, en ’s middags was de logistiek rondom inclusie, behan-
deling en follow-up tot in de puntjes geregeld. Heel veel dank voor jullie hulp.
De hepatitis B-poli op dinsdagmiddag vormde een welkome afwisseling. Alhoewel het 
enige levensdoel van een medische status is om op die plek te gaan liggen, waar jij niet 
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verwacht dat hij ligt, wisten Esther, Wilma, Nermin, Lakshmie, Ellen, Esther, en Ronald 
deze toch altijd weer terug te vinden. 
Menno en BP, super dat jullie mijn paranimfen willen zijn. Menno, we kennen elkaar nu 
al meer dan twintig jaar. Je bent een van mijn beste vrienden, en voormalig ploeg- en 
huisgenoot. Vanuit Klundert trokken we samen naar Rotterdam om in de gezellige 
Bas Jungeriusstraat in een van de kansenwijken van Rotterdam te gaan resideren. Jij 
hebt het daar uiteindelijk zelfs je hele studie volgehouden. Het blijft bijzonder hoe we 
konden genieten van een ontbijtje onder GTST, Lingo, of Get the Picture, en hoe vol 
we onze agenda vonden als we een of twee colleges die dag hadden (en die dan nog 
wisten te missen). Inmiddels woon je al weer een paar jaar met Lil in Breda. Ik wens 
jullie alle geluk van de wereld. Bas-P, one-of-the-boyz, en voormalig huisgenoot. De 
mooiste herinneringen blijven toch hoe je wekelijks werd drooggelegd op RS, je de hele 
dansvloer nodig had om al je moves ten toon te spreiden, om een uurtje of vier aftaaide 
naar Jaffa voor een knofl ooksoepje met hier en der wat shoarma, we samen onze 
vriend PJ Plakpoep van zijn bedje keerde, en jij vervolgens besloot nog een tweede 
keer van je broodje shoarma te gaan genieten. BP, (jij) inmiddels de dertig gepasseerd, 
binnenkort ga je trouwen, ook wij zijn inmiddels “trotse” burgermannen. Ik vind het 
supergaaf om straks je getuige te zijn, maar eerst ben jij mijn paranimf.
Lieve pap en mam, jullie bijdrage aan wat ik tot nu toe bereikt heb, is enorm. Jullie 
steun en belangstelling is van onschatbare waarde. Mam, een zoon praat nu eenmaal 
niet zo veel over emoties en dergelijke als een dochter, zeker ik niet. Het belangrijkste 
is echter dat ik weet dat ik altijd en overal op jullie terug kan vallen. Pap, als dit laatste 
drukke jaar met de start van mijn opleiding en het afronden van de promotie voorbij, is 
moeten onze bijna-wekelijkse uitjes in ere worden hersteld.  
Lieve Liek, jij bent verreweg het mooiste wat me tijdens mijn promotietijd is overkomen. 
Inmiddels zijn we alweer drie jaar bij elkaar, hebben we een schitterend huis, en kan je 
het zeker niet “pril” meer noemen;-). Het afgelopen jaar heb je er voor gezorgd dat ik 
werkelijk niets te kort kwam, en heb je er alles aan gedaan om mij zoveel mogelijk te 
ontlasten. Ik weet niet hoe ik je dit kan terugbetalen, maar ik ga zeker een poging doen. 
Lieverd, er ligt een wereld van vrije tijd op ons te wachten na november, en bedenk dat 
we pas een paar procent van onze tijd samen achter de rug hebben.
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C urriculum vitae
Jurriën Gerben Peter werd geboren op 24 september 1982 te Klundert. In 2000 behaalde 
hij zijn V.W.O. diploma aan het Markland College te Oudenbosch. Aansluitend startte 
hij met de opleiding Geneeskunde aan de Erasmus Universiteit te Rotterdam. In zijn 
tweede studiejaar besloot hij naast Geneeskunde, een Master of Science opleiding 
te volgen op het gebied genaamd Genetic Epidemiology. Een plezierig onderdeel 
van de Master studie was dat hij een maand aan de Harvard School of Public Health 
mocht studeren. Deze opleiding werd in 2004 voltooid. Zijn oudste coschap doorliep 
hij op de afdeling Maag-, Darm-, en Leverziekten van het Erasmus MC te Rotterdam, 
waarna hij in oktober 2006 zijn artsexamen behaalde. In november 2006 startte hij met 
promotieonderzoek naar de behandeling van chronische hepatitis B met nucleos(t)
ideanalogen onder supervisie van prof. dr. H.L.A. Janssen. Per september 2009 is hij 
met de opleiding tot Maag-Darm-Leverarts begonnen (opleider: Dr. R.A. de Man). De 
vooropleiding interne geneeskunde wordt thans verricht in het Ikazia Ziekenhuis Rot-
terdam (opleider: dr. A. Dees). 
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Summary of PhD training and teaching
Name PhD student: Jurriën G.P. Reijnders PhD period: 2006 - 2010
Erasmus MC Department: Gastroenterology Promotor: Prof. dr. H.L.A. Janssen
and Hepatology
1. PhD training
Year Workload
Presentations and workshops
Chronic hepatitis B: a patient-tailored approach. Meeting 
of the Laboratory for Infectious Diseases, Paterswolde, The 
Netherlands
2008 12 hours
Liver cirrhosis at baseline is an important predictor 
of resistance to adefovir. Twice annual meeting of the 
Netherlands Association of Hepatology, Veldhoven, The 
Netherlands
2008 12 hours
Antiviral effi cacy of entecavir: results from 153 chronic 
hepatitis B patients in an international multicenter cohort 
study. Twice annual meeting of the Netherlands Association 
of Hepatology, Veldhoven, The Netherlands
2008 12 hours
Resistance and new anti-HBV drugs. Hepatitis B Masterclass, 
Utrecht, The Netherlands
2009 18 hours
Clinical decisions in viral hepatitis: using nucleos(t)ide 
analogue for the treatment of chronic hepatitis B. Cursus 
Klinische Hepatologie, Lunteren, The Netherlands
2009 8 hours
Five year tenofovir therapy is associated with maintained 
virologic response, but signifi cant decline in renal function 
in HIV/HBV coinfected patients. Twice annual meeting of 
the Netherlands Association of Hepatology, Veldhoven, The 
Netherlands
2009 12 hours
Jurrien BW.indd   153 19-Oct-10   11:35:39 AM
154
P
hD
 P
o
rt
fo
lio
HBeAg seroconversion during nucleos(t)ide analogue therapy 
does not lead to durable remission of chronic hepatitis B. 60th 
Annual meeting of the American Association of the Study of 
Liver Diseases, Boston, MA, United States of America.
2009 36 hours
Antiviral effect of entecavir: infl uence of prior exposure to 
nucleos(t)ide analogues. 44th Annual meeting of the European 
Association of the Study of the Liver, Copenhagen, Denmark.
2009 36 hours
Treatment of chronic hepatitis B: from clinical trial to clinical 
practice. BMS satellite symposium. King’s College Hospital, 
University of London, Royal Free Hospital (London), Leeds 
Hospital (Leeds), United Kingdom.
2009 48 hours
Poster presentations
Entecavir: a rescue therapy for chronic hepatitis B patients 
with a limited virologic response to adefovir. 58th Annual 
meeting of the American Association of the Study of Liver 
Diseases, Boston, MA, United States of America.
2007 32 hours
Frequency and clinical outcome of fl ares related to nucleos(t)
ide analogues in patients with chronic hepatitis B. 59th Annual 
meeting of the American Association of the Study of Liver 
Diseases, Boston, MA, United States of America.
2008 24 hours
HBeAg seroconversion induced by nucleos(t)ide analogues 
in chronic hepatitis B is not durable in majority of cases. 59th 
Annual meeting of the American Association of the Study of 
Liver Diseases, Boston, MA, United States of America.
2008 24 hours
Liver cirrhosis at baseline is an important predictor of 
resistance to adefovir. 59th Annual meeting of the American 
Association of the Study of Liver Diseases, Boston, MA, 
United States of America.
2008 24 hours
Five year tenofovir therapy is associated with maintained 
virologic response, but signifi cant decline in renal function 
in HIV/HBV coinfected patients. 60th Annual meeting of the 
American Association of the Study of Liver Diseases, Boston, 
MA, United States of America.
2009 32 hours
HBsAg levels during antiviral therapy for chronic hepatitis 
B: peginterferon vs. entecavir. 45th Annual meeting of the 
European Association of the Study of the Liver, Vienna, 
Austria.
2010 32 hours
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International conferences
2nd International Conference on the Management of Patients 
with Viral Hepatitis, Paris, France.
2007 28 hours
42nd Annual Meeting of the European Association for the 
Study of the Liver (EASL), Barcelona, Spain.
2007 28 hours
The Liver Meeting 2007, 58th Annual Meeting of the American 
Association for the Study of Liver Diseases (AASLD), Boston, 
MA, United States of America.
2007 28 hours
EASL-AASLD-APASL-ALEH-IASL Conference Hepatitis B and 
C virus resistance to antiviral therapies, Paris, France.
2008 28 hours
The Liver Meeting 2008, 59th Annual Meeting of the American 
Association for the Study of Liver Diseases (AASLD), San 
Francisco, CA, United States of America.
2008 28 hours
44th Annual Meeting of the European Association for the 
Study of the Liver (EASL), Copenhagen, Denmark.
2009 28 hours
The Liver Meeting 2009, 60th Annual Meeting of the American 
Association for the Study of Liver Diseases (AASLD), Boston, 
MA, United States of America.
2009 28 hours
45th Annual Meeting of the European Association for the 
Study of the Liver (EASL), Vienna, Austria.
2010 28 hours
Attended seminars and workshops
De Sterkste Schakel hepatitis B en C. September 26, Utrecht, 
The Netherlands
2007 2 hours
5e Post AASLD symposium. December 6, Rotterdam, The 
Netherlands
2007 4 hours
Refereeravond Laboratorium voor Infectieziekten: Chronische 
hepatitis B virusinfectie – Nieuwe richtlijnen voor diagnostiek 
en behandeling. March 31, Paterswolde, The Netherlands
2008 2 hours
Studiemiddag HIV en hepatitis B: maakt de dokter het 
verschil? March 19, Rotterdam, The Netherlands.
2008 2 hours
Eerste Lagerhuisdebat Hepatitis B en C. September 25, 
Amsterdam, The Netherlands
2008 2 hours
2. Teaching
Year Workload 
Lecturing
Hepatitis B. 2nd year Erasmus MC medical students 
participating in a 4-week Infectious diseases training 
program. Rotterdam, The Netherlands.
2009 8 hours
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Hepatitis B. 3rd year Erasmus MC medical students 
participating in a 4-week Gastroenterology and Hepatology 
training program. Rotterdam, The Netherlands.
2009 8 hours
Supervising Master’s theses
Frequency and clinical outcome of fl ares related to nucleos(t)
ide analogues in patients with chronic hepatitis B – N.P. 
Zhang
2008 - 2010 60 hours
HBeAg seroconversion during nucleos(t)ide analogue therapy 
does not lead to durable remission of chronic hepatitis B – 
M.J. Perquin
2008 - 2010 60 hours
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